Browse Biomarkers Based on Source

This page shows data for Tissue source.
Total Entries Retrieved: 1066
IDBiomarkerBiomoleculeSubjectsRegulationTypeExperimentLevel of SignificanceSourcePMID
1 p4036+ p4361+ p4413+p4639+p4749+p5666+p28422 (PSA) Protein Humans Upregulated in PCa: [p4036; p4361; p4413; p4639; p4749; p28422 (PSA)] Downregulated in PCa: [p5666] Diagnostic Prostate Cancer or Prostatic intraepithelial neoplasia Vs Benign Prostatic Hyperplasia or Normal Prostate NA Tissue 12171882
2 p4036 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
3 p4361 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
4 p4639 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
5 p4749 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
6 p4036+p4361 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
7 p4036+p4639 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
8 p4361+p4639 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
9 p4036+p4749 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
10 p4361+p4749 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
11 p4639+p4749 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
12 p4036+p4361+p4639 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
13 p4036+p4361+p4749 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
14 MGC5466+Wnt5A+KIAA0476+ITPR1+TCF2 mRNA Humans Differentially Expressed in Recurrent Cancer Prognostic Recurrence Vs No Recurrence p<0.0001 Tissue 15067324
15 MGC5466+CHAF1A+CDS2+IER3 mRNA Humans Differentially Expressed in Recurrent Cancer Prognostic Recurrence Vs No Recurrence p<0.0001 Tissue 15067324
16 PPFIA3+COPEB+FOS+JUNB+ZFP36 mRNA Humans Differentially Expressed in Recurrent Cancer Prognostic Recurrence Vs No Recurrence p=0.001 Tissue 15067324
17 MGC5466+Wnt5A+KIAA0476+ITPR1+TCF2+CHAF1A+CDS2+IER3+PPFIA3+COPEB+FOS+JUNB+ZFP36 mRNA Humans Differentially Expressed in Recurrent Cancer Prognostic Recurrence Vs No Recurrence p<0.0001 Tissue 15067324
19 XLKD1/LYVE1 mRNA Humans Downregulated in PCa(atleast 2 fold) Diagnostic Normal Prostate vs Prostate Cancer p<0.05 Tissue 14654526
20 CGA mRNA Humans Downregulated in PCa(atleast 2 fold) Diagnostic Normal Prostate vs Prostate Cancer p<0.05 Tissue 14654526
21 F2R/PAR1 mRNA Humans Downregulated in PCa(atleast 2 fold) Diagnostic Normal Prostate vs Prostate Cancer p<0.05 Tissue 14654526
22 BCL-G mRNA Humans Downregulated in PCa(atleast 2 fold) Diagnostic Normal Prostate vs Prostate Cancer p<0.05 Tissue 14654526
23 XLKD1/LYVE1+CGA+ F2R/PAR1+ BCL-G mRNA Humans Differentially Expressed Prognostic Patients with Relapse Vs Without Relapse p<0.05 Tissue 14654526
24 Caveolin-1 Protein Humans Upregulated in African American Men (AA: 39% vs WA: 17%) Prognostic African Americans vs White American men with Prostate Cancer p=0.0048 Tissue 10999725
27 BCL-2 Protein Humans Upregulated in High Gleason Score Prognostic High (8-10) vs Low (2-4) Gleason Score p<0.001 Tissue 11500787
29 Alpha Methylacyl Coenzyme A Racemase (AMACR) mRNA Humans Upregulated in Localised Prostate Cancer (3.1 fold) Diagnostic Benign Prostate vs Localised Prostate Cancer p<0.001 Tissue 11926890
30 Alpha Methylacyl Coenzyme A Racemase (AMACR) mRNA Humans Upregulated in Metastatic Prostate Cancer (1.67 fold) Diagnostic Benign Prostate vs Metastatic Prostate Cancer p<0.004 Tissue 11926890
31 Alpha Methylacyl Coenzyme A Racemase (AMACR) Protein Humans Upregulated in Localised Prostate Cancer [Mean expression Value: (Localised Prostate Cancer: 3.2 vs Normal Prostate: 1.3)] Diagnostic Benign Prostate vs Localised Prostate Cancer p<0.001 Tissue 11926890
37 Lycopene Protein Humans Downregulated (36% fold) Diagnostic Normal vs Cancerous p<0.05 Tissue 12497123
38 Annexin 1 Protein Humans Downregulated in Metastatic hormone refractory PCa (2.23 fold) Prognostic Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer p<0.001 Tissue 12507908
39 Annexin 2 Protein Humans Downregulated in Metastatic hormone refractory PCa (1.51 fold) Prognostic Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer p=0.009 Tissue 12507908
40 Annexin 4 Protein Humans Downregulated in Metastatic hormone refractory PCa (1.3 fold) Prognostic Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer p=0.001 Tissue 12507908
41 Annexin 7 Protein Humans Downregulated in Metastatic hormone refractory PCa (1.42 fold) Prognostic Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer p<0.001 Tissue 12507908
42 Annexin 11 Protein Humans Downregulated in Metastatic hormone refractory PCa (1.81 fold) Prognostic Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer p<0.001 Tissue 12507908
43 Fatty Acid Synthase (FAS) mRNA Humans Upregulated in PCa (3 fold) [Mean Value: PCa:158 Vs Normal: 53] Diagnostic Prostate Cancer Vs Normal Adjacent p<0.00000029 Tissue 12939396
44 Fatty Acid Synthase (FAS) mRNA Humans Upregulated in Metastatic PCa (12 fold) [Mean Value: GS7 :149.2 Vs Metastatic: 1960.8] Prognostic Gleason Score 7 Vs Metastatic Tumor p<0.00000029 Tissue 12939396
45 Fatty Acid Synthase (FAS) Intensity Protein Humans Upregulated in Metastatic PCa (12 fold) [Mean Value: GS7 :149.2 Vs Metastatic: 1960.8] Diagnostic Prostate Cancer Vs Normal Adjacent p<0.00000000857 Tissue 12939396
46 alpha-Methylacyl Coenzyme A Racemase (AMACR) Protein Humans Upregulated in PCa (Prostate Cancer: 3.14 Vs Benign Prostate: 1.3) Diagnostic Benign Prostate Vs Localised Prostate Cancer p<0.00001 Tissue 14982837
47 alpha-Methylacyl Coenzyme A Racemase (AMACR) Protein Humans Upregulated in PCa (Prostate Cancer: 21.6 Vs Benign Prostate: 7.3) Diagnostic Benign Prostate Vs Localised Prostate Cancer p<0.05 Tissue 14982837
48 phosphorylated Akt (pAkt) Protein Humans Upregulated in PSA failures (PSA Failure: [222.18±33.9 vs PSA Non-Failure: 108.79±104.57) Prognostic PSA failure versus PSA non failure p<0.001 Tissue 15289328
49 phosphorylated Akt (pAkt) + phosphorylated ERK (extracellular signal-regulated kinase) (pERK) Protein Humans pAKT: Upregulated in PSA failures; pERK: Downregulated in PSA failures Prognostic PSA failure versus PSA non failure NA Tissue 15289328
50 GalNAc-T3+PSMA+Hepsin+DD3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs benign prostatic hyperplasia NA Tissue 15609297
51 PSMA+Hepsin+DD3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs benign prostatic hyperplasia NA Tissue 15609297
52 GalNAc-T3+Hepsin+DD3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs benign prostatic hyperplasia NA Tissue 15609297
53 GalNAc-T3,+Hepsin+PSMA mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs benign prostatic hyperplasia NA Tissue 15609297
54 GalNAc-T3+PSMA+DD3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs benign prostatic hyperplasia NA Tissue 15609297
55 DDR/PCA3 mRNA Humans Upregulated (140 fold) Diagnostic Prostate Cancer Vs benign prostatic hyperplasia p=0.007 Tissue 15609297
56 HEPSIN mRNA Humans Upregulated (21 fold) Diagnostic Prostate Cancer Vs benign prostatic hyperplasia p=0.049 Tissue 15609297
57 PSMA mRNA Humans Upregulated (66 fold) Diagnostic Prostate Cancer Vs benign prostatic hyperplasia p=0.047 Tissue 15609297
58 GalNAc-T3 mRNA Humans Upregulated (4.6 fold) Diagnostic Prostate Cancer Vs benign prostatic hyperplasia p=0.005 Tissue 15609297
59 Kallikrein 4 (KLK4/hK4) Protein Humans Upregulated in PCa Diagnostic Benign prostatic hyperplasia Vs Prostate Cancer p<0.05 Tissue 16172196
60 BCL-2 Protein Humans Upregulated in PCa Patients: PSA >10 ng/ml Prognostic PSA ≤10 ng/ml Vs PSA >10 ng/ml p<0.01 Tissue 15655565
61 COX-2 Protein Humans Upregulated in PCa Patients: PSA >10 ng/ml Prognostic PSA ≤10 ng/ml Vs PSA >10 ng/ml p<0.01 Tissue 15655565
62 BCL-2 Protein Humans Upregulated in Patients with relapse Prognostic PCa Relapse Vs No Relapse p<0.01 Tissue 15655565
63 COX-2 Protein Humans Upregulated in Patients with relapse Prognostic PCa Relapse Vs No Relapse p<0.01 Tissue 15655565
64 Heat Shock Protein (Hsp70) Protein Mice Upregulated in PCa (2 fold) Diagnostic Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate p<0.05 Tissue 15666362
65 Proliferating cell nuclear antigen (PCNA) Protein Mice Upregulated in PCa (1.44 fold) Diagnostic Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate p<0.05 Tissue 15666362
66 Apoliprotein A-1 Protein Mice Upregulated in PCa (1.65 fold) Diagnostic Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate p<0.05 Tissue 15666362
67 Phospholipase C Protein Mice Upregulated in PCa (1.95 fold) Diagnostic Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate p<0.05 Tissue 15666362
68 Glucose regulated protein (GRP 58) Protein Mice Upregulatd in PCa (2 fold) Diagnostic Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate p<0.05 Tissue 15666362
69 Enolase 1, Non-Neuron Protein Mice Upregulatd in PCa (1.8 fold) Diagnostic Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate p<0.05 Tissue 15666362
70 AMACR (o-methylacyl-CoA racemaÌŠse) mRNA Humans Upregulated in PCa (3.3 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
71 SIM2 (single-minded homolog 2) mRNA Humans Upregulated in PCa (2.3 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
72 EST (similar to cDS4 retroviral related polyprotein) mRNA Humans Upregulated in PCa (2.3 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
73 EST (weakly similar to protease) mRNA Humans Upregulated in PCa (2.2 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
74 TRGV9 (Tcell receptory variable 9) mRNA Humans Upregulated in PCa (2.1 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
75 EST (AGR2 anterior gradient 2 homolog) mRNA Humans Upregulated in PCa (2.1 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
76 HPN (hepsin transmembrane protease, serine I) mRNA Humans Upregulated in PCa (2.0 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
77 KCNA5 (potassium voltage-gated channel), mRNA Humans Upregulated in PCa (2.0 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
78 TM4SF13 (transmembrane 4 superfamily member 13) mRNA Humans Upregulated in PCa (2.0 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
79 SOX9 (SRY sex determining region Y-box 9) mRNA Humans Upregulated in PCa (2.0 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
80 SOX4 (SRY sex determining region Y-box 4) mRNA Humans Upregulated in PCa (1.9 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
81 SLC26A2 (solute carrier family 26 member 2) mRNA Humans Upregulated in PCa (1.9 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
82 SYNP02 (synaptopodin) mRNA Humans Downregulated in PCa (4.2 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
83 SLC18A2 (solute carrier family 18 member 2) mRNA Humans Downregulated in PCa (3.0 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
84 CALD1 (caldesmon 1) mRNA Humans Downregulated in PCa (2.8 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
85 MRE11A (meiotic recombination 11 homologue A) mRNA Humans Downregulated in PCa (2.8 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
86 KRT15 (keratin 15) mRNA Humans Downregulated in PCa (2.7 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
87 ACTG2 (actin gamma 2 smooth muscle, enteric) mRNA Humans Downregulated in PCa (2.5 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
88 DSIPI (delta sleep inducing peptide, immunoreactor) mRNA Humans Downregulated in PCa (2.5 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
89 SLC18A2 (solute carrier family 18 member 2) mRNA Humans Downregulated in PCa (2.5 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
90 MME [membrane metallo-endopeptidase] mRNA Humans Downregulated in PCa (2.4 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
91 KRT17 (similar to keratin 17) mRNA Humans Downregulated in PCa (2.4 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
92 LY96 (lymphocyte antigen 96) mRNA Humans Downregulated in PCa (2.4 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
93 SYNP02 (synaptopodin) mRNA Humans Downregulated in PCa (2.4 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
99 Ghrelin Protein Humans Upregulated in PCa Diagnostic Benign Prostatic Hypertrophy Vs Prostate Cancer p<0.05 Tissue 16322288
100 Preproghrelin Protein Humans Upregulated in PCa Diagnostic Benign Prostatic Hypertrophy Vs Prostate Cancer p<0.05 Tissue 16322288
102 Methylation status of GSTP1 mRNA Humans Hypermethylated in Patients who relapsed Prognostic Time to Progression p<0.03 Tissue 16322291
103 Methylation status of GSTP1 mRNA Humans Hypermethylated in Patients who relapsed Prognostic Time to Progression P = 0.004 Tissue 16322291
104 Methylation status of APC mRNA Humans Hypermethylated in Patients who relapsed Prognostic Time to Progression P = 0.004 Tissue 16322291
105 Methylation status of GSTP1 mRNA Humans Hypermethylated in Patients who relapsed Prognostic Time to Progression P = 0.01 Tissue 16322291
106 Methylation status of Cyclin D2 + APC mRNA Humans Hypermethylated in Patients who relapsed Prognostic Time to Progression 0.01 Tissue 16322291
116 PP2A mRNA Humans Downregulated in PCa Diagnostic Benign Prostatic Hyperplasia (BPH) vs Prostate Cancer (PCa) p=0.0073 Tissue 17977648
123 Neuropeptide Y (NPY) Protein Humans Upregulated in PCa Diagnostic Benign Prostate Vs Prostate Cancer p<0.0001 Tissue 16614113
124 Neuropeptide Y (NPY) Protein Humans Upregulated in PCa Diagnostic HGPIN vs PCa p=0.0108 Tissue 16614113
125 Neuropeptide Y (NPY) Protein Humans Upregulated in Gleason Pattern 4 Prognostic Gleason Pattern 3 Vs Gleason Pattern 4 p=0.042 Tissue 16614113
126 Neuropeptide Y (NPY) Protein Humans Upregulated in Gleason Pattern 5 Prognostic Gleason Pattern 4 Vs Gleason Pattern 5 p=0.037 Tissue 16614113
127 Neuropeptide Y (NPY) Protein Humans Increased expression with increase in relapse Prognostic Relapse Vs No Relapse after Radical Prosteactomy p=0.037 Tissue 16614113
128 Macrophage Inhibitory Cytokine-1 (MIC-1) Protein Humans Upregulated in PCa Diagnostic Benign Prostate Vs Prostate Cancer p<0.0001 Tissue 16614113
129 Macrophage Inhibitory Cytokine-1 (MIC-1) Protein Humans Upregulated in PCa Diagnostic HGPIN vs PCa p<0.0001 Tissue 16614113
130 Macrophage Inhibitory Cytokine-1 (MIC-1) Protein Humans Increased expression with increase in relapse Prognostic Relapse Vs No Relapse after Radical Prosteactomy p=0.037 Tissue 16614113
138 CCNE2+CDC6+FBP1+HOXC6+MKI67+MYBL2+PTTG1+DTL+UBE2C+WNT5A+ALCAM+AZGP1+CCK+MYLK+PPAP2B+PROK1 mRNA Humans Upregulated GEX score in PCa Patients (PCa: 7.38 ± 0.35 Vs Non Cancer: 7.2±0.16) Diagnostic No Cancer Vs Prostate Cancer p=0.0013 Tissue 17459658
139 CCNE2+CDC6+FBP1+HOXC6+MKI67+MYBL2+PTTG1+DTL+UBE2C+WNT5A+ALCAM+AZGP1+CCK+MYLK+PPAP2B+PROK1 mRNA Humans Increased GEX Score with relapse Prognostic Relapse Vs No Relapse p=0.007 Tissue 17459658
140 PARP Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.02 Tissue 15491717
141 BCL-2 Protein Humans Downregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.01 Tissue 15491717
142 EGFR Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.01 Tissue 15491717
143 BAD Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.01 Tissue 15491717
144 H3 Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.01 Tissue 15491717
145 Lipoxygenase Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.01 Tissue 15491717
146 p27 Protein Humans Downregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.01 Tissue 15491717
147 Racemase 3 Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.01 Tissue 15491717
148 Ki-67 Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.01 Tissue 15491717
149 PARP Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Japanese American p=0.01 Tissue 15491717
150 BCL-2 Protein Humans Downregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Japanese American p=0.01 Tissue 15491717
151 EGFR Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Japanese American p=0.01 Tissue 15491717
152 BAD Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Japanese American p=0.01 Tissue 15491717
153 Lipoxygenase Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Japanese American p=0.01 Tissue 15491717
154 p27 Protein Humans Downregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Japanese American p=0.01 Tissue 15491717
155 Racemase 3 Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Japanese American p=0.01 Tissue 15491717
156 Ki-67 Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Japanese American p=0.01 Tissue 15491717
157 Lipoxygenase Protein Humans Downregulated (in JA compared to NJ) Diagnostic Cancerous Tissue in Japanese American (JA) Vs Native Japanese (NJ) p=0.01 Tissue 15491717
158 Caspase-3 Protein Humans Downregulated (in JA compared to NJ) Diagnostic Cancerous Tissue in Japanese American (JA) Vs Native Japanese (NJ) p=0.01 Tissue 15491717
159 AMACR (α-methylacyl-CoA racemåse) [AMACR 2094, 2097, 2098, 2095] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 2.12E-08 Tissue 16618727
160 PYCR1 (Pyroline 5 - Carboxylate reductase1) mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 8.58E-10 Tissue 16618727
161 MYO6 (Myosin VI) [MYO6-0041] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.15E-08 Tissue 16618727
162 SMPDL3B (Sphingomyelinase like phosphodiesterase 3B) [SMPDL3B 2030] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 2.32E-08 Tissue 16618727
163 NOX4 (NADPH oxidase 4) [NOX4 1355] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.57E-07 Tissue 16618727
164 FASN (Fatty Acid Synthase) [FASN 1432,1433, 1435] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 4.78E-05 Tissue 16618727
165 CACNA1D (Voltage-dep. L-type Calcium Channel Alpha 1D Subunit) [CACNA1D 2040, 2039] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 3.32E-06 Tissue 16618727
166 FBP1 (Fructose 1,6 Bisphosphatase 1) [FBP1 0807] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.46E-07 Tissue 16618727
167 IMPDH2 (Inosine-5′-monophosphate dehydrogenase 2) [IMPDH2 0144,0145] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.68E-05 Tissue 16618727
168 ABCC4 (Multidrug Resistance-Associated Protein 4) [ABCD4 2013] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.09E-05 Tissue 16618727
169 GART (Phosphoribosylglycinamide Formyltransferase) [GART 0310, 0307] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.57E-05 Tissue 16618727
170 CLN3 (ceroid lipofuscinosis, neuronal 3, juvenile) [CLN3 1132] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.50E-05 Tissue 16618727
171 DHPS (Deoxyhypusine Synthase) [DHPS 2028] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.68E-05 Tissue 16618727
172 BIRC5 (Baculoviral IAP Repeat Containing 5 (survivin)) [BIRC5 0847] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.73E-05 Tissue 16618727
173 REPS2 (RALBP1 Associated Eps Domain Containing 2) [REPS2 0732, 0733] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 2.18E-05 Tissue 16618727
174 RPS2 (40S Ribosomal Protein S2) [RPS2-0809] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.051607 Tissue 16618727
175 TMSNB (Thymosin, Beta, identified in neuroblastoma cells) [TMSNB 0227] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 2.34E-05 Tissue 16618727
176 EPB41 (Erythrocyte Membrane Protein Band 4.1) [EPB41 1096,1092] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 2.69E-05 Tissue 16618727
177 GCNT1 (Core 2 Beta1,6 N-Acetylglucosaminyltransferase-I) [GCNT1 0981, 0982,0985] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 8.15E-05 Tissue 16618727
178 LYPLA1 (Lysophospholipase 1) [LYPLA1 0862, 0860] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.006744 Tissue 16618727
179 RET1 (Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret) [RET1 0252 0250] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.008659 Tissue 16618727
180 HSPD1 (Heat Shock 60kDa Protein 1 (Chaperonin)) [HSPD1 0152, 0154] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.033554 Tissue 16618727
181 MAPT (Microtubule Associated Protein Tau) [MAPT 1060] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.000885 Tissue 16618727
182 C7ORF24 (Chromosome 7 Open Reading Frame 24) [C7ORF24 0.001028] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.001028 Tissue 16618727
183 ERBB3 (Erb-B2 Receptor Tyrosine Kinase 3) [ERBB3 1431] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.001238 Tissue 16618727
184 PLA2G2A (Phospholipase A2 Group IIA) [PLA2G2A 1380] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.001569 Tissue 16618727
185 NME1 (Nucleoside Diphosphate Kinase A) [NME1 0827] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.001945 Tissue 16618727
186 CDK7 (Cyclin Dependent Kinase 7) [CDK7 0899] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.002319 Tissue 16618727
187 MMP9 (Matrix Metallopeptidase 9) [MMP9 1185] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.00262 Tissue 16618727
188 BGN (Biglycan) [BGN 1274] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.002956 Tissue 16618727
189 PPIB (Peptidylprolyl Isomerase B (Cyclophilin B)) [PPIB 0969] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.006963 Tissue 16618727
190 IQGAP2 (IQ Motif Containing GTPase Activating Protein 2) [IQGAP2 0234] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.010253 Tissue 16618727
191 DKFZP564B167 (DKFZP564B167 Protein) [DKFZP564B167 0717] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.015526 Tissue 16618727
192 TMEPAI (Transmembrane Prostate Androgen- Induced Protein) [TMEPAI 2074] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.023696 Tissue 16618727
193 STAC (SH3 And Cysteine Rich Domain) [STAC 1045, 1044, 1047] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 4.42E-07 Tissue 16618727
194 FGFR2 (Fibroblast Growth Factor Receptor 2) [FGFR2 0101,0095,0100,0106, 0107, 0097] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.42E-07 Tissue 16618727
195 CDC42BPA (CDC42 Binding Protein Kinase Alpha) [CDC42BPA 1051] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.56E-08 Tissue 16618727
196 KRT15 (keratin 15) [KRT15 1335, 1333, 1334,1341] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.60E-06 Tissue 16618727
197 TRIM29 (Tripartite Motif Containing 29) [TRIM29 1353, 1348, 1346] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 4.38E-06 Tissue 16618727
198 CES1 (Carboxylesterase ) [CES1 0942, 0937] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.43E-05 Tissue 16618727
199 CLU (Clusterin) [CLU 0196, 0192, 0191] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.000272 Tissue 16618727
200 ALDH1A2 (Aldehyde Dehydrogenase 1A2) [ALDH1A2 0004,0001, 0006] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.000266 Tissue 16618727
201 DRR1 (Collagen and Wnt5a regulated receptor tyrosin kinase) [DRR1 - 0753] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.88E-07 Tissue 16618727
202 ROBO1 (Roundabout, Axon Guidance Receptor, Homolog 1) [ROBO1 1419] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 2.26E-07 Tissue 16618727
203 LTBP4 (Latent TFG Beta Binding Protein 4) [LTBP4 0752, 0747, 0742, 1519, 1518, 0745, 0748, 0746] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.002361 Tissue 16618727
204 PGR (Progesterone Receptor) [PGR 1161, 1162] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 3.77E-06 Tissue 16618727
205 EDNRB (Endothelin Receptor Type B) [EDNRB 1187] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.88E-06 Tissue 16618727
206 ANGPT1 (Angiopoietin 1) [ANGPT1 1032, 1031] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 3.72E-05 Tissue 16618727
207 IGF1 (Insulin like Growth Factor 1 Somatomedin C) [IGF1 0025] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 3.77E-06 Tissue 16618727
208 COL6A2 (Collagen, Type VI, Alpha 2) [COL6A2 1489] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 8.16E-06 Tissue 16618727
209 PTGDS (Prostaglandin D2 Synthase 21kDa) [PTGDS 0787] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.09E-05 Tissue 16618727
210 ANGPTL2 (Angiopoietin-related Protein 2) [ANGPTL2 0950] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.20E-05 Tissue 16618727
211 VCL (Vinculin) [VCL 1534, 0933, 0936] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.011744 Tissue 16618727
212 GSTP1 (Glutathione S-transferase P) [GSTP1 0927, 0923] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.030854 Tissue 16618727
213 SAT (Spermidine/Spermine N1-acetyltransferase) [SAT 0840, 0842] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.052888 Tissue 16618727
214 TGFB2 (Transforming Growth Factor, Beta 2) [TGFB2 0085] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.095398 Tissue 16618727
229 ENC1 + GJB1 mRNA Humans Differentially Expressed Diagnostic Benign Prostate Vs Prostate Cancer p<0.0005 Tissue 17460773
230 MYO6 + AMACR mRNA Humans Differentially Expressed Diagnostic Benign Prostate Vs Prostate Cancer p<0.0005 Tissue 17460773
231 TSPAN13 + PRKCBP1 mRNA Humans Differentially Expressed Diagnostic Benign Prostate Vs Prostate Cancer p<0.0005 Tissue 17460773
232 C20ORF74 + DAPK1 mRNA Humans Differentially Expressed Diagnostic Benign Prostate Vs Prostate Cancer p<0.0005 Tissue 17460773
233 IMAGE:396839 + ENC1 mRNA Humans Differentially Expressed Diagnostic Benign Prostate Vs Prostate Cancer p<0.0005 Tissue 17460773
234 Metaclassifier: ENC1+GJB1+MYO6+AMACR+TSPAN13+PRKCBP+C20ORF74+DAPK1+IMAGE:396839 + ENC1 mRNA Humans Differentially Expressed Prognostic Benign Prostate Vs Prostate Cancer p<0.0005 Tissue 17460773
235 ARL6IP+MYH11 mRNA Humans Differentially Expressed Prognostic Primary Vs Metastatic Prostate Cancer NA Tissue 17460773
248 PI3-K p85 α mRNA Humans Downregulated in Gleason Score 7-10 Prognostic Gleason Score 5-6 Vs Gleason Score 7-10 p<0.05 Tissue 18336616
249 ILK mRNA Humans Downregulated in Gleason Score 7-11 Prognostic Gleason Score 5-6 Vs Gleason Score 7-10 p<0.05 Tissue 18336616
250 PTEN mRNA Humans Downregulated in Gleason Score 7-12 Prognostic Gleason Score 5-6 Vs Gleason Score 7-10 p<0.05 Tissue 18336616
251 PHLPP mRNA Humans Downregulated in Gleason Score 7-13 Prognostic Gleason Score 5-6 Vs Gleason Score 7-10 p<0.05 Tissue 18336616
252 FOXO1A mRNA Humans Downregulated in Gleason Score 7-14 Prognostic Gleason Score 5-6 Vs Gleason Score 7-10 p<0.05 Tissue 18336616
253 AMACR (Alpha-methylacyl-coA racemase ) Protein Humans Upregulated in PCa Diagnostic High Grade Prostatic Intraepithelial Neoplasia Vs Prostate Cancer p=0.0044 Tissue 18343427
256 TOP2A mRNA Humans Upregulated in PCa (≥2 fold) Diagnostic Prostate Cancer Vs Nonneoplastic Sample p<0.05 Tissue 18347174
257 ERG mRNA Humans Upregulated in PCa (≥2 fold) Diagnostic Prostate Cancer Vs Nonneoplastic Sample p<0.05 Tissue 18347174
258 NRP1 mRNA Humans Upregulated in Aggressive Prostate Cancer Prognostic Non Aggressive Vs Aggressive prostate cancer phenotype p=0.007 Tissue 18347174
259 TOP2A mRNA Humans Upregulated in Aggressive Prostate Cancer Prognostic Non Aggressive Vs Aggressive prostate cancer phenotype p<0.0001 Tissue 18347174
260 RRM2 mRNA Humans Upregulated in Aggressive Prostate Cancer Prognostic Non Aggressive Vs Aggressive prostate cancer phenotype p<0.0001 Tissue 18347174
261 KHRDSB3 mRNA Humans Upregulated in Aggressive Prostate Cancer Prognostic Non Aggressive Vs Aggressive prostate cancer phenotype p=0.015 Tissue 18347174
262 SSTR1 mRNA Humans Upregulated in Aggressive Prostate Cancer Prognostic Non Aggressive Vs Aggressive prostate cancer phenotype p=0.006 Tissue 18347174
263 Methylation Status of NKX2-5 mRNA Humans Hypermethylated (2.7% normal vs 14% in Cancerous condition) Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
264 Methylation Status of CALSTN1 mRNA Humans Hypermethylated (2.5% normal vs 12.1% in Cancerous condition) Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
265 Methylation Status of SPOCK2 mRNA Humans Hypermethylated (7.5% normal vs 15.2% in Cancerous condition) Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
266 Methylation Status of NSE1 mRNA Humans Hypermethylated (10.3% normal vs 20.5% in Cancerous condition) Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
267 Methylation Status of SLC16A12 mRNA Humans Hypermethylated (9% normal vs 22% in Cancerous condition) Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
268 Methylation Status of FOXN4 mRNA Humans Hypermethylated (2.4% normal vs 4.3% in Cancerous condition) Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
269 Methylation Status of GALR2 mRNA Humans Hypermethylated (2% normal vs 4.3% in Cancerous condition) Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
270 Methylation Status of DPYS mRNA Humans Hypermethylated (24.2% normal vs 42.71% in Cancerous condition) Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
271 Methylation Status of (DPYS or NKX2-5) mRNA Humans Hypermethylated in Prostate Cancer Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
272 Methylation Status of (CALSTN1 or DYPS) mRNA Humans Hypermethylated in Prostate Cancer Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
273 Methylation Status of (NSE1 or DPYS) mRNA Humans Hypermethylated in Prostate Cancer Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
274 Methylation Status of (NSE1 or SPOCK2) mRNA Humans Hypermethylated in Prostate Cancer Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
275 Methylation Status of (SLC16A12 or DPYS) mRNA Humans Hypermethylated in Prostate Cancer Diagnostic prostate cancer Vs normal prostate p<0.05 Tissue 18446232
276 Fusion Status of TMPRSS2:ERG mRNA Humans Increased fusion in patients with biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence p=0.0523 Tissue 18500259
277 Mutation of PTEN mRNA Humans Deletion found in patients with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence p=0.0009 Tissue 18500259
278 Fusion Status of TMPRSS2:ERG + PTEN deletion mRNA Humans Fusion + Deletion Prognostic Biochemical Recurrence Vs no Recurrence p=0.001 Tissue 18500259
279 Fusion Status of TMPRSS2:ERG + PTEN deletion mRNA Humans Fusion + Deletion Prognostic Biochemical Recurrence Vs no Recurrence p=0.036 Tissue 18500259
280 Golgi phosphoprotein 2 (GOLPH2) mRNA Humans Upregulated in Prostate Cancer(3.04 fold) Diagnostic prostate cancer Vs normal prostate p<0.001 Tissue 18543251
281 Golgi phosphoprotein 2 (GOLPH2) Protein Humans Upregulated in Prostate Cancer Diagnostic prostate cancer Vs normal prostate p<0.01 Tissue 18543251
282 Golgi phosphoprotein 2 (GOLPH2) Protein Humans Upregulated in Prostate Cancer Diagnostic prostate cancer Vs normal prostate epithelium p<0.001 Tissue 18543251
283 Myosin VI (MYO6) mRNA Humans Upregulated in Prostate Cancer Diagnostic Tumor and adjacent normal prostate tissues NA Tissue 18543251
287 40S ribosomal protein S25 Protein Humans Upregulated (Mean Ratio: 2.13 ±0.44) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
288 40S ribosomal protein S7 Protein Humans Upregulated (Mean Ratio: 5.24 ±0.66) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
289 α-1-antitrypsin precursor (α-1protease inhibitor) Protein Humans Upregulated (Mean Ratio: 3.19 ±0.97) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
290 Cellular nucleic acid-binding protein (CNBP) (Zinc finger protein 9) Protein Humans Upregulated (Mean Ratio: 2.33 ±0.79) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
291 Chondroitin sulfate proteoglycan 2 (Versican) variant (Fragment) Protein Humans Upregulated (Mean Ratio: 2.28 ±0.58) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
292 Chromobox protein homologue 1 (Heterochromatin protein 1 homologue β) Protein Humans Upregulated (Mean Ratio: 3.36 ±0.50) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
293 Cofilin-1 (Cofilin, nonmuscle isoform) (18 kDa phosphoprotein) (p18) Protein Humans Upregulated (Mean Ratio: 3.29 ± 1.2) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
294 Complement component 1 Q subcomponent-binding protein (p33) Protein Humans Upregulated (Mean Ratio: 4.55 ± 1.70) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
295 Elongation factor 1-R 2 (Elongation factor 1 A-2) (Statin S1) Protein Humans Upregulated (Mean Ratio: 2.68 ±0.73) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
296 Ezrin (p81) (Cytovillin) (Villin-2) Protein Humans Upregulated (Mean Ratio: 2.26 ±0.0.49) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
297 FASN variant protein (Fragment) Protein Humans Upregulated (Mean Ratio: 2.78 ±0.91) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
298 FK506-binding protein 4 (Peptidyl-prolyl cis-trans isomerase) (Rotamase) Protein Humans Upregulated (Mean Ratio: 2.46 ±0.29) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
299 Glutamate carboxypeptidase 2 (Folate hydrolase 1) (Prostate- specific membrane antigen) Protein Humans Upregulated (Mean Ratio: 2.82 ±0.95) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
300 Glutathione peroxidase 3 precursor Protein Humans Upregulated (Mean Ratio: 2.19 ±0.57) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
301 Glutathione S-transferase ω-1 Protein Humans Upregulated (Mean Ratio: 2.36 ±0.58) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
302 Heat shock protein HSP90-β Protein Humans Upregulated (Mean Ratio: 3.2 ±0.61) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
303 Histone cluster 1, H1e Protein Humans Upregulated (Mean Ratio: 3.5 ±0.82) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
304 Histone H1.2 (Histone H1d) Protein Humans Upregulated (Mean Ratio: 2.98 ±1.07) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
305 Lactoylglutathione lyase (Aldoketomutase) (Glyoxalase I) Protein Humans Upregulated (Mean Ratio: 2.06 ±0.56) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
306 α-methylacyl-CoA racemase (AMAC) Protein Humans Upregulated (Mean Ratio: 2.51 ±0.62) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
307 Nucleophosmin (NPM) (Nucleolar phosphoprotein B23) (Numatrin) Protein Humans Upregulated (Mean Ratio: 2.6 ±1.01) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
308 Periostin, osteoblast specific factor Protein Humans Upregulated (Mean Ratio: 3.38 ± 1.59) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
309 Prostaglandin E synthase 3 (Telomerase-binding protein p23) (Hsp90 co-chaperone) (Progesterone receptor complex p23) Protein Humans Upregulated (Mean Ratio: 3.14 ±0.56) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
310 Proteasome subunit alpha type 5 (Multicatalytic endopeptidase complex ?-chain) Protein Humans Upregulated (Mean Ratio: 2.07 ±1.70) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
311 Protein mago nashi homologue 2 Protein Humans Upregulated (Mean Ratio: 2.18 ±0.43) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
312 Protein-glutamine γ-glutamyltransferase 4 (Prostate transglutaminase) (Prostate-specific transglutaminase) Protein Humans Upregulated (Mean Ratio: 3.45 ±1.00) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
313 Thioredoxin domain-containing protein 4 precursor Protein Humans Upregulated (Mean Ratio: 2.54 ±0.45) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
314 Ubiquinol-cytochrome c reductase complex 11 kDa protein Protein Humans Upregulated (Mean Ratio: 2.90 ±0.59) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
315 14-3-3 protein β/α Protein Humans Downregulated (Mean Ratio: 0.52 ±0.1) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
316 Androgen receptor-associated protein of 55 kDa (ARA 55) Protein Humans Downregulated (Mean Ratio: 0.38 ±0.11) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
317 α-parvin (Calponin-like integrin-linked kinase-binding protein) (CH-ILKBP) Protein Humans Downregulated (Mean Ratio: 0.53 ±0.08) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
318 Angiotensin-converting enzyme, somatic isoform (precursor) (CD143 antigen) Protein Humans Downregulated (Mean Ratio: 0.32 ±0.09) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
319 Ankyrin repeat domain-containing protein 25 (SRC-1-interacting protein) Protein Humans Downregulated (Mean Ratio: 0.46 ±0.11) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
320 BCL2-associated athanogene 3 variant (Fragment) Protein Humans Downregulated (Mean Ratio: 0.32 ±0.11) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
321 CD44 antigen precursor (Phagocytic glycoprotein I) (Hyaluronate receptor) (Epican) Protein Humans Downregulated (Mean Ratio: 0.23 ±0.07) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
322 Cell surface glycoprotein MUC18 precursor (Melanoma cell adhesion molecule) (CD146 antigen) Protein Humans Downregulated (Mean Ratio: 0.49 ±0.08) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
323 Ciliary dynein heavy chain 10 (Axonemal beta dynein heavy chain 10) (Fragment) Protein Humans Downregulated (Mean Ratio: 0.35 ±0.05) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
324 Collagen α-1(V) chain precursor Protein Humans Downregulated (Mean Ratio: 0.41 ±0.19) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
325 Collagen α-1(VI) chain precursor Protein Humans Downregulated (Mean Ratio: 0.43 ±0.15) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
326 Flotillin-1 Protein Humans Downregulated (Mean Ratio: 0.33 ±0.10) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
327 G antigen family C member 1 (Prostate-associated gene 4 protein) Protein Humans Downregulated (Mean Ratio: 0.25 ±0.09) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
328 γ-synuclein (Persyn) (Breast cancer-specific gene 1 protein) (Synoretin) Protein Humans Downregulated (Mean Ratio: 0.18 ±0.07) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
329 Glutathione S-transferase μ-1 Protein Humans Downregulated (Mean Ratio: 0.42 ±0.09) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
330 Glutathione S-transferase π-1 Protein Humans Downregulated (Mean Ratio: 0.29 ±0.10) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
331 Hsc70-interacting protein (Hip) (Putative tumor suppressor ST13) (Progesterone receptor-associated p48 protein) Protein Humans Downregulated (Mean Ratio: 0.33 ±0.11) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
332 Insulin-degrading enzyme (Insulysin) (Insulinase) (Insulin protease) Protein Humans Downregulated (Mean Ratio: 0.38 ±0.12) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
333 Insulin-like growth factor-binding protein 7 precursor (IGFBP-7) (Prostacyclin-stimulating factor) (PGI2-stimulating factor) Protein Humans Downregulated (Mean Ratio: 0.42 ±0.10) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
334 Kallikrein-11 precursor (Hippostasin) Protein Humans Downregulated (Mean Ratio: 0.41 ±0.09) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
335 Keratin, type I cytoskeletal 17 (Cytokeratin-17) Protein Humans Downregulated (Mean Ratio: 0.38 ±0.14) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
336 Leiomodin-1 (64 kDa autoantigen 1D) Protein Humans Downregulated (Mean Ratio: 0.21 ±0.07) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
337 Microtubule-associated protein 1B (MAP 1B) Protein Humans Downregulated (Mean Ratio: 0.46 ±0.11) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
338 Olfactomedin-like protein 1 precursor Protein Humans Downregulated (Mean Ratio: 0.33 ±0.09) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
339 Phosphoglucomutase-like protein 5 (Aciculin) Protein Humans Downregulated (Mean Ratio: 0.47 ±0.10) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
340 Platelet-activating factor acetylhydrolase IB subunit α Protein Humans Downregulated (Mean Ratio: 0.42 ±0.09) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
341 Prostatic acid phosphatase [Precursor] Protein Humans Downregulated (Mean Ratio: 0.42 ±0.14) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
342 Ras-related protein R-Ras (p23) Protein Humans Downregulated (Mean Ratio: 0.31 ±0.10) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
343 Retinol binding protein I, cellular Protein Humans Downregulated (Mean Ratio: 0.28 ±0.12) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
344 Selenium binding protein 1 (SELENBP1 protein) Protein Humans Downregulated (Mean Ratio: 0.36 ±0.11) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
345 TFIIH basal transcription factor complex helicase XPB subunit (DNA-repair protein complementing XP-B) Protein Humans Downregulated (Mean Ratio: 0.32 ±0.13) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
346 Ubiquitin carboxyl-terminal hydrolase isozyme L1 (Ubiquitin thioesterase L1 Protein Humans Downregulated (Mean Ratio: 0.38 ±0.12) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
347 Vinculin (Metavinculin) Protein Humans Downregulated (Mean Ratio: 0.46 ±0.12) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
348 Zinc-α-2-glycoprotein precursor Protein Humans Downregulated (Mean Ratio: 0.43 ±0.13) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
349 Zyxin Protein Humans Downregulated (Mean Ratio: 0.45 ±0.13) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
360 IL-8 Protein Humans Upregulated in Recurrent Group (Recurrent Group: 181.1 ± 89.3; Non Recurrent Group: 96.4 ± 85.6) Prognostic Reccurance Free Survival Vs Recurrance in 5 years p<0.001 Tissue 18593988
361 Osteopontin Protein Humans Upregulated in Recurrent Group (Recurrent Group: 203.2 ± 78.4; Non Recurrent Group: 127.76 ± 76.6) Prognostic Reccurance Free Survival Vs Recurrance in 5 years p<0.001 Tissue 18593988
362 IL8 + Osteopontin Protein Humans Upregulated in Recurrent Group Prognostic Reccurance Free Survival Vs Recurrance in 5 years p<0.001 Tissue 18593988
363 Lactate Metabolites Humans Upregulated (Benign: 0.61 ± 0.28 Vs Cancerous: 1.59 ± 0.61) Diagnostic Benign Vs Malignant p<0.0001 Tissue 18727052
364 Alanine Metabolites Humans Upregulated (Benign: 0.14 ± 0.06 Vs Cancerous: 0.26 ± 0.07) Diagnostic Benign Vs Malignant p<0.0001 Tissue 18727052
365 CD31 Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.009 Tissue 18767028
366 Ki67 Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.003 Tissue 18767028
367 Her-2/neu Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.006 Tissue 18767028
368 CD31 Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.001 Tissue 18767028
369 Ki67 Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.03 Tissue 18767028
370 PCNA Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.03 Tissue 18767028
371 Her-2/neu Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.049 Tissue 18767028
372 CD31 Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.028 Tissue 18767028
373 Her-2/neu Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.025 Tissue 18767028
374 Ki67 Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.027 Tissue 18767028
375 Her-2/neu Protein Humans Negative Staining in Patients with Progression Free Survival Prognostic Progression Free Survival Vs No Progression Survival p=0.001 Tissue 18767043
376 Her-2/neu Protein Humans Negative Staining in Patients with Metastatic Free Survival Prognostic Metastatic Vs Non Metastatic Prostate cancer p=0.002 Tissue 18767043
377 Her-2/neu Protein Humans Negative Staining in Patients with PCa Death Free Survival Prognostic PCa Specific Death Vs No PCa Specific Death p=0.021 Tissue 18767043
393 Ornithine Decarboxylase (ODC) + Ornithine Decarboxylase antizyme (OAZ) +Adenosylmethionine Decarboxylase (AdoMetDC)+ Spermidine/Spermine N(1)-acetyltransferase (SSAT)+ histone H3 (H3)+ growth arrest specific gene (GAS1)+glyceraldehyde 3-phosphate dehydrogenase (GAPDH) + Clusterin (CLU) mRNA Humans Downgregulated in PCa: (GAS1,SSAT, CLU, OAZ, GAPDH); Upregulated in PCa (H3, ODC) Diagnostic Benign Vs Prostate Cancer Clusterin: p<0.01 Tissue 18974881
394 Ornithine Decarboxylase (ODC) + Ornithine Decarboxylase antizyme (OAZ) +Adenosylmethionine Decarboxylase (AdoMetDC)+ Spermidine/Spermine N(1)-acetyltransferase (SSAT)+ histone H3 (H3)+ growth arrest specific gene (GAS1)+glyceraldehyde 3-phosphate dehydrogenase (GAPDH) + Clusterin (CLU) mRNA Humans Downgregulated in PCa: (GAS1,SSAT, CLU, OAZ, GAPDH); Upregulated in PCa (H3, ODC) Prognostic Gleason Score <7 Vs Gleason Score ≥ 7 NA Tissue 18974881
395 CCL4 Protein Humans Differentially Expressed Prognostic Biochemical Recurrence Vs No Recurrence p=0.011 Tissue 19047106
396 CX3CL1 Protein Humans Differentially Expressed Prognostic Biochemical Recurrence Vs No Recurrence p<0.0001 Tissue 19047106
397 CCL4 Protein Humans Differentially Expressed Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p=0.04 Tissue 19047106
398 CX3CL1 Protein Humans Differentially Expressed Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p<0.0001 Tissue 19047106
399 PSA+Surgical Margins+ seminal vesicle invasion+ Gleason Score+CX3CL1+CCL4+IL-15 Protein Humans Differentially Expressed Prognostic Biochemical Recurrence Vs No Recurrence NA Tissue 19047106
400 Ki-67 Protein Humans Upregulated in PCa Diagnostic Localized prostate cancer Vs benign prostate p<0.01 Tissue 19050681
401 p53 Protein Humans Upregulated in PCa Diagnostic Localized prostate cancer Vs benign prostate p<0.01 Tissue 19050681
402 BCL-2 Protein Humans Upregulated in PCa Diagnostic Localized prostate cancer Vs benign prostate p<0.01 Tissue 19050681
403 Ki-67 Protein Humans Downregulated with Flaxseed supplemented Diet [ Control Diet: 3.23 (95% CI: 2.42-3.92), Flaxseed Supplementation: 1.66 (95% CI: 1.13-2.64)] Predictive Controls Vs Flaxseed Supplementation in Patients with PCa p=0.0013 Tissue 19064574
406 Androgen Receptor (AR) mRNA Humans Upregulated in Hormone Refactory Prostate Cancer (11 fold) Prognostic Hormone Naive Vs Hormone Refractory Prostate Cancer p<0.0001 Tissue 19117982
407 Androgen Receptor AR-V1 mRNA Humans Upregulated in Hormone Refactory Prostate Cancer (22 fold) Prognostic Hormone Naive Vs Hormone Refractory Prostate Cancer p<0.0001 Tissue 19117982
408 Androgen Receptor AR-V7 mRNA Humans Upregulated in Hormone Refactory Prostate Cancer (20 fold) Prognostic Hormone Naive Vs Hormone Refractory Prostate Cancer p<0.0001 Tissue 19117982
409 Androgen Receptor AR-V7 mRNA Humans Higher expression in patients with biochemical recurrence Prognostic PSA Recurrence Vs No PSA Recurrence p=0.012 Tissue 19117982
426 p53 Protein Humans Increased Expression with PCa Specific Death Prognostic Prostate Cancer Specific Survival Vs No Survival Univariate: p<0.001; Multivariate: p=0.03; Tissue 19239456
427 p53 Protein Humans Increased Expression with Overall Death Prognostic Overall Survival Vs No Survival Univariate: p<0.001; Multivariate: p=0.001; Tissue 19239456
428 p53 Protein Humans Increased Expression with PCa Specific Death Prognostic Prostate Cancer Specific Survival Vs No Survival Univariate: p=0.01; Multivariate: p=0.01; Tissue 19239456
429 p53 Protein Humans Increased Expression with Overall Death Prognostic Overall Survival Vs No Survival Univariate: p=0.001; Multivariate: p=0.004; Tissue 19239456
430 TMPRSS2 mRNA Humans Upregulated in PCa: (Normal: 0.26 ± 0.04 vs PCa: 3.91 ± 0.78) Diagnostic prostate cancer Vs Adjacent Normal p=0.001 Tissue 19242826
431 TMPRSS2 mRNA Humans Upregulated (Clinical Stage 1&2: 3.43 ± 0.62 ; Vs Clinical Stage 3: 5.45 ± 0.92) Prognostic Clincal Stage (1-2) Vs Clinical Stage 3 p=0.02 Tissue 19242826
432 TMPRSS2 mRNA Humans Upregulated (GS<6 4.64 ± 0.35 vs GS>6: 8.34 ± 1.53) Prognostic Gleason Score ≤6, Vs Gleason Score>6 p=0.008 Tissue 19242826
433 TMPRSS2 mRNA Humans Upregulated (Tumor Grade 1-2: 2.35 ± 1.45 vs Tumor Grade 3: 3.41 ± 2.31) Prognostic Tumor Grade (1-2) Vs Tumor Grade 3 p=0.016 Tissue 19242826
434 KLK11 mRNA Humans Upregulated in PCa: (Normal: 0.49 ± 0.07 vs PCa: 3.63 ± 0.42) Diagnostic prostate cancer Vs Adjacent Normal p=0.003 Tissue 19242826
435 KLK11 mRNA Humans Upregulated (CS: (1-2) 6.05 ± 1.34 vs CS 3: 3.93 ± 0.45) Prognostic Clincal Stage (1-2) Vs Clinical Stage 3 p=0.009 Tissue 19242826
436 KLK11 mRNA Humans Upregulated (GS<6 4.64 ± 0.35 vs GS>6: 8.34 ± 1.53) Prognostic Gleason Score ≤6, Vs Gleason Score>6 p=0.01 Tissue 19242826
437 KLK11 mRNA Humans Upregulated (Tumor Grade 1-2 : 2.35 ± 1.45 vs Tumor Grade 3: 3.41 ± 2.31) Prognostic Tumor Grade (1-2) Vs Tumor Grade 3 p=0.006 Tissue 19242826
438 Methylation Status of: Chromosome 20 open reading frame 103 (C20orf103); Homeobox D9 (HOXD9); Nuclear receptor subfamily, group A, member 2 (NR5A2); Distal-less homeobox 5 (DLX5); Iroquois homeobox 1 (IRX1); Spastic paraplegia 20 (SPG20); Transcription factor AP-2 alpha (TFAP2A); Wilms tumor 1 (WT1); SIX homeobox 6 (SIX6); Homeobox D4 (HOXD4) ; Transcription factor 7-like 1 (TCF7L1); Sonic hedgehog homolog (SHH); Protocadherin, gamma subfamily C,5 (PCDHG5); Methionine aminopeptidase 1D (MAP1D); Runt-related transcription factor 1 (RUNX1) Methylation Humans Hypermethylated in PCa: [Chromosome 20 open reading frame 103 (C20orf103) (3.7 fold); Homeobox D9 (HOXD9) (3.2 fold); Nuclear receptor subfamily, group A, member 2 (NR5A2) (3.1 fold); Distal-less homeobox 5 (DLX5) (3.7 fold); Iroquois homeobox 1 (IRX1) (3.0 fold); Spastic paraplegia 20 (SPG20) (3.0 fold); Transcription factor AP-2 alpha (TFAP2A) (2.9 fold); Wilms tumor 1 (WT1) (2.9 fold); SIX homeobox 6 (SIX6) (2.8 fold); Homeobox D4 (HOXD4) (2.7 fold) ; Transcription factor 7-like 1 (TCF7L1) (2.6 fold); Sonic hedgehog homolog (SHH) (2.5 fold) ; Protocadherin , gamma subfamily C,5 (PCDHG5) (2.4 fold); Methionine aminopeptidase 1D (MAP1D) (2.3 fold); Runt-related transcription factor 1 (RUNX1) (2.3 fold);] Diagnostic Cancer Vs Non Cancer p<0.05 Tissue 19283074
439 Methylation Status of: Ventral anterior homeobox 1 (VAX1); Homeobox D3 (HOXD3); CAP-GLY domain containing linker protein family (CLIP4); Calcium channel, voltage dependent, T-type, alpha 1G 2.0 subunit (CACNA1G) ; Glycoprotein V (GP5); Somatostatin receptor 1 (SSTR1); Methylthioadenosine phosporylase (MTAP); NK2 homeobox 2 (NKX2-2); Homeobox C11 (HOXC11); Ladybird homeobox 1 (LBX1); Motor neuron and pancreas homeobox 1 (MNX1); Glutamate receptor, metabotropic 1 (GRM1); LIM homeobox 9 (LHX9); Microtubule-associated protein tau (MAPT); Galactosidase, beta 1-like (GLB1L) Methylation Humans Hypermethylated in Progression (PP4): [Ventral anterior homeobox 1 (VAX1) (2.7 fold); Homeobox D3 (HOXD3) (2.3 fold); CAP-GLY domain containing linker protein family (CLIP4) (2.1 fold); Calcium channel, voltage dependent, T-type, alpha 1G 2.0 subunit (CACNA1G) (2.0 fold); Glycoprotein V (GP5) (1.9 fold); Somatostatin receptor 1 (SSTR1) (1.8 fold); Methylthioadenosine phosporylase (MTAP) (1.8 fold); NK2 homeobox 2 (NKX2-2) (1.7 fold); Homeobox C11 (HOXC11) (1.6 fold); Ladybird homeobox 1 (LBX1) (1.6 fold); Motor neuron and pancreas homeobox 1 (MNX1) (1.6 fold); Glutamate receptor, metabotropic 1 (GRM1) (1.6 fold); LIM homeobox 9 (LHX9) (1.6 fold); Microtubule-associated protein tau (MAPT) (1.5 fold); Galactosidase, beta 1-like (GLB1L) (1.5 fold)] Prognostic Gleason Score 6 (Pure pattern 3) vs Gleason Score 8 (Pure Pattern 4) p<0.05 Tissue 19283074
440 Ki-67 Protein Humans Differentially Expressed Prognostic Cause Specific Survival Vs No Survival p<0.001 Tissue 19293807
441 Ki-67 Protein Humans Differentially Expressed [Cause Specific Survial (Δχ2 = 24.6) and overall survival (Δχ2 = 20.5)] Prognostic Overall Survival Vs No Survival p<0.001 Tissue 19293807
468 DNA Ploidy - Diploid Mutation Humans DIPLOID: 5 year disease free survival - (80.5% ); 10 year disease free survival - (72.9%) Prognostic 5 and 10 years disease free survival Vs no survival p<0.001 Tissue 19633362
469 DNA Ploidy - Tetraploid Mutation Humans TETRAPLOID: 5 year disease free survival - (67.8% ); 10 year disease free survival - (61.6%) Prognostic 5 and 10 years disease free survival Vs no survival p<0.001 Tissue 19633362
470 DNA Ploidy - Aneploid Mutation Humans ANUEPLOID: 5 year disease free survival - (49.5% ); 10 year disease free survival - (31.8%) Prognostic 5 and 10 years disease free survival Vs no survival p<0.001 Tissue 19633362
471 DNA Ploidy - Diploid Mutation Humans DIPLOID: 5 year disease free survival - (88.7% ); 10 year disease free survival - (84.8%) Prognostic 5 and 10 years disease free survival Vs no survival for Gleason Score=7 p<0.001 Tissue 19633362
472 DNA Ploidy - Tetraploid Mutation Humans TETRAPLOID: 5 year disease free survival - (74.3% ); 10 year disease free survival - (64.7%) Prognostic 5 and 10 years disease free survival Vs no survival for Gleason Score=7 p<0.001 Tissue 19633362
473 DNA Ploidy - Anueploid Mutation Humans ANUEPLOID: 5 year disease free survival - (25.0% ); 10 year disease free survival - (0%) Prognostic 5 and 10 years disease free survival Vs no survival for Gleason Score=7 p<0.001 Tissue 19633362
474 CCNB1 (cyclin B1); CENPF (centromere protein F, 350/400 ka (mitosin)); BUB1B (BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast)); CLDN4 (claudin 4); KIAA0101 (KIAA0101); LOC400879 (Hypothetical gene supported by AK096951); SLC39A6 (solute carrier family 39 (zinc transporter), member 6); SOX4 (SRY (sex determining region Y)-box 4); TOP2A (topoisomerase (DNA) II alpha 170 kDa) mRNA Humans Upregulated: CCNB1 (cyclin B1) [1.8 fold]; CENPF (centromere protein F, 350/400 ka (mitosin)) [1.4 fold]; BUB1B (BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast)) [1.4 fold]; CLDN4 (claudin 4) [2.4 fold]; KIAA0101 (KIAA0101) [1.6 fold]; LOC400879 (Hypothetical gene supported by AK096951) [1.7 fold]; SLC39A6 (solute carrier family 39 (zinc transporter), member 6) [1.6 fold]; SOX4 (SRY (sex determining region Y)-box 4) [1.8 fold]; TOP2A (topoisomerase (DNA) II alpha 170 kDa) [1.7 fold] Diagnostic Tumor Vs Adjacent To Tumor p=0.05 Tissue 19652763
475 ABLIM3 (actin binding LIM protein family, member 3); AOX1 (aldehyde oxidase 1); CES1 (carboxylesterase 1 (monocyte/macrophage serine esterase 1)); DSCR1 (Down syndrome critical region gene 1); GLRX (glutaredoxin (thioltransferase)); IGFBP4 (insulin-like growth factor binding protein 4); MT1B (metallothionein 1B); MT1E (metallothionein 1E); MT1F (metallothionein 1F); MT1H (metallothionein 1H); C1QB (complement component 1, q subcomponent, B chain); CYB5R3 (cytochrome b5 reductase 3); DARC (Duffy blood group, chemokine receptor); DUSP3 (dual specifi city phosphatase 3 (vaccinia virus phosphatase VH1−related)); F13A1 (coagulation factor XIII, A1 polypeptide); FEZ1 (fasciculation and elongation protein zeta 1 (zygin I)); G0S2 (G0/G1switch 2); GAS6 (growth arrest-specifi c 6); IFITM2 (interferon induced transmembrane protein 2 (1–8D)); ITGA1 (integrin, alpha 1); MAP4 (microtubule-associated protein 4); MT1A (metallothionein 1A); MT2A (metallothionein 2A); PCMT1 (protein-L-isoaspartate (D-aspartate) O-methyltransferase); PROS1 (protein S (alpha)); RBPMS (RNA binding protein with multiple splicing); RDX (Radixin); RNF11 (ring finger protein 11); S100A8 (S100 calcium binding protein A8); SERINC1 (serine incorporator 1); SERPING1 (serpin peptidase inhibitor, clade G (C1 inhibitor), member 1, (angioedema, hereditary)); STOM (stomatin); TGFBR3 (transforming growth factor, beta receptor III); TGM2 (transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase)); WDR47 (WD repeat domain 47) mRNA Humans Downregulated: ABLIM3 (actin binding LIM protein family, member 3) [1.6 fold]; AOX1 (aldehyde oxidase 1) [2.6 fold]; CES1 (carboxylesterase 1 (monocyte/macrophage serine esterase 1)) [1.7 fold]; DSCR1 (Down syndrome critical region gene 1) [1.6 fold]; GLRX (glutaredoxin (thioltransferase)) [1.7 fold]; IGFBP4 (insulin-like growth factor binding protein 4) [2.5 fold]; MT1B (metallothionein 1B) [2.3 fold]; MT1E (metallothionein 1E) [1.9 fold]; MT1F (metallothionein 1F) [2.3 fold]; MT1H (metallothionein 1H) [2.4 fold]; C1QB (complement component 1, q subcomponent, B chain) [1.4 fold]; CYB5R3 (cytochrome b5 reductase 3) [1.4 fold]; DARC (Duffy blood group, chemokine receptor) [2.9 fold]; DUSP3 (dual specifi city phosphatase 3 (vaccinia virus phosphatase VH1−related)) [1.4 fold]; F13A1 (coagulation factor XIII, A1 polypeptide) [2.1 fold]; FEZ1 (fasciculation and elongation protein zeta 1 (zygin I)) [1.6 fold]; G0S2 (G0/G1switch 2) [2.2 fold]; GAS6 (growth arrest-specifi c 6) [2 fold]; IFITM2 (interferon induced transmembrane protein 2 (1–8D)) [2 fold]; ITGA1 (integrin, alpha 1) [1.4 fold]; MAP4 (microtubule-associated protein 4) [1.6 fold]; MT1A (metallothionein 1A) [2.6 fold]; MT2A (metallothionein 2A) [2.5 fold]; PCMT1 (protein-L-isoaspartate (D-aspartate) O-methyltransferase) [1.3 fold]; PROS1 (protein S (alpha)) [1.7 fold]; RBPMS (RNA binding protein with multiple splicing) [2.4 fold]; RDX (Radixin) [1.4 fold]; RNF11 (ring finger protein 11) [1.4 fold]; S100A8 (S100 calcium binding protein A8) [2.3 fold]; SERINC1 (serine incorporator 1) [1.5 fold]; SERPING1 (serpin peptidase inhibitor, clade G (C1 inhibitor), member 1, (angioedema, hereditary)) [2.2 fold]; STOM (stomatin) [1.8 fold]; TGFBR3 (transforming growth factor, beta receptor III) [1.7 fold]; TGM2 (transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase)) [1.8 fold]; WDR47 (WD repeat domain 47) [1.5 fold] Diagnostic Tumor Vs Adjacent To Tumor p=0.05 Tissue 19652763
476 GLUT1 Protein Humans Increased expression in Biochemical Recurrence Prognostic PSA recurrence Vs No PSA recurrence p=0.005 Tissue 19854473
492 ezrin; lamin B1; succinate dehydrogenase complex, subunit A, flavoprotein precursor; succinate dehydrogenase complex, subunit A, flavoprotein precursor; acute morphine dependence related protein 2; methylcrotonoyl Coenzyme A carboxylase 2 (beta); 3-oxoacid CoA transferase 1 precursor; CCT2; CCT2; CCT2; keratin 8; lamin A/C transcript variant 1; Chain A, X-ray Structure Of The Human mitogen activated protein kinase kinase 2 (Mek2)in A Complex; Stomatin (EPB72)-like 2; Heterogeneous nuclear ribonucleoprotein C (C1/C2), hnRNP; Heterogeneous nuclear ribonucleoprotein C (C1/C2); SEC13 homologue (S. cerevisiae); HSPC124; Enoyl Coenzyme A hydratase 1, peroxisomal; Chain A, Structure Of Inositol Monophosphatase the Putative Target Of Lithium Therapy; cathepsin D preproprotein; chloride intracellular channel 4; endoplasmic reticulum protein 29 isoform 1 precursor; heat shock 27 kDa protein 1; Chain A, Native Human Lysosomal Beta-Hexosaminidase Isoform B; thioredoxin peroxidase, peroxiredoxin 4; Chain A, Human Glyoxalase I With Benzyl-Glutathione inhibitor; Chain A, Human Glyoxalase I With Benzyl-Glutathione inhibitor; hypothetical protein LOC79017; ATP synthase, H+ transporting, mitochondrial F0; Ferritin, light polypeptide; nonmetastatic cells 1, protein (NM23A) expressed in isoform a; keratin-10; ubiquitin-conjugating enzyme E2N; fatty acid binding protein 5 (psoriasis-associated); Protein Humans Upregulated ratio in LNMPCA: ezrin [2.4]; lamin B1 [2.76]; succinate dehydrogenase complex, subunit A, flavoprotein precursor [2.22]; succinate dehydrogenase complex, subunit A, flavoprotein precursor [1.86]; acute morphine dependence related protein 2 [1.94]; methylcrotonoyl Coenzyme A carboxylase 2 (beta) [5.27]; 3-oxoacid CoA transferase 1 precursor [1.90]; CCT2 [2.74]; CCT2 [2.22]; CCT2 [1.82]; keratin 8 [4.19]; lamin A/C transcript variant 1 [3.66]; Chain A, X-ray Structure Of The Human mitogen activated protein kinase kinase 2 (Mek2)in A Complex [2.95]; Stomatin (EPB72)-like 2 [2.10]; Heterogeneous nuclear ribonucleoprotein C (C1/C2), hnRNP [2.25]; Heterogeneous nuclear ribonucleoprotein C (C1/C2) [2.01]; SEC13 homologue (S. cerevisiae) [2.62]; HSPC124 [4.70]; Enoyl Coenzyme A hydratase 1, peroxisomal [3.79]; Chain A, Structure Of Inositol Monophosphatase the Putative Target Of Lithium Therapy [2.39]; cathepsin D preproprotein [2.49]; chloride intracellular channel 4 [2.16]; endoplasmic reticulum protein 29 isoform 1 precursor [2.54]; heat shock 27 kDa protein 1 [3.47]; Chain A, Native Human Lysosomal Beta-Hexosaminidase Isoform B [4.62]; thioredoxin peroxidase, peroxiredoxin 4 [2.12]; Chain A, Human Glyoxalase I With Benzyl-Glutathione inhibitor [4.19]; Chain A, Human Glyoxalase I With Benzyl-Glutathione inhibitor [4.56]; hypothetical protein LOC79017 [3.15]; ATP synthase, H+ transporting, mitochondrial F0 [2.46]; Ferritin, light polypeptide [2.49]; nonmetastatic cells 1, protein (NM23A) expressed in isoform a [2.99]; keratin-10 [3.84]; ubiquitin-conjugating enzyme E2N [2.23]; fatty acid binding protein 5 (psoriasis-associated) [20.86]; Prognostic Lymph Node Metastatic Prostate Cancer Vs Localised PCA p<0.05 Tissue 19894759
493 collagen, type VI, alpha 1 precursor; vinculin isoform meta-VCL; FLNA protein; gelsolin isoform b; transferrin; transferrin; lamin A/C transcript variant 1; archain; Dihydropyrimidinase-like 3; mutant desmin; PREDICTED: similar to actin, alpha 1, skeletal muscle isoform 2; Chain A, human B lactate dehydrogenase complexed with NAD+ and Hydroxy-1,2,5-Oxadiazole-3-Carbox; splicing factor, arginine/ serine-rich 1 isoform 1; Unknown (protein for IMAGE:3906970); ubiquitin carboxy-terminal hydrolase L1; Chain A, Ligand-Free Human Glutathione S-Transferase M2–2; Chain A, Crystal Structure Of Human Glutathione S-Transferase P1-1 Complexed With (9r,10r)-9; regulatory myosin light chain long version; smooth muscle protein (SM22); haptoglobin-related protein precursor; smooth muscle protein (SM22); smooth muscle protein (SM22); Chain A, X-ray Crystal Structure Of Human Galectin-1; Protein Humans Downregulated ratio in LNMPCA: collagen, type VI, alpha 1 precursor [2.15]; vinculin isoform meta-VCL [3.47]; FLNA protein [1.99]; gelsolin isoform b [2.15]; transferrin [2.04]; transferrin [2.15]; lamin A/C transcript variant 1 [2.06]; archain [1.63]; Dihydropyrimidinase-like 3 [1.86]; mutant desmin [2.38]; PREDICTED: similar to actin, alpha 1, skeletal muscle isoform 2 [2.89]; Chain A, human B lactate dehydrogenase complexed with NAD+ and Hydroxy-1,2,5-Oxadiazole-3-Carbox [2.68]; splicing factor, arginine/ serine-rich 1 isoform 1 [2.6]; Unknown (protein for IMAGE:3906970) [2.04]; ubiquitin carboxy-terminal hydrolase L1 [2.78]; Chain A, Ligand-Free Human Glutathione S-Transferase M2–2 [3.32]; Chain A, Crystal Structure Of Human Glutathione S-Transferase P1-1 Complexed With (9r,10r)-9 [2.85]; regulatory myosin light chain long version [4.25]; smooth muscle protein (SM22) [13.98]; haptoglobin-related protein precursor [6.16]; smooth muscle protein (SM22) [5.08]; smooth muscle protein (SM22) [3.30]; Chain A, X-ray Crystal Structure Of Human Galectin-1 [2.46]; Prognostic Lymph Node Metastatic Prostate Cancer Vs Localised PCA p<0.05 Tissue 19894759
494 transglutaminase 2 isoform a; TPM1 protein; FTH1 protein; S100 calcium binding protein A9; splicing factor, arginine/ serine-rich 1 isoform 1; chromatin modifying protein 4B; Protein Humans Upregulated ratio in Localised PCA: transglutaminase 2 isoform a [2.03]; TPM1 protein [4.18]; FTH1 protein [2.28]; S100 calcium binding protein A9 [3.81]; splicing factor, arginine/ serine-rich 1 isoform 1 [2.07]; chromatin modifying protein 4B [2.16]; Diagnostic Localized PCa and BPH p<0.05 Tissue 19894759
495 keratin 5; mutant desmin; histone cluster 2, H2bf; Protein Humans Downregulated ratio in Localised PCA: keratin 5 [2.08]; mutant desmin [2.03]; histone cluster 2, H2bf [2.02]; Diagnostic Localized PCa and BPH p<0.05 Tissue 19894759
498 e-FABP5, MCCC2, PPA2, Ezrin, and SLP2 Protein Humans Upregulated in LNM PCa Prognostic Lymph Node Metastatic Prostate Cancer Vs Localised PCA p<0.01 Tissue 19894759
499 SM22 Protein Humans Downregulated in LNM PCa Prognostic Lymph Node Metastatic Prostate Cancer Vs Localised PCA p<0.01 Tissue 19894759
500 Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP)[Fixed DNA (Gene) Humans Differentially Expressed Prognostic Biochemical recurrence (within 1 year ) Vs No recurrence (24 months) NA Tissue 20028763
501 Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) [Floating] DNA (Gene) Humans Differentially Expressed Prognostic Biochemical recurrence (within 1 year ) Vs No recurrence (24 months) NA Tissue 20028763
502 Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) [Integrated] DNA (Gene) Humans Differentially Expressed Prognostic Biochemical recurrence (within 1 year ) Vs No recurrence (24 months) NA Tissue 20028763
503 ANXA5; APLP2; COL1A2; CRIM1; ECHS1; HMGB1; MAP3K5; NGFRAP1; NPM1; NUB1; PDIA3; PLA2G2A; ROCK1; TEGT; TMEM16G; TMEM69; TRAF4; VCAN; VCP; VDAC1; mRNA Humans Differentially Expressed: ANXA5 [1.47 fold]; APLP2 [1.22 fold]; COL1A2 [1.18 fold]; CRIM1 [1.20 fold]; ECHS1 [1.18 fold]; HMGB1 [1.40 fold]; MAP3K5 [1.35 fold]; NGFRAP1 [1.32 fold]; NPM1 [1.30 fold]; NUB1 [1.12 fold]; PDIA3 [1.43 fold]; PLA2G2A [1.75 fold]; ROCK1 [1.17 fold]; TEGT [1.32 fold]; TMEM16G [0.66 fold]; TMEM69 [1.08 fold]; TRAF4 [1.26 fold]; VCAN [1.31 fold]; VCP [1.18 fold]; VDAC1 [1.51 fold]; Prognostic Gleason Score 6 Vs Gleason Score (8-10) p<0.05 Tissue 20035634
504 ANXA5; APLP2; COL1A2; CRIM1; ECHS1; HMGB1; MAP3K5; NGFRAP1; NPM1; NUB1; PDIA3; PLA2G2A; ROCK1; TEGT; TMEM16G; TMEM69; TRAF4; VCAN; VCP; VDAC1; mRNA Humans Differentially Expressed: ANXA5 [4.28 fold]; APLP2 [2.83 fold]; COL1A2 [2.02 fold]; CRIM1 [3.23 fold]; ECHS1 [1.89 fold]; HMGB1 [4.68 fold]; MAP3K5 [2.98 fold]; NGFRAP1 [3.95 fold]; NPM1 [3.07 fold]; NUB1 [1.62 fold]; PDIA3 [2.40 fold]; PLA2G2A [3.00 fold]; ROCK1 [9.76 fold]; TEGT [2.77 fold]; TMEM16G [0.35 fold]; TMEM69 [2.77 fold]; TRAF4 [2.59 fold]; VCAN [2.92 fold]; VCP [2.75 fold]; VDAC1 [5.41 fold]; Prognostic Gleason Score 6 Vs Gleason Score (8-10) p<0.05 Tissue 20035634
505 MAP3K5 mRNA Humans Upregulated in Gleason Score 8-10 Prognostic Gleason Score 6 Vs Gleason Score (8-10) qRT-PCR: p=0.0129 Tissue 20035634
506 PDIA3 mRNA Humans Upregulated in Gleason Score 8-10 Prognostic Gleason Score 6 Vs Gleason Score (8-10) qRT-PCR: p=0.00167 Tissue 20035634
507 TRPM8 (transient receptor potential member 8) mRNA Humans Upregulated in PCa Diagnostic Tumors Vs patient matched non-tumor NA Tissue 20043080
508 TRPM8 (transient receptor potential member 8) mRNA Humans Upregulated in PCa (ratio = 1.94±0.256) Diagnostic Tumors Vs patient matched non-tumor p<0.01 Tissue 20043080
511 TMPRSS2–ERG mRNA Humans Fusion Positive in Recurrence Prognostic Biochemical recurrence Vs No recurrence p=0.0000000354 Tissue 20068566
512 ERG expression in TMPRSS2–ERG mRNA Humans Upregulated in Fusion (3.07-fold) Prognostic ERG Fusion Vs No Fusion p=3.48E-11 Tissue 20068566
513 CSPG2+ WNT10B+E2F3+CDKN2A+TYMS+TGFB3+ALOX12+CD44+LAF4 mRNA Humans Upregulated with Biochemical Recurrence Prognostic Biochemical recurrence Vs No recurrence Univariate: p=0.0000002; Multivariate: p=0.0270 Tissue 20068566
519 EGFR [SNP rs884419] Mutation Humans AG And GG Phenotypes associated with decreased risk of recurrence Prognostic Biochemical recurrence Vs No recurrence A/G Phenotype: p= 0.0018; G/G Phenotype: p = 0.0016 Tissue 20303520
520 CB:SA ratio: (cathepsin B/stefin A) Protein Humans Upregulated in Cancer: (BPH Geometric Mean : 1.448 Vs Cancer Geometric Mean : 2.990) Diagnostic benign prostatic hyperplasia Vs Prostate Cancer p=0.0001 Tissue 20392989
521 CB:SA ratio: (cathepsin B/stefin A) Protein Humans Upregulated in Cancer (Gleason Score 6): (BPH Geometric Mean : 1.448 Vs GS6 Geometric Mean : 3.452) Diagnostic benign prostatic hyperplasia Vs Prostate Cancer (Gleason Score 6) p=0.0003 Tissue 20392989
522 CB:SA ratio: (cathepsin B/stefin A) Protein Humans Upregulated in Cancer (Gleason Score 7): (BPH Geometric Mean : 1.448 Vs GS7: Geometric Mean : 2.756) Diagnostic benign prostatic hyperplasia Vs Prostate Cancer (Gleason Score 7) p=0.0052 Tissue 20392989
529 miRNA-375 miRNA Humans Upregulated in PCa Diagnostic Tumor Vs Normal p<0.001 Tissue 20473869
530 miRNA-141 miRNA Humans Upregulated in PCa Diagnostic Tumor Vs Normal p<0.001 Tissue 20473869
531 KLK15 (kallikrein-related peptidase) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Adjacent p = 0.045 Tissue 20473923
532 KLK15 (kallikrein-related peptidase) Protein Humans High levels associated with shorter progression-free survival. Prognostic PSA recurrence Vs No PSA recurrence Univariate: p = 0.002; Multivariate: p=0.037; StepWise Inclusion: p=0.032 Tissue 20473923
538 SPATA19 mRNA Humans Upregulated in PCa (Increased Prostate cancer risk with High expression) Diagnostic Benign Prostatic Hyperplasia Vs Prostate Cancer p<0.0001 Tissue 20682177
539 LEMD1 mRNA Humans Upregulated in PCa (Increased Prostate cancer risk with High expression) Diagnostic Benign Prostatic Hyperplasia Vs Prostate Cancer p=0.012 Tissue 20682177
540 MMP-9 % Protein Humans Increased expression in Recurrence free survival Prognostic Biochemical Recurrence Vs No Recurrence p=0.03 Tissue 20889560
541 MMP-9 intensity Protein Humans Increased expression in Disease Specific Mortality Prognostic Disease Specific Mortality Vs No Mortality p<0.001 Tissue 20889560
542 MMP-9 intensity Protein Humans Increased expression in Overall Mortality Prognostic Overall Mortality Vs No Mortality p<0.001 Tissue 20889560
555 Fructose-bisphosphate aldolase A; Isocitrate dehydrogenase; Citrate synthase; L-Lactate dehydrogenase A; ATP synthase gamma chain; Alpha-enolase; Phosphoglycerate mutase 1; Malate dehydrogenase; Core protein II; Transketolase; 60 kDa heat shock protein; Flotillin 1; 26S protease regulatory subunit 8; Annexin A2; Protein Humans Upregulated (with Regulation Coefficient): Fructose-bisphosphate aldolase A [1.15]; Isocitrate dehydrogenase [1.09]; Citrate synthase [1.18]; L-Lactate dehydrogenase A [1.40]; ATP synthase gamma chain [1.28]; Alpha-enolase [1.48]; Phosphoglycerate mutase 1 [1.56]; Malate dehydrogenase [1.64]; Core protein II [1.19]; Transketolase [1.31]; 60 kDa heat shock protein [1.83]; Flotillin 1 [1.07]; 26S protease regulatory subunit 8 [1.14]; Annexin A2 [1.29]; Diagnostic Gleason 6 Vs Benign Prostate p<0.05 Tissue 20977276
556 Lamin A; Cytokeratin-1; Mimecan; Prostatic acid phosphatase; Prostate-specific antigen; Protein Humans Downregulated (with Regulation Coefficient): Lamin A [-1.52]; Cytokeratin-1 [-1.09]; Mimecan [-1.08]; Prostatic acid phosphatase [-2.85]; Prostate-specific antigen [-1.15]; Diagnostic Gleason 6 Vs Benign Prostate p<0.05 Tissue 20977276
557 Fructose-bisphosphate aldolase A; Isocitrate dehydrogenase; Citrate synthase; L-Lactate dehydrogenase A; ATP synthase gamma chain; Alpha-enolase; Phosphoglycerate mutase 1; Malate dehydrogenase; Core protein II; Transketolase; 60 kDa heat shock protein; Lamin A; Flotillin 1; Cytokeratin-1; Mimecan; 26S protease regulatory subunit 8; Annexin A2; Protein Humans Upregulated (with Regulation Coefficient): Fructose-bisphosphate aldolase A [1.85]; Isocitrate dehydrogenase [1.79]; Citrate synthase [1.76]; L-Lactate dehydrogenase A [1.75]; ATP synthase gamma chain [1.7]; Alpha-enolase [1.67]; Phosphoglycerate mutase 1 [1.65]; Malate dehydrogenase [1.64]; Core protein II [1.61]; Transketolase [1.59]; 60 kDa heat shock protein [2.13]; Lamin A [2.08]; Flotillin 1 [1.85]; Cytokeratin-1 [1.65]; Mimecan [1.58]; 26S protease regulatory subunit 8 [1.47]; Annexin A2 [1.46]; Prognostic Gleason Score 6 Vs Gleason Score 8 and above p<0.05 Tissue 20977276
558 Prostatic acid phosphatase; Prostate-specific antigen; Protein Humans Downregulated (with Regulation Coefficient): Prostatic acid phosphatase [-1.84]; Prostate-specific antigen [-3.04]; Prognostic Gleason Score 6 Vs Gleason Score 8 and above p<0.05 Tissue 20977276
559 HSP60 Protein Humans Upregulated in PCa Diagnostic Gleason 6 Vs Benign Prostate p<0.05 Tissue 20977276
560 Lamin A Protein Humans Upregulated in GS 8 and above Prognostic Gleason Score 6 Vs Gleason Score 8 and above p<0.05 Tissue 20977276
561 C8orf4; TMC5; PDLIM5; JAG1; HOXA9; C4A; STEAP4; HLA-DMB; COL12A1; DHRS8; C10orf137; SLC7A1; PDZRN3; F3; ACER3; POLB; PXDN; PROM2; GUCY1A3; SOX4; mRNA Humans Upregulated (Fold Change): [C8orf4 (5.14 fold); TMC5 (4.83 fold) ; PDLIM5 (4.51 fold); JAG1 (4.36 fold); HOXA9 (4.25 fold) ; C4A (3.98 fold); STEAP4 (3.92 fold); HLA-DMB (3.85fold); COL12A1 (3.81 fold); DHRS8 (3.81 fold); C10orf137 (3.62 fold); SLC7A1 (3.44 fold); PDZRN3 (3.30 fold); F3 (3.26 fold) ; ACER3 (3.17fold); POLB (3.16 fold); PXDN (3.12 fold); PROM2 (3.11 fold); GUCY1A3 (3.10 fold); SOX4 (3.02 fold);] Diagnostic High BMI Tumor Vs High BMI Normal p<0.05 Tissue 21060327
562 ACADL; PHLDA2; GPD1; L; NTAN1; LOC389048; SFN; HSRG1; PAK1IP1; EBP; ANPEP; ANTXR2; COL4A6; LOC400880; RHOU; GREB1; FLJ30428; C3orf14; ZNF532; SCD; PTN; SC4MOL; MAF; NPAL3; CYP3A5; NOV; ALOX15B; LOC399959; VGL-3; INSIG1; Rcan3; Poteg; P704P; EFS; mRNA Humans Downregulated (Fold Change): [ACADL (0.33 fold); PHLDA2 (0.33 fold); GPD1L (0.33 fold); NTAN1 (0.33 fold); LOC389048 (0.32 fold); SFN (0.32 fold); HSRG1 (0.32 fold); PAK1IP1 (0.32 fold); EBP (0.31 fold); ANPEP (0.31 fold); ANTXR2 (0.29 fold); COL4A6 (0.29 fold); LOC400880 (0.29 fold); RHOU (0.29 fold); GREB1 (0.28 fold); FLJ30428 (0.27 fold); C3orf14 (0.27 fold); ZNF532 (0.26 fold); SCD (0.25 fold); PTN (0.24 fold); SC4MOL (0.24 fold); MAF (0.22 fold); NPAL3 (0.22 fold); CYP3A5 (0.21 fold); NOV (0.20 fold); ALOX15B (0.17 fold); LOC399959 (0.17 fold); VGL-3 (0.16 fold); INSIG1 (0.16 fold); Rcan3 (0.15 fold); Poteg (0.14 fold); P704P (0.13 fold); EFS (0.13 fold)] Diagnostic High BMI Tumor Vs High BMI Normal p<0.05 Tissue 21060327
580 Methylation Status of [A4GALT; ADAM8; ALOX15B; BIK; CCK; CRCP; CTSC; CXCL2; CXCL3; CYBA; EIF4B; GSTM1 ; GSTM2; IGF2; LTF; MCAM; PDCD1; PDPN; PKMYT1; PPP1R3C; RAB32; RFTN1; SERPINB1; SLC16A5; SOCS1; TIMP3; TNF] Methylation Humans HyperMethylated in PCa ( Positive Fold change): [A4GALT(2.0 fold) ; ADAM8(3.9 fold); ALOX15B(5.1fold, 2.7 fold); BIK(2.6 fold); CCK(9.3 fold); CRCP(2.1fold); CTSC(3.7 fold); CXCL2(3.2 fold); CXCL3(3.0fold); CYBA(3.8 fold); EIF4B(3.5 fold); GSTM1 (20.5 fold); GSTM2(4.1 fold); IGF2(4.2 fold); LTF(2.1 fold); MCAM(2.7 fold); PDCD1(3.2 fold); PDPN(4.5 fold); PKMYT1(2.9 fold); PPP1R3C(8.2 fold) ; RAB32(3.3 fold); RFTN1(5.5 fold); SERPINB1(2.4 fold); SLC16A5(17.2fold, 4.2 fold); SOCS1(2.6 fold); TIMP3(2.2 fold); TNF(2.0 fold)] Diagnostic Tumor Vs Tumor Adjacent p=0.013 Tissue 21237555
581 Methylation Status of [ALDH1A3; NR4A2; PF4; RELB; SOCS1; TNFRSF1B; ZBTB11; ZNF365] Methylation Humans HypoMethylated in PCa: ( Negative Fold change): [ALDH1A3(2.6 fold); NR4A2(2.5 fold); PF4(3.4 fold); RELB(2.1 fold); SOCS1(8.2 fold); TNFRSF1B(3.0 fold); ZBTB11(2.9 fold); ZNF365(5.0 fold)] Diagnostic Tumor Vs Tumor Adjacent p=0.013 Tissue 21237555
582 GSTP1, BCL2, ADCY4, CACNA1G, LOC63928, and D4S234E mRNA Humans Downregulated Diagnostic Tumor Vs Tumor Adjacent p<0.05 Tissue 21237555
583 β-microseminoprotein (MSMB) Protein Humans increased expression with decreased biochemical recurrence-free survival Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.001 Tissue 21240253
584 SLCO1B1; SLCO1B3; SLCO2A1; SLCO3A1; mRNA Humans Upregulated in CRPC metastases: SLCO1B1 (5.5 fold); SLCO1B3( 3.6 fold); SLCO2A1 (3.2 fold); SLCO3A1 (5.4 fold); Prognostic CRPC metastases versus untreated prostate cancer p<0.053 Tissue 21266523
587 Tropomyosin β chain fibroblast and epithelia, Keratin type II cytoskeletal 8 Cytokeratin 8 K, 14-3-3 protein γ protein kinase C inhibitor p, Protein disulfide isomerase precursor PDI EC 5, Keratin type I cytoskeletal 19 Cytokeratin 19, Actin muscle type A2, Desmin, α1 antitrypsin precursor, Tubulin β2 chain, 78 kDa glucose regulated protein prec GRP 78, Rho GDP dissociation inhibitor 1, Creatine kinase B chain EC 2 7 3 2 B CK, Fibrinogen γ chain precursor, Heat shock cognate 71 kDa protein, Stress 70 protein mitochondrial precursor 75 kD, Heat shock 70 kDa protein 1 HSP70 1a, Enoyl CoA hydratase mitochprecursor EC 4, Prohibitin, Apolipoprotein A I precursor Apo AI, ATP synthase β chain mitochondrial precursor, Small nuclear ribonucleoprotein 200 kDa helicas, Glycerol 3 phosphate acyltransferase EC 2 3 1 15, Keratin type I cytoskeletal 18 Cytokeratin 18, Serum albumin precursor, Annexin A4 Lipocortin IV Endonexin, Serum albumin precursor, 60 kDa heat shock protein mitochondrial precursor. Protein Humans Differentially Expressed Diagnostic BPH Vs Prostate Cancer p<0.05 Tissue 21305254
588 Annexin A4 (ANXA4); Apolipoprotein A-I (APOA1); ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B); Creatine kinase, brain (CKB); Desmin (DES); Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1); Fibrinogen γ chain (FGG); Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5); Heat shock 60 kDa protein 1 (chaperonin) (HSPD1); Prolyl 4-hydroxylase, β polypeptide (P4HB); Prohibitin (PHB); Serpin peptidase inhibitor, clade A (α-1 antiproteinase, antitrypsin), member 1) (SERPINA1); Protein Humans Upregulated in Gleason Score 7(Fold Change) : Annexin A4 (ANXA4) [1.000]; Apolipoprotein A-I (APOA1) [2.691]; ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B) [7.440]; Creatine kinase, brain (CKB) [1.000]; Desmin (DES) [2.059]; Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1) [2.335]; Fibrinogen γ chain (FGG) [7.634]; Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5) [2.339]; Heat shock 60 kDa protein 1 (chaperonin) (HSPD1) [1.000]; Prolyl 4-hydroxylase, β polypeptide (P4HB) [11.540]; Prohibitin (PHB) [1.000]; Serpin peptidase inhibitor, clade A (α-1 antiproteinase, antitrypsin), member 1) (SERPINA1) [2.992]; Prognostic Gleason Score 5 Vs Gleason Score 7 p<0.05 Tissue 21305254
589 Albumin (ALB); Rho GDP dissociation inhibitor (GDI) α (ARHGDIA); Keratin 18 (KRT18); Keratin 19 (KRT19); Keratin 8 (KRT8); Protein Humans Downregulated in Gleason Score 7(Fold Change) : Albumin (ALB) [2.155]; Rho GDP dissociation inhibitor (GDI) α (ARHGDIA) [2.571]; Keratin 18 (KRT18) [3.322]; Keratin 19 (KRT19) [4.950]; Keratin 8 (KRT8) [4.950]; Prognostic Gleason Score 5 Vs Gleason Score 7 p<0.05 Tissue 21305254
590 Albumin (ALB); Annexin A4 (ANXA4); Apolipoprotein A-I (APOA1); ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B); Fibrinogen γ chain (FGG); Protein Humans Upregulated in Stage T3 (Fold Change) : Albumin (ALB) [2.684]; Annexin A4 (ANXA4) [1.000]; Apolipoprotein A-I (APOA1) [2.691]; ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B) [1.000]; Fibrinogen γ chain (FGG) [1.000]; Prognostic Stage T2 Vs Stage T3 p<0.05 Tissue 21305254
591 Rho GDP dissociation inhibitor (GDI) α (ARHGDIA); Desmin (DES); Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1); Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5); Keratin 18 (KRT18); Keratin 19 (KRT19); Keratin 8 (KRT8); Protein Humans Downregulated in Stage T3(Fold Change) : Rho GDP dissociation inhibitor (GDI) α (ARHGDIA) [2.165]; Desmin (DES) [8.929]; Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1) [7.407]; Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5) [1.613]; Keratin 18 (KRT18) [3.322]; Keratin 19 (KRT19) [4.950]; Keratin 8 (KRT8) [4.950]; Prognostic Stage T2 Vs Stage T3 p<0.05 Tissue 21305254
596 Engrailed-2 (EN2) Protein Humans Upregulated in PCa Diagnostic Biopsy Positive Vs Biopsy Negative p<0.05 Tissue 21364037
599 vascular endothelial growth factor (VEGF) Protein Humans Upregulated in PCa Diagnostic BPH Vs Prostate Cancer p<0.001 Tissue 21367627
600 matrix metalloproteinase-9 (MMP-9) Protein Humans Upregulated in PCa Diagnostic BPH Vs Prostate Cancer p=0.004 Tissue 21367627
601 vascular endothelial growth factor (VEGF) Protein Humans Upregulated in Lymph Node Metastatis Prognostic Lymph Node Metastatis Posititve Lymph Node Metastatis Negative p<0.001 Tissue 21367627
602 matrix metalloproteinase-9 (MMP-9) Protein Humans Upregulated in Lymph Node Metastatis Prognostic Lymph Node Metastatis Posititve Lymph Node Metastatis Negative p<0.001 Tissue 21367627
603 Stromal cell-derived factor-1 (SDF-1) Protein Humans Upregulated in Lymph Node Metastatis Prognostic Lymph Node Metastatis Posititve Lymph Node Metastatis Negative p<0.001 Tissue 21367627
604 Stromal cell-derived factor-1 (SDF-1) Protein Humans Patients with low levels survived longer than those with high levels Prognostic Prostate Cancer Specific Survival VS No Survival Univariate: p<0.001; Multivariate: p=0.017 Tissue 21367627
605 vascular endothelial growth factor (VEGF) Protein Humans Patients with low levels survived longer than those with high levels Prognostic Prostate Cancer Specific Survival VS No Survival Univariate: p<0.001; Multivariate: p<0.001 Tissue 21367627
606 matrix metalloproteinase-9 (MMP-9) Protein Humans Patients with low levels survived longer than those with high levels Prognostic Prostate Cancer Specific Survival VS No Survival p<0.001 Tissue 21367627
607 let-7a; miR-101; miR-106a; miR-106b; miR-1274; miR-141; miR-17; miR-182; miR-1826; miR-200b; miR-200c; miR-20a; miR-20b; miR-21; miR-375; miR-720; miR-768-3p; miR-93 miRNA Humans Upregulated in PCa(Fold Change): let-7a(1.53 fold) ; miR-101(1.13 fold) ; miR-106a(2.41 fold); miR-106b(1.70 fold); miR-1274(1.87 fold); miR-141(1.44 fold); miR-17(2.69 fold); miR-182(2.39 fold) ; miR-1826(1.73 fold) ; miR-200b( 1.54 fold) ; miR-200c( 2.92 fold); miR-20a(2.67 fold); miR-20b(2.81 fold); miR-21( 1.40 fold); miR-375(3.90 fold) ; miR-720(1.41 fold); miR-768-3p(1.67 fold); miR-93(2.52 fold) Diagnostic Prostate Cancer Vs Normal p<0.001 Tissue 21400514
608 miR-136-star; miR-145; miR-214; miR-221; miR-222; miR-302d-star; miR-378-star miRNA Humans Downregulated in PCa (Fold Change): miR-136-star(1.18 fold) ; miR-145(1.44 fold); miR-214(1.74 fold); miR-221(2.16 fold) ; miR-222(2.91 fold) ; miR-302d-star(1.13 fold); miR-378-star(1.30 fold) Diagnostic Prostate Cancer Vs Normal p<0.001 Tissue 21400514
609 miRNA- 375; miRNA-143; miRNA-145 (Individual assesment) miRNA Humans Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 145 Diagnostic Prostate Cancer Vs Normal miRNA- 375 (p=0.002) ; miRNA-143 (p=0.001); miRNA-145 (p<0.0001); Tissue 21400514
610 miRNA- 375 + miRNA-143+ miRNA-145 (Combined assesment) miRNA Humans Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 146 Diagnostic Prostate Cancer Vs Normal p<0.0001 Tissue 21400514
611 miRNA- 375; miRNA-143; miRNA-145 (Individual assesment) miRNA Humans Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 147 Diagnostic Prostate Cancer Vs Normal miRNA- 375 (p=0.005) ; miRNA-143 (p=0.005); miRNA-145 (p<0.0001); Tissue 21400514
612 miRNA- 375 + miRNA-143+ miRNA-145 (Combined assesment) miRNA Humans Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 148 Diagnostic Prostate Cancer Vs Normal p<0.0001 Tissue 21400514
613 miRNA- 375; miRNA-143; miRNA-145 (Individual assesment) miRNA Humans Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 149 Diagnostic Prostate Cancer Vs Normal miRNA- 375 (p<0.0001) ; miRNA-143 (p<0.0001); miRNA-145 (p<0.0001); Tissue 21400514
614 miRNA- 375 + miRNA-143+ miRNA-145 (Combined assesment) miRNA Humans Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 150 Diagnostic Prostate Cancer Vs Normal p<0.0001 Tissue 21400514
636 40S ribosomal protein S8; Heterogeneous nuclear ribonucleoprotein H; 78 kDa glucose-regulated protein; Cytochrome c oxidase polypeptide VIc; Cytochrome c oxidase subunit 5B, mitochondrial ATP synthase subunit beta, mitochondrial Stress-70 protein, mitochondrial Biglycan; Elongation factor Tu mitochondrial; Ubiquitin-like modifier-activating enzyme 1; Protein disulfide-isomerase A4; Heterochromatin protein 1-binding protein 3; Tumor protein D52 Prohibitin-2; Protein disulfide-isomerase; EH domain-containing protein 2; 60 kDa heat shock protein mitochondrial; Nucleophosmin Periostin; Sorbitol dehydrogenase Protein Humans Upregulated in PCA(Fold Change) : Diagnostic Prostate Cancer Vs BPH p<0.05 Tissue 21504578
637 Desmin; Serum deprivation-response protein 3; Sorbin and SH3 domain-containing protein 1; Vimentin; Calponin-1; Heat shock protein beta-1; Actin, gamma-enteric smooth muscle; Protein kinase C delta-binding protein; Collagen alpha-1(VI) chain Laminin subunit gamma-1; Sorbin and SH3 domain-containing protein 2; Tenascin; Zyxin; Talin-1; Collagen alpha-1(I) chain; Vinculin; Mimecan; Lipoma-preferred partner; Neuroblast differentiation-associated protein AHNAK; Decorin; Basement membrane-specific heparan sulfate proteoglycan core protein; Phosphatidylethanolamine-binding protein 1 Protein Humans Downregulated in PCA(Fold Change): Diagnostic Prostate Cancer Vs BPH p<0.05 Tissue 21504578
638 Neuroblast differentiation-associated protein AHNAK; Glutamate dehydrogenase 1, mitochondrial; Protein disulfide-isomerase A4; Cytochrome c oxidase subunit 5B, mitochondrial; Collagen alpha-3(VI) chain; Heterogeneous nuclear ribonucleoprotein H; 10 kDa heat shock protein, mitochondrial; Elongation factor Tu, mitochondrial; 78 kDa glucose-regulated protein; Myosin-9; Protein disulfide-isomerase; Biglycan; Nucleoside diphosphate kinase B; 60 kDa heat shock protein, mitochondrial; Periostin; 60S ribosomal protein L10a Nucleophosmin; Asporin; Sorbitol dehydrogenase; Protein Humans Upregulated in PCA(Fold Change) : Diagnostic Prostate Cancer Vs BPH with Local PIN p<0.05 Tissue 21504578
639 Desmin; Myosin regulatory light polypeptide 9; Serum deprivation-response protein 3; Sorbin and SH3 domain- containing protein 1; Tropomyosin alpha-1 chain; Protein kinase C delta-binding protein; Calponin-1; Vinculin; Prostatic acid phosphatase; Zyxin; Fibrinogen alpha chain; Histone H1.0; Talin-1; Protein disulfide-isomerase A3; Protein Humans Downregulated in PCA(Fold Change): Diagnostic Prostate Cancer Vs BPH with Local PIN p<0.05 Tissue 21504578
640 Periostin Protein Humans Upregulated in PCA Diagnostic Prostate Cancer Vs BPH with Local PIN p<0.01 Tissue 21504578
641 Ki-67 Protein Humans Upregulated in Black men Prognostic Prostate Cancer in Black Men Vs Prostate Cancer in White Men Univariate: p=0.02; Multivariate: =0.002 Tissue 21519348
642 Norm AR (Androgen Receptor) Protein Humans Upregulated in Black men Prognostic Prostate Cancer in Black Men Vs Prostate Cancer in White Men Univariate: p=0.006; Multivariate: p=0.001 Tissue 21519348
643 Ki-67/lum Protein Humans Upregulated in Black men Prognostic Prostate Cancer in Black Men Vs Prostate Cancer in White Men p=0.022 Tissue 21519348
655 enhancer of zeste homologue 2 (EZH2) Protein Humans Progression Vs No Progression Prognostic Progression Free Survival Vs No Progression Free Survival p=0.004 Tissue 21592298
656 minichromosome maintenance protein 7 (MCM7) Protein Humans Progression Vs No Progression Prognostic Progression Free Survival Vs No Progression Free Survival p<0.001 Tissue 21592298
657 Ki-67 Protein Humans Increased expression in patients with Progression Prognostic Progression Free Survival Vs No Progression Free Survival p<0.001 Tissue 21592298
665 MKI67 (Ki-67) + TOP2A (DNA topoisomerase II, alpha) + E2F1 (E2F transcription factor 1) Genes Humans TOP2A, E2F1: Increased expression with earlier Biochemical Recurrence, Prognostic PSA Reccurence Vs No Recurrence for 8 years p=0.001 Tissue 21629784
666 PSA+ Grade + Stage +MKI67 (Ki-67) + TOP2A (DNA topoisomerase II, alpha) + E2F1 (E2F transcription factor 1) Genes Humans TOP2A, E2F1: Increased expression with earlier Biochemical Recurrence, Prognostic PSA Reccurence Vs No Recurrence for 8 years p=0.005 Tissue 21629784
667 NA miRNA Humans Downregulated in Bone Metastatis: Prognostic Primary vs Bone Metastatis p<0.05 Tissue 21647377
668 NA miRNA Humans Upregulated in Bone Metastatis: Prognostic Primary vs Bone Metastatis p<0.05 Tissue 21647377
669 miR-143 miRNA Humans Downregulated in Bone Metastatis: 12.9 fold Prognostic Primary vs Bone Metastatis p=0.012 Tissue 21647377
670 miR-145 miRNA Humans Downregulated in Bone Metastatis: 17.3 fold Prognostic Primary vs Bone Metastatis p=0.014 Tissue 21647377
671 miR-143 miRNA Humans Downregulated in Bone Metastatis Prognostic Bone Metastatis Vs No Bone Metastasis p=0.039 Tissue 21647377
672 miR-145 miRNA Humans Downregulated in Bone Metastatis Prognostic Bone Metastatis Vs No Bone Metastasis p=0.041 Tissue 21647377
673 Androgen Receptor mRNA Humans Downregulated in PCa Diagnostic Tumor Vs Normal Tissues p=0.018 Tissue 21667031
685 miR-96; miR-182; miR-32; miR-221; miR-25; miR-93; miR-182*; miR-106b; miR-183; miR-153; miR-602; miR-455-5p; miR-205 miR-183*; miR-425; miR-375; miR-193b; miR-30e*; miR-95; miR-378; miR-455-3p; miR-133a; miR-873; miR-222; miR-21; miR-142-3p; miR-575 ;miR-130b; miR-339-3p; miR-149; miR-338-3p; miR-19a; miR-148a; miR-146b-5p; miR-125a-5p; miR-27b; miR-10b*; miR-141; miR-7; miR-505; miR-30c-1*; miR-145*; miR-145; miR-125b; miR-99a; miR-378*; miR-583; miR-221*; miR-20a; miR-124; miR-103; miR-542-5p; miR-193b*; miR-940 miRNA Humans Differentially Expressed (Fold Change): [miR-96 (2.12 fold); miR-182 (2.02 fold); miR-32 (2.01 fold); miR-221 (2.27 fold); miR-25 (1.53 fold); miR-93 (1.61 fold); miR-182* (2.25 fold); miR-106b (1.56 fold); miR-183 (2.18 fold); miR-153 (2.74 fold); miR-602 (1.57 fold); miR-455-5p (2.01 fold); miR-205 (6.29 fold); miR-183* (1.8 fold); miR-425 (1.66 fold); miR-375 (1.72 fold); miR-193b (1.58 fold); miR-30e* (1.32 fold); miR-95 (378 fold); miR-378 (1.65 fold); miR-455-3p (2.12 fold); miR-133a (2.19 fold); miR-873 (2.3 fold); miR-222 (2.17 fold); miR-21 (1.71 fold); miR-142 -3p (1.65 fold); miR-575 (1.7 fold) ;miR-130b (1.62 fold); miR-339-3p (1.19 fold); miR-149 (1.82 fold); miR-338-3p (1.96 fold); miR-19a (1.4 fold); miR-148a (1.63 fold); miR-146b-5p (1.68 fold); miR-125a-5p (1.41 fold); miR-27b (1.27 fold); miR-10b* (1.94 fold); miR-141 (1.42 fold); miR-7 (1.76 fold); miR-505 (1.33 fold); miR-30c-1* (1.41 fold); miR-145* (2.01 fold); miR-145 (2.01 fold); miR-125b (1.37 fold); miR-99a (1.34 fold); miR-378* (1.97 fold); miR-583 (1.82 fold); miR-221* (2.1 fold); miR-20a (1.4 fold); miR-124 (1.67 fold); miR-103 (1.21 fold); miR-542-5p (1.77 fold); miR-193b* (1.68 fold); miR-941 (1.52 fold)] Diagnostic Prostate Cancer (PCa)Vs Normal Adjacent Prostate (NAP) p= 0.0046 Tissue 21765474
686 miR-96; miR-182; miR-32; miR-221; miR-25; miR-93; miR-182*; miR-106b; miR-183; miR-153; miR-602; miR-455-5p; miR-205 miR-183*; miR-425; miR-375; miR-193b; miR-30e*; miR-95; miR-378; miR-455-3p; miR-133a; miR-873; miR-222; miR-21; miR-142-3p; miR-575 ;miR-130b; miR-339-3p; miR-149; miR-338-3p; miR-19a; miR-148a; miR-146b-5p; miR-125a-5p; miR-27b; miR-10b*; miR-141; miR-7; miR-505; miR-30c-1*; miR-145*; miR-145; miR-125b; miR-99a; miR-378*; miR-583; miR-221*; miR-20a; miR-124; miR-103; miR-542-5p; miR-193b*; miR-941 miRNA Humans Differentially Expressed (Fold Change): [miR-96 (2.12 fold); miR-182 (2.02 fold); miR-32 (2.01 fold); miR-221 (2.27 fold); miR-25 (1.53 fold); miR-93 (1.61 fold); miR-182* (2.25 fold); miR-106b (1.56 fold); miR-183 (2.18 fold); miR-153 (2.74 fold); miR-602 (1.57 fold); miR-455-5p (2.01 fold); miR-205 (6.29 fold); miR-183* (1.8 fold); miR-425 (1.66 fold); miR-375 (1.72 fold); miR-193b (1.58 fold); miR-30e* (1.32 fold); miR-95 (378 fold); miR-378 (1.65 fold); miR-455-3p (2.12 fold); miR-133a (2.19 fold); miR-873 (2.3 fold); miR-222 (2.17 fold); miR-21 (1.71 fold); miR-142 -3p (1.65 fold); miR-575 (1.7 fold) ;miR-130b (1.62 fold); miR-339-3p (1.19 fold); miR-149 (1.82 fold); miR-338-3p (1.96 fold); miR-19a (1.4 fold); miR-148a (1.63 fold); miR-146b-5p (1.68 fold); miR-125a-5p (1.41 fold); miR-27b (1.27 fold); miR-10b* (1.94 fold); miR-141 (1.42 fold); miR-7 (1.76 fold); miR-505 (1.33 fold); miR-30c-1* (1.41 fold); miR-145* (2.01 fold); miR-145 (2.01 fold); miR-125b (1.37 fold); miR-99a (1.34 fold); miR-378* (1.97 fold); miR-583 (1.82 fold); miR-221* (2.1 fold); miR-20a (1.4 fold); miR-124 (1.67 fold); miR-103 (1.21 fold); miR-542-5p (1.77 fold); miR-193b* (1.68 fold); miR-941 (1.52 fold)] Diagnostic Prostate Cancer (PCa)Vs Normal Adjacent Prostate (NAP) p= 0.0046 Tissue 21765474
687 miR-139-5p; miR-1; miR-133b; miR-133a; miR-143*; miR-145*; miR-143; miR-145; miR-27b, miR-221; miR-222; miR-378; miR-204; miR-141*; miR-32; let-7b; miR-183*, miR-301b; miR-106b; miR-93; miR-25; miR-183; miR-96; miR-425; miR-663 miRNA Humans NA Prognostic group I (good prognosis) from group II (poor prognosis) p=0.0005 Tissue 21765474
698 PCAT-1 ncRNA Humans Upregulated in a subset of metastatic and high-grade localized (Gleason score ≥7) cancers Prognostic High grade tumor vs. low grade tumor/non-tumor NA Tissue 21804560
703 Methylation Status of RARB Methylation Humans Hypermethylated in Cancer Prognostic Methylation in Patients with PCa NA Tissue 21822036
720 Katanin p60 Protein Humans Upregulated in PCa Prognostic bone metastasis (Met) Vs No bone metastasis (controls) p<0.05 Bone Marrow (Tissue) 21681775
721 Methylation Status of APC Methylation Humans Hypermethylated in PCa Diagnostic negative histology followed by a positive biopsy less than 24 months later NA Tissue 19755651
722 Methylation Status of RAR-2β Methylation Humans Hypermethylated in PCa Diagnostic negative histology followed by a positive biopsy less than 24 months later NA Tissue 19755651
723 Methylation Status of GST-Pi Methylation Humans Hypermethylated in PCa Diagnostic negative histology followed by a positive biopsy less than 24 months later NA Tissue 19755651
752 CEP55 Protein Humans Upregulated in Patients with Recurrence Prognostic PSA Reccurence Vs No Recurrence p<0.0001 Tissue 21917134
753 NUF2 Protein Humans Upregulated in Patients with Recurrence Prognostic PSA Reccurence Vs No Recurrence p<0.0001 Tissue 21917134
754 PAGE4 Protein Humans Downregulated in Patients with Recurrence Prognostic PSA Reccurence Vs No Recurrence p=0.0045 Tissue 21917134
755 CEP55 Protein Humans Upregulated with high Gleason Score Prognostic Gleason Score (≤6, (3+4), (4+3), 8-10) For Hazrard Ratio: (p = 0.003) Tissue 21917134
756 NUF2 Protein Humans Upregulated with high Gleason Score Prognostic Gleason Score (≤6, (3+4), (4+3), 8-10) For Hazrard Ratio: (p = 0.002) Tissue 21917134
757 PBK Protein Humans Upregulated with high Gleason Score Prognostic Gleason Score (≤6, (3+4), (4+3), 8-10) For Hazrard Ratio: (p = 0.001) Tissue 21917134
758 TTK Protein Humans Upregulated with high Gleason Score Prognostic f For Hazrard Ratio: (p = 0.002) Tissue 21917134
759 PAGE4 Protein Humans Downregulated with high Gleason Score Prognostic Gleason Score (≤6, (3+4), (4+3), 8-10) For Hazrard Ratio: (p = 0.002) Tissue 21917134
760 OPNa (osteopontin -a ) mRNA Humans Upregulated in Cancerous Conditions (PCA: Median: 62.43; BPH: Median: 0.20) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.05 Tissue 21963599
761 OPNb (osteopontin -b ) mRNA Humans Upregulated in Cancerous Conditions (PCA: Median: 43.47; BPH: Median: 0.50) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.05 Tissue 21963599
762 OPNc (osteopontin -c ) mRNA Humans Upregulated in Cancerous Conditions (PCA: Median: 200.36; BPH: Median: 0.0) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.05 Tissue 21963599
764 OPNa+OPNb+OPNc mRNA Humans Upregulated in Cancerous Conditions Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.05 Tissue 21963599
765 OPNa+OPNb+OPNc+PSA mRNA Humans Upregulated in Cancerous Conditions Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.05 Tissue 21963599
766 OPNc+PSA mRNA Humans Upregulated in Cancerous Conditions Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.05 Tissue 21963599
767 OPNa (osteopontin -a ) mRNA Humans Upregulated with high Gleason Score (Median for GS< 7: 0.35, Median for GS ≥ 7: 84.54) Prognostic Gleason Score <7 Vs Gleason Score ≥ 7 p= 0.006 Tissue 21963599
768 OPNb (osteopontin -b ) mRNA Humans Upregulated with high Gleason Score (Median for GS< 7: 3.54, Median for GS ≥ 7: 61.19) Prognostic Gleason Score <7 Vs Gleason Score ≥ 7 p = 0.003 Tissue 21963599
769 OPNa (osteopontin -a ) mRNA Humans Upregulated with high Gleason Score (Median for GS< 7: 112.06, Median for GS ≥ 7: 526.39) Prognostic Gleason Score <7 Vs Gleason Score ≥ 7 p= 0.001 Tissue 21963599
770 miR-7; miR-126; miR-144; miR-144*; miR-335*; miR-374a;miR-374a*; miR-28-3p; miR-542-3p miRNA Humans Upregulated: [miR-7: (3.22 fold); miR-126: (14.45 fold); miR-144 (6.78 fold);miR-144* (12.98 fold); miR-335* (1.39 fold) ; miR-374a (2.43 fold) ; miR-374a (1.16 fold) ; miR-28-3p (1.69 fold); miR-542-3p (3.72 fold)] Prognostic Metastatic Vs Non Metastatic p<0.001 Tissue 21980368
771 miR-7-1*; miR-126*; miR-335; miR-28-5p; miR-339-3p; miR-339-5p; miR-542-5p miRNA Humans Downregulated: [miR-7-1* (8.88 fold); miR-126* (3.46b fold); miR-335 (2,42 fold); miR-28-5p (6.84 fold); miR-339-3p (-1.57 fold); miR-339-5p (5.26 fold); miR-542-5p (13.31 fold)] Prognostic Metastatic Vs Non Metastatic p<0.001 Tissue 21980368
786 AMACR+CSTA+HPN+MYO6+LAMB3+ABCC4 mRNA Humans Upregulated: [ABCC4, AMACR, HPN and MYO6]; Downregulated: [CSTA and LAMB3] Diagnostic Tumor Vs Normal Tissues p<0.001 Tissue 22009027
804 Methylation of GSTP1 Methylation Humans Hypermethylated in PCa Prognostic negative histology followed by a positive biopsy more than 24 months later NA Tissue 22077694
805 Methylation of APC Methylation Humans Hypermethylated in PCa Prognostic negative histology followed by a positive biopsy more than 24 months later P=0.012 Tissue 22077694
806 Methylation of GSTP1 + APC Methylation Humans Hypermethylated in PCa Prognostic negative histology followed by a positive biopsy more than 24 months later NA Tissue 22077694
813 TGFβ1 (transforming growth factor beta 1) mRNA Humans Associated with Prostate cancer specific Survival Prognostic disease specific survival Vs no survival p=0.0 Tissue 22113713
814 (IL-7) Interleukin-7 mRNA Humans Associated with Prostate cancer specific Survival Prognostic disease specific survival Vs no survival p=0.03 Tissue 22113713
815 miRNA - 221 and miRNA-222 miRNA Humans Upregulated in aggressive Prostate Cancer (Aggressive: 20.1 ± 2.4; Non Aggressive: 3.4 ± 0.2) Prognostic Agressive Vs Non - Agressive Prostate Cancer p=0.001 Tissue 22117988
816 ARHI mRNA Humans Downregulated in aggressive Prostate Cancer (Aggressive:9.6 ± 1.2; Non Agressive: 8.3 ± 2.3 ) Prognostic Agressive Vs Non - Agressive Prostate Cancer p=0.001 Tissue 22117988
821 Methylation Status of AIM1 Methylation Humans Decreased hypermethylation in progression Prognostic Time To Progression Univariate: p = 0.02 ; Multivariate: p = 0.05 Tissue 22127895
822 TDRD1 mRNA Humans Upregulated in Prostate cancer Diagnostic Benign Vs Tumor p<0.05 Tissue 22142399
823 TDRD1 mRNA Humans Upregulated in TMPRSS2-ERG gene fusion (36 fold) compared to benign samples and TMPRSS2-ERG gene fusion compared to non fusion (23 fold). Prognostic Benign Vs TMPRSS2-ERG gene fusion Vs non-fusion TMPRSS2-ERG positive tumors compared to normal (p = 1.77*10^-9) and fusion-negative samples (p = 1.51*10^-9) Tissue 22142399
824 CRISP3 mRNA Humans Upregulated in Prostate cancer Diagnostic Benign Vs Tumor p<0.05 Tissue 22142399
825 CRISP3 mRNA Humans Upregulated in TMPRSS2-ERG gene fusion (37 fold) compared to benign samples, normal and fusion-negative tumor samples (FC = 1.2) Diagnostic Benign Vs TMPRSS2-ERG gene fusion Vs non-fusion TMPRSS2-ERG positive tumors compared to normal tissue (p = 2.2*10-12), normal and fusion-negative tumor samples (p = 0.03) Tissue 22142399
826 CRISP3, AMACR , OR51E2, SPRR2F , TDRD1, F5, ACSM1, C20orf74, GOLM1 , MYC, CACNA1D, SFRP4, TRIB1, GDF15, LRRN1, FOLH1 , PRR16, LUZP2, RRM2, ERG, COL1A1, DNAH5, ZNF417 , SPON2, RICS, HIPK2 , ACACA , TUG1, COQ6 , LARP1, NETO2, FLJ20184, FASN, NEDD4L, LOC286161, MAOA, XPO6, ABCC4, RAB3B, TMEM45B, IMPDH2, DAPK1, LOC100131821 , C19orf48, KIAA1244 , GPI , HIVEP1, NAALADL2, C11orf92, THBS4, MYO6, BAMBI, ZNF462, SPOCK1, REPS2, SGEF, TBC1D16, TRIM36, LBH, AGPAT3, CAMKK2, GCNT1, F2R, BAT2L , LRIG1, GLYATL1 , DDX21, PLA1A, TMEFF2, SLC7A1, KIAA0368, PCDHB13 , UGT2B10 , EEF2 , C10orf137 , MICAL2, BGN, BICC1 , EIF4A1 , STX19, CHD6, ASPN, PTPN13, RAB3IP, ZNF146, BCOR, SH3RF1, TMTC4, ZDHHC9, MS4A8B, UTRN, DIP2B, UAP1, C4A , HDLBP, KIF5C, PMEPA1, GRPR , ZNF217, HUWE1, ZNF417 , AAK1 , CCDC6, BRD2, CRKRS, TP53INP1, ABCA1 , H2BFS , LIG3, PHF12, FAM117B, MED13L, TMEM2, PLA2G7, DICER1, SRRM2, BAGE2 , USP54, MYH10, SLC36A1, SLC7A11, LOC651907 , CREB3L1, ATP13A5 , ATP2B1, ANKRD34B, BAZ2A, C10orf12, POSTN, CALR3 , ZNF828, CS, ERGIC1, BXDC1, EIF4G1, PRKCSH, ABHD2, SIM2, NUFIP2, SPP1, RPL9P11 , HSN2 , JAG1, TPX2, MOSC1, TMEM161B , C4orf18 , BAT2L, DDAH1, NOLC1, ANKRD17, LOC100130958 , CMTM4, APOF, GALNT7, SETD5, HIST1H3B, TSPAN13, EPCAM, MLL, ADAR, EGR1, DNAJC10, MLEC, SEL1L, HYOU1, COL1A2, PSD3, MYO10 , ENC1 , BAT2D1, DDI2 , KDM2A , ENO1, C20orf191 , EP300, ALDH1A3, FAM119A , SLC27A2, C9orf91, TKT, NCL , ABHD2, STK33, ACTG2, IGJ, SLC26A4, SLC39A2, ZNF701 , COCH , BZW1 , CCDC68, PTPLA, VSNL1, GCNT2 , RND3, SCN7A, CYP27A1, CYP3A5 , GJA1, GSTM3, CFL2, C2 , HBB, SPATA6, KRT23, GPR87, MPPED2, HIST1H4C, OGN, LRCH2, C12orf75, NTN4, LOC100188947 , NEFH, SRD5A2, ADAM32, DPT, AZGP1, ACSS3, SLC15A2, PROM1, CACNA2D1, CXCL13, MME, ZNF483, L3MBTL4, APLF , CHRDL1, HIST1H1A, LEPREL1, ARMCX1, ANGPT1, MT1M , DSC3, B3GALT2, SLC22A3, ANO5, MT1G, PCP4, ANXA1 , PLN, EAF2 , ANPEP, TCEAL2 , LTF, PRDM5, LOC100134430 , ATRNL1, KRT15, SPOCK3, PI15, CD177, GDEP, CD38, FLRT3, SLC18A2, AOX1, MSMB, TGM4, OLFM4, SLC14A1, AMY1A mRNA Humans Differentially expressed (Log fold change) [CRISP3 ( 2.93 fold); , AMACR ( 2.85 fold); , OR51E2 ( 2.46 fold); , SPRR2F ( 2.36 fold); , TDRD1 ( 2.31 fold); , F5 ( 2.23 fold); , ACSM1 ( 2.23 fold); , C20orf74 ( 2.05 fold); , GOLM1 ( 2.01 fold); , MYC ( 1.83 fold); , CACNA1D ( 1.73 fold); , SFRP4 ( 1.68 fold); , TRIB1 ( 1.68 fold); , GDF15 ( 1.67 fold); , LRRN1 ( 1.67 fold); , FOLH1 ( 1.66 fold); , PRR16 ( 1.59 fold); , LUZP2 ( 1.58 fold); , RRM2 ( 1.57 fold); , ERG ( 1.57 fold); , COL1A1 ( 1.57 fold); , DNAH5 ( 1.57 fold); , ZNF417 ( 1.56 fold); , SPON2 ( 1.56 fold); , RICS ( 1.55 fold); , HIPK2 ( 1.54 fold); , ACACA ( 1.54 fold); , TUG1 ( 1.51 fold); , COQ6 ( 1.5 fold); , LARP1 ( 1.49 fold); , NETO2 ( 1.49 fold); , FLJ20184 ( 1.48 fold); , FASN ( 1.48 fold); , NEDD4L ( 1.47 fold); , LOC286161 ( 1.46 fold); , MAOA ( 1.45 fold); , XPO6 ( 1.43 fold); , ABCC4 ( 1.43 fold); , RAB3B ( 1.42 fold); , TMEM45B ( 1.42 fold); , IMPDH2 ( 1.39 fold); , DAPK1 ( 1.38 fold); , LOC100131821 ( 1.38 fold); , C19orf48 ( 1.37 fold); , KIAA1244 ( 1.36 fold); , GPI ( 1.35 fold); , HIVEP1 ( 1.34 fold); , NAALADL2 ( 1.34 fold); , C11orf92 ( 1.34 fold); , THBS4 ( 1.33 fold); , MYO6 ( 1.31 fold); , BAMBI ( 1.31 fold); , ZNF462 ( 1.3 fold); , SPOCK1 ( 1.3 fold); , REPS2 ( 1.28 fold); , SGEF ( 1.28 fold); , TBC1D16 ( 1.27 fold); , TRIM36 ( 1.27 fold); , LBH ( 1.26 fold); , AGPAT3 ( 1.26 fold); , CAMKK2 ( 1.25 fold); , GCNT1 ( 1.24 fold); , F2R ( 1.24 fold); , BAT2L ( 1.24 fold); , LRIG1 ( 1.23 fold); , GLYATL1 ( 1.23 fold); , DDX21 ( 1.23 fold); , PLA1A ( 1.22 fold); , TMEFF2 ( 1.22 fold); , SLC7A1 ( 1.22 fold); , KIAA0368 ( 1.22 fold); , PCDHB13 ( 1.21 fold); , UGT2B10 ( 1.21 fold); , EEF2 ( 1.2 fold); , C10orf137 ( 1.2 fold); , MICAL2 ( 1.2 fold); , BGN ( 1.19 fold); , BICC1 ( 1.19 fold); , EIF4A1 ( 1.19 fold); , STX19 ( 1.18 fold); , CHD6 ( 1.18 fold); , ASPN ( 1.18 fold); , PTPN13 ( 1.18 fold); , RAB3IP ( 1.18 fold); , ZNF146 ( 1.18 fold); , BCOR ( 1.17 fold); , SH3RF1 ( 1.17 fold); , TMTC4 ( 1.16 fold); , ZDHHC9 ( 1.16 fold); , MS4A8B ( 1.16 fold); , UTRN ( 1.16 fold); , DIP2B ( 1.15 fold); , UAP1 ( 1.15 fold); , C4A ( 1.15 fold); , HDLBP ( 1.15 fold); , KIF5C ( 1.14 fold); , PMEPA1 ( 1.14 fold); , GRPR ( 1.14 fold); , ZNF217 ( 1.13 fold); , HUWE1 ( 1.13 fold); , ZNF417 ( 1.13 fold); , AAK1 ( 1.13 fold); , CCDC6 ( 1.12 fold); , BRD2 ( 1.12 fold); , CRKRS ( 1.12 fold); , TP53INP1 ( 1.12 fold); , ABCA1 ( 1.12 fold); , H2BFS ( 1.12 fold); , LIG3 ( 1.11 fold); , PHF12 ( 1.11 fold); , FAM117B ( 1.11 fold); , MED13L ( 1.11 fold); , TMEM2 ( 1.11 fold); , PLA2G7 ( 1.11 fold); , DICER1 ( 1.11 fold); , SRRM2 ( 1.1 fold); , BAGE2 ( 1.1 fold); , USP54 ( 1.1 fold); , MYH10 ( 1.1 fold); , SLC36A1 ( 1.1 fold); , SLC7A11 ( 1.1 fold); , LOC651907 ( 1.1 fold); , CREB3L1 ( 1.1 fold); , ATP13A5 ( 1.09 fold); , ATP2B1 ( 1.09 fold); , ANKRD34B ( 1.09 fold); , BAZ2A ( 1.08 fold); , C10orf12 ( 1.08 fold); , POSTN ( 1.08 fold); , CALR3 ( 1.07 fold); , ZNF828 ( 1.07 fold); , CS ( 1.07 fold); , ERGIC1 ( 1.07 fold); , BXDC1 ( 1.07 fold); , EIF4G1 ( 1.06 fold); , PRKCSH ( 1.06 fold); , ABHD2 ( 1.06 fold); , SIM2 ( 1.06 fold); , NUFIP2 ( 1.06 fold); , SPP1 ( 1.06 fold); , RPL9P11 ( 1.06 fold); , HSN2 ( 1.05 fold); , JAG1 ( 1.05 fold); , TPX2 ( 1.05 fold); , MOSC1 ( 1.04 fold); , TMEM161B ( 1.04 fold); , C4orf18 ( 1.04 fold); , BAT2L ( 1.04 fold); , DDAH1 ( 1.04 fold); , NOLC1 ( 1.03 fold); , ANKRD17 ( 1.03 fold); , LOC100130958 ( 1.03 fold); , CMTM4 ( 1.03 fold); , APOF ( 1.03 fold); , GALNT7 ( 1.02 fold); , SETD5 ( 1.02 fold); , HIST1H3B ( 1.02 fold); , TSPAN13 ( 1.02 fold); , EPCAM ( 1.02 fold); , MLL ( 1.02 fold); , ADAR ( 1.02 fold); , EGR1 ( 1.02 fold); , DNAJC10 ( 1.02 fold); , MLEC ( 1.02 fold); , SEL1L ( 1.01 fold); , HYOU1 ( 1.01 fold); , COL1A2 ( 1.01 fold); , PSD3 ( 1.01 fold); , MYO10 ( 1.01 fold); , ENC1 ( 1.01 fold); , BAT2D1 ( 1.01 fold); , DDI2 ( 1.01 fold); , KDM2A ( 1.01 fold); , ENO1 ( 1.01 fold); , C20orf191 ( 1.01 fold); , EP300 ( 1.01 fold); , ALDH1A3 ( 1.01 fold); , FAM119A ( 1.01 fold); , SLC27A2 ( 1.0 fold); , C9orf91 ( 1.0 fold); , TKT ( 1.0 fold); , NCL ( 1.0 fold); , ABHD2 ( 1.0 fold); , STK33 ( -1.0 fold); , ACTG2 ( -1.01 fold); , IGJ ( -1.01 fold); , SLC26A4 ( -1.01 fold); , SLC39A2 ( -1.01 fold); , ZNF701 ( -1.01 fold); , COCH ( -1.02 fold); , BZW1 ( -1.03 fold); , CCDC68 ( -1.03 fold); , PTPLA ( -1.04 fold); , VSNL1 ( -1.04 fold); , GCNT2 ( -1.05 fold); , RND3 ( -1.05 fold); , SCN7A ( -1.05 fold); , CYP27A1 ( -1.05 fold); , CYP3A5 ( -1.05 fold); , GJA1 ( -1.06 fold); , GSTM3 ( -1.07 fold); , CFL2 ( -1.09 fold); , C2 ( -1.09 fold); , HBB ( -1.1 fold); , SPATA6 ( -1.1 fold); , KRT23 ( -1.11 fold); , GPR87 ( -1.11 fold); , MPPED2 ( -1.11 fold); , HIST1H4C ( -1.11 fold); , OGN ( -1.12 fold); , LRCH2 ( -1.12 fold); , C12orf75 ( -1.12 fold); , NTN4 ( -1.12 fold); , LOC100188947 ( -1.12 fold); , NEFH ( -1.13 fold); , SRD5A2 ( -1.15 fold); , ADAM32 ( -1.16 fold); , DPT ( -1.16 fold); , AZGP1 ( -1.16 fold); , ACSS3 ( -1.17 fold); , SLC15A2 ( -1.17 fold); , PROM1 ( -1.18 fold); , CACNA2D1 ( -1.18 fold); , CXCL13 ( -1.18 fold); , MME ( -1.18 fold); , ZNF483 ( -1.19 fold); , L3MBTL4 ( -1.19 fold); , APLF ( -1.21 fold); , CHRDL1 ( -1.21 fold); , HIST1H1A ( -1.23 fold); , LEPREL1 ( -1.25 fold); , ARMCX1 ( -1.25 fold); , ANGPT1 ( -1.26 fold); , MT1M ( -1.27 fold); , DSC3 ( -1.29 fold); , B3GALT2 ( -1.29 fold); , SLC22A3 ( -1.3 fold); , ANO5 ( -1.31 fold); , MT1G ( -1.31 fold); , PCP4 ( -1.32 fold); , ANXA1 ( -1.32 fold); , PLN ( -1.32 fold); , EAF2 ( -1.33 fold); , ANPEP ( -1.35 fold); , TCEAL2 ( -1.39 fold); , LTF ( -1.4 fold); , PRDM5 ( -1.42 fold); , LOC100134430 ( -1.42 fold); , ATRNL1 ( -1.42 fold); , KRT15 ( -1.43 fold); , SPOCK3 ( -1.44 fold); , PI15 ( -1.44 fold); , CD177 ( -1.46 fold); , GDEP ( -1.47 fold); , CD38 ( -1.53 fold); , FLRT3 ( -1.58 fold); , SLC18A2 ( -1.69 fold); , AOX1 ( -1.72 fold); , MSMB ( -1.74 fold); , TGM4 ( -1.76 fold); , OLFM4 ( -1.85 fold); , SLC14A1 ( -1.95 fold); , AMY1A ( -2.11 fold)] Diagnostic Benign Vs Tumor p<0.006857824 Tissue 22142399
829 Secreted frizzled-related protein (SFRP)-2 Protein Humans Downregulated in Prostate cancer (PCa: 2.28 ± 0.33 Vs Controls: 1.11 ± 0.09) Diagnostic Benign Vs malignant prostate glands p<0.0001 Tissue 22175903
830 Secreted frizzled-related protein (SFRP)-2 Protein Humans Upregulated in Gleason Grade 5 (PCa: 3.16 ± 0.99; Control: 0.77±0.15) Prognostic Gleason Grade 3,4 Vs Gleason Grade 5 p<0.0001 Tissue 22175903
834 Mutation Status of StAR Mutation Humans Allelic Loss in StAR in Recurrence Prognostic Biochemical Recurrenece (5 years) p=0.00269 Tissue 22213075
835 Mutation Status of HSD17B2 Mutation Humans Allelic Loss in HSD17B2 in Recurrence Prognostic Biochemical Recurrenece (5 years) p=0.031 Tissue 22213075
836 Mutation Status of StAR or HSD17B2 Mutation Humans Allelic Loss in atleast one (HSD17B2 or StaR) in Recurrence Prognostic Biochemical Recurrenece (5 years) p=0.0028 Tissue 22213075
842 breast cancer antiestrogen resistance 1 (BCAR1) Protein Humans Significantly associated with Biochemical Relapse Prognostic Biochemical Recurrence p=0.02 Tissue 22241677
882 ANRIL; H19; PCA3; MALAT1; PCGEM1; PTENP1 LncRNA Humans Differentially expressed (Median Fold Change): [ANRIL (MFD: −1.17 fold); H19 (MFD: 1.32 fold); PCA3 (MFD: 14.3 fold); MALAT1 (MFD: −1.64 fold); PCGEM1 (MFD: 1.75 fold); PTENP1 (MFD: −1.34 fold);] Diagnostic Primary Vs Normal p<0.01 Tissue 22371711
883 ANRIL; H19; PCA3; MALAT1 LncRNA Humans Differentially expressed (Median Fold Change): [ANRIL (MFD: 1.49 fold); H19 (MFD: 1.43 fold); PCA3 (MFD: 4.46 fold); MALAT1 (MFD: -3.33 fold)] Diagnostic Metastatic Vs Normal p<0.01 Tissue 22371711
884 ANRIL; H19; PCA3; MALAT1; PCGEM1; PTENP1 LncRNA Humans Differentially expressed (Median Fold Change): [ANRIL (MFD: 1.33 fold); H19 (MFD: -1.12 fold); PCA3 (MFD: -3.44 fold); MALAT1 (MFD: -2.63 fold); PCGEM1 (MFD: -4 fold); PTENP1 (MFD: 1.50 fold);] Diagnostic Metastatic Vs Primary p<0.04 Tissue 22371711
885 miR145; miR221; miRNA Humans Differentially expressed (Median Fold Change): [miR145 (MFD: -7.98 fold); miR221 (MFD: -2.11 fold);] Diagnostic Metastatic Vs Normal p<0.01 Tissue 22371711
886 miR143; miR145; miR221; miRNA Humans Differentially expressed (Median Fold Change): [miR143 (MFD: -1.78 fold); miR145 (MFD: -4.77 fold); miR221 (MFD: -1.52 fold);] Diagnostic Metastatic Vs Primary p<0.04 Tissue 22371711
887 kallikrein-related peptide 4 (KLK4) mRNA Humans Downregulated in genistein treated patients compared to placebo treated Predictive Treated with Placebo Vs Treated with Genistein (30mg capsule) p=0.033 Tissue 22397815
888 NK3 homeobox 1 (NKX3-1) Protein Humans Downregulated in Gleason Grade 3 Diagnostic Normal Prostate Vs Gleason Grade 3 p=0.012 Tissue 22397815
889 Methylation Status of TBX15 Methylation Humans Highly methylated in ERG positive fusion compared to ERG negative fusion Prognostic ERG positive fusion compared to ERG negative fusion in Prostate cancer p<0.01 Tissue 22452941
890 Methylation Status of HOXD3 Methylation Humans Highly methylated in ERG positive fusion compared to ERG negative fusion Prognostic ERG positive fusion compared to ERG negative fusion in Prostate cancer p<0.01 Tissue 22452941
891 Methylation Status of CYP26A1 Methylation Humans Highly methylated in ERG positive fusion compared to ERG negative fusion Prognostic ERG positive fusion compared to ERG negative fusion in Prostate cancer p≤0.041 Tissue 22452941
892 Methylation Status of HOXD3 Methylation Humans Differentially Expressed Prognostic Pathological Stage (pT2 Vs pT3/pT4) p=0.026 Tissue 22452941
893 Methylation Status of TBX15 Methylation Humans Differentially Expressed Prognostic Pathological Stage (pT2 Vs pT3/pT4) p=0.010 Tissue 22452941
894 Methylation Status of HOXD3 Methylation Humans Differentially Expressed Prognostic Gleason score as ≤ 7 Vs 8 and above p<0.001 Tissue 22452941
895 Methylation Status of TBX15 or HOXD3 Methylation Humans Differentially Expressed Prognostic Disease specific survival Vs no survival p=0.044 Tissue 22452941
900 Transthyretin (TTR) Protein Humans Upregulated in Prostate Cancer Diagnostic Normal Tissue Vs BPH Vs PCa p<0.01 Tissue 22496929
901 Clusterin (CLU) Protein Humans Upregulated in Prostate Cancer Diagnostic Normal Tissue Vs BPH Vs PCa p<0.01 Tissue 22496929
903 ERG mRNA Humans Upregulated in TMPRSS2-ERG positive fusion cases Prognostic TMPRSS2-ERG positive fusion compared to TMPRSS2-ERG negative fusion in Prostate cancer p<0.0001 Tissue 22505341
904 SPINK1 mRNA Humans Upregulated in TMPRSS2-ERG negative fusion cases Prognostic TMPRSS2-ERG positive fusion compared to TMPRSS2-ERG negative fusion in Prostate cancer p=0.03 Tissue 22505341
905 ERG mRNA Humans Upregulated in TERT positive cases Prognostic TERT positive compared to TERT negative in Prostate cancer p=0.016 Tissue 22505341
911 Minichromosome Maintenance Complex Protein 2 (MCM2) product scores Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs No Tumor p<0.001 Tissue 22554381
912 Minichromosome Maintenance Complex Protein 2 (MCM2) product scores Protein Humans Upregulated with Increasing Gleason Score Prognostic Gleason Score ≤6 Vs 7 Vs ≥8 p=0.002 Tissue 22554381
913 Ki-67 Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs No Tumor p<0.001 Tissue 22554381
914 Ki-67 Protein Humans Upregulated with Increasing Gleason Score Prognostic Gleason Score ≤ 6 Vs 7 Vs ≥ 8 p=0.008 Tissue 22554381
915 Minichromosome Maintenance Complex Protein 2 (MCM2) product scores Protein Humans High in Patients with BCR Prognostic Biochemical Recurrence (Group 1) p=0.001 Tissue 22554381
916 Minichromosome Maintenance Complex Protein 2 (MCM2) product score OR ki-67 Product Score Protein Humans High in Patients with BCR Prognostic Biochemical Recurrence (Group 1) p=0.02 Tissue 22554381
917 Minichromosome Maintenance Complex Protein 2 (MCM2) product score AND ki-67 Product Score Protein Humans High in Patients with BCR Prognostic Biochemical Recurrence (Group 1) p=0.002 Tissue 22554381
921 Methylation Status Of A0X1; CYBA; EDG3; ELF4; EPB41L3; FLJ12056; FLJ90650; FLT4; GAS6; GRASP; GSTP1; HAAO; HIF3A; HOXC11; LEP; MGC39606; MOBKL2B; RAB34; RARb; RHCG; RND2; SLC34A2; SPATA6; TPM4; ZNF154 Methylation Humans Methylated in PCA: Diagnostic Tumor Vs Normal Tissues p<0.0001 Tissue 22589488
922 Methylation Status Of ACTL6B; AEBP1; AMID; CD8A; CRIP1; FLJ30934; FLNC; FMOD; FOXE3; GAS7; GDPD5; HS3ST2; LOC349136; NEUROG1; PLTP; PTGER2; RASGRF2; RUNX3; SIX6; SLC9A3; SPSB4; SRD5A2; SUSD3; SYT10; TMEM74 Methylation Humans Hypermethlated in recurrent prostate cancer : Prognostic recurrent prostate cancer Vs nonrecurrent cancer NA Tissue 22589488
923 Methylation Status Of CHST7; LMX1B; RAFTLIN; RASGRF2; TNFRSF10D; ZNF135 Methylation Humans Methylated with Clinical Recurrence Prognostic clinical recurrence Vs biochemical recurrence NA Tissue 22589488
924 Methylation Status Of ALPL; AMPH; BCDIN3; BCL11B; BRD4; C18orf34; DCAMKL1; FGF5; FLJ42486; JAM2; LHX9; LOC283537; LRAT; PDE4B; POU3F3; PTGS2; RASGRF2; SLC27A6; SLC03A1; SPSB4; STAT3; SYN2; TACR3; TIRAP; WNT11 Methylation Humans Methylated with Systemic Recurrence Prognostic systemic recurrence Vs local recurrence NA Tissue 22589488
925 Methylation Status Of HIF3A; HAAO; RARb; GSTP1 Methylation Humans Methylated with Systemic Recurrence Diagnostic Tumor Vs Normal Tissues p<0.0182 Tissue 22589488
926 Methylation Status Of CRIP1; RUNX3; HS3ST2; FLNC; RASGRF2 Methylation Humans Methylated in PCA: Prognostic recurrent prostate cancer Vs nonrecurrent cancer NA Tissue 22589488
927 Methylation Status Of PHLDA3; RASGRF2; TNFRSF10D; ZNF135 Methylation Humans Hypermethlated in recurrent prostate cancer : Prognostic clinical recurrence Vs biochemical recurrence NA Tissue 22589488
928 Methylation Status Of BCL11B; POU3F3; RASGRF2 Methylation Humans Methylated with Clinical Recurrence Prognostic systemic recurrence Vs local recurrence NA Tissue 22589488
931 Spondin-2 (SPON2) Protein Humans Upregulated with Gleason Score >=7 and 8 Diagnostic Gleason Score (2-6), (7-8) and (9-10) p=0.001 Tissue 22615945
934 NACA + CCNB1 mRNA Humans CCNB1 upregulated in Prostate cancer; NACA Downregulated in Prostate Cancer Diagnostic BPC VS BP p<0.05 Tissue 22640805
935 GPR37; SOX4; CCNB1; TOP2A; DLG5; NACA; NR2C2; PDCD5; IDSP1 mRNA Humans Upregulated: [GPR37; SOX4; CCNB1; TOP2A;] Downregulated: [DLG5; NACA; NR2C2; PDCD5; IDSP1] Diagnostic BPC (benign prostates containing PCa) VS BP GPR37 (training: 0.018, testing: 0.003); SOX4 (training: 0.03, testing: 0.03); CCNB1 (training: 0.002, testing: 0.007); TOP2A (training: 0.018); DLG5 (training: p< 0.001, testing: 0.004); NACA (p<0.001, testing: 0.003) ; NR2C2 (training: p<0.001, testing: 0.02); PDCD5 (training: p<0.001); IDSP1 (training: p<0.001) Tissue 22640805
936 PCA3 mRNA Humans Upregulated (RQ = NP: 7.4 Vs LG = 202) Diagnostic Normal adjacent to Prostate (NP) Vs Low Grade PCa <0.005 Tissue 22674214
937 TMPRSS2:ERG Fusion mRNA Humans Upregulated (RQ = NP: 0.6 Vs LG = 11) Diagnostic Normal adjacent to Prostate (NP) Vs Low Grade PCa <0.005 Tissue 22674214
938 PCA3 + TMPRSS2:ERG gene fusion mRNA Humans Upregulated in PCa Diagnostic Normal adjacent to Prostate (NP) Vs Low Grade PCa NA Tissue 22674214
939 TMPRSS2:ERG gene fusion (given that PCA3 test is negative) mRNA Humans Upregulated in PCa Diagnostic Normal adjacent to Prostate (NP) Vs Low Grade PCa NA Tissue 22674214
968 GADD45B; CDKN1A; NLRP1; ERBB3; FMO5; SERINC2; AMFR; DPP4; PGC; YWHAE; EHF; TF; TNFSF10; EIF5A; TGM4; mRNA Humans Upregulated in Relapse: [GADD45B (4.86 fold); CDKN1A (2.65 fold); NLRP1 (1.57 fold)]; Downregulated in Relapse: [ERBB3 (0.55 fold); FMO5 (0.55 fold); SERINC2 (0.43 fold); AMFR (0.41 fold); DPP4 (0.40 fold); PGC (0.38 fold); YWHAE (0.34 fold); EHF(0.33 fold); TF (0.33 fold); TNFSF10 (0.31 fold); EIF5A (0.15 fold); TGM4 (0.03 fold);] Prognostic Relpase Vs No Relapse p<0.05 Tissue 22870216
970 miR-375; miR-141; miR-378*; miRNA Humans Upregulated in Primary Tumors: [miR-375 and miR-141]; Downregulated in Primary Tumors: [miR-378*] Prognostic Normal Vs Primary Tumor p<0.0001 Tissue 22887127
971 miR-375; miR-141; miR-378*; miR-409-3p miRNA Humans Upregulated in Low Risk PCa: [miR-375 ; miR-141]; Downregulated in Low Risk PCa: [miR-378*, miR-409-3p] Prognostic Normal Vs Low Risk Prostate Cancer miR-375; miR-141; miR-378*[p<0.0001]; miR-409-3p [p=0.004] Tissue 22887127
976 RhoC score Protein Humans 10-point increase in the RhoC score reduced the subsequent risk of PSA failure by about 6% Prognostic Time to PSA Failure p=0.009 Tissue 22935975
977 RhoC score Protein Humans Decreased in Cases Prognostic Time to PSA Failure p=0.009 Tissue 22935975
978 ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; ABCC4-004; ALK-001; ATP1A1-002; NAMPT-006; NAMPT-007; RP11-627G23.1-004; genes or ncRNA Humans Upregulated: AOX1-001, RSRC2-017, ABCC4-004, ALK-001, ATP1A1-002, NAMPT-006, RP11-627G23.1-004 get upregulated with fold change >1.2; Downregualted: Others get downregulated with Fold Change < 1.0 Diagnostic Primary Vs Normal p<0.05 Tissue 22956952
979 ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; ABCC4-004; ALK-001; ATP1A1-002; NAMPT-006; NAMPT-007; RP11-627G23.1-004; genes or ncRNA Humans Upregulated: C19orf46-002, RSRC2-017 get upregulated with fold change >1.2; Downregualted: Others get downregulated with Fold Change < 1.1 Prognostic Metastatic Vs Primary p<0.05 Tissue 22956952
980 ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; genes or ncRNA Humans Upregulated: C19orf46-002, RSRC2-017 get upregulated with fold change >1.2; Downregualted: Others get downregulated with Fold Change < 1.1 Diagnostic Metastatic Vs Normal p<0.05 Tissue 22956952
981 ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; ABCC4-004; ALK-001; ATP1A1-002; NAMPT-006; NAMPT-007; RP11-627G23.1-004; genes or ncRNA Humans NA Prognostic Biochemical Recurrence p<0.005 Tissue 22956952
982 EGFR Protein Humans Overexpressed for Progression Free Survival Prognostic Progression Free Survival p= 0.01 Tissue 22977195
983 EGFR mRNA Humans Overexpressed for Progression Free Survival Prognostic Progression Free Survival p= 0.005 Tissue 22977195
984 PTEN Protein Humans Overexpressed for Progression Free Survival Prognostic Progression Free Survival p= 0.02 Tissue 22977195
985 PTEN mRNA Humans Overexpressed for Progression Free Survival Prognostic Progression Free Survival p= 0.0003 Tissue 22977195
986 PTEN mRNA Humans Overexpressed for Progression Free Survival Prognostic Overall Survival p= 0.02 Tissue 22977195
987 EGFR + PTEN mRNA Humans Overexpressed for Progression Free Survival Prognostic Progression Free Survival NA Tissue 22977195
990 FLIP Protein Humans NA Prognostic PSA Failure Vs Non Failure p<0.05 Tissue 23028678
991 Sp1 Protein Humans NA Prognostic PSA Failure Vs Non Failure p<0.05 Tissue 23028678
992 Sp3 Protein Humans NA Prognostic PSA Failure Vs Non Failure p<0.05 Tissue 23028678
993 FLIP + Sp1 + Sp3 + Gleason Score Protein Humans NA Prognostic PSA Failure Vs Non Failure p<0.05 Tissue 23028678
994 Ras-related GTP binding D (RRAGD) + polyglutamine binding protein 1 (PQBP1) +histone cluster 1, H2bg (HIST1H2BC)+ aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) +tripartite motif-containing 22 (TRIM22) + RNA binding protein with multiple splicing (RBPMS) + heat shock 22 kDa protein 8 (HSPB8) mRNA Humans Upregulated: [histone cluster 1, H2bg (HIST1H2BC) (1.88 fold); polyglutamine binding protein 1 (PQBP1) (2.08 fold)]; Downregulated: [Ras-related GTP binding D (RRAGD) (0.45 fold); aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) (0.49 fold) ; tripartite motif-containing 22 (TRIM22) (0.54 fold) ; RNA binding protein with multiple splicing (RBPMS) (0.49 fold) + heat shock 22 kDa protein 8 (HSPB8) (0.44 fold)] Prognostic Biochemical relapse Vs No biochemical Relpase p<0.002 Tissue 23028830
995 Ras-related GTP binding D (RRAGD) + polyglutamine binding protein 1 (PQBP1) +histone cluster 1, H2bg (HIST1H2BC)+ aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) +tripartite motif-containing 22 (TRIM22) + RNA binding protein with multiple splicing (RBPMS) + heat shock 22 kDa protein 8 (HSPB8) + Cell Type Hetrogenity + Gleason Score mRNA Humans Upregulated: [histone cluster 1, H2bg (HIST1H2BC) (1.88 fold); polyglutamine binding protein 1 (PQBP1) (2.08 fold)]; Downregulated: [Ras-related GTP binding D (RRAGD) (0.45 fold); aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) (0.49 fold) ; tripartite motif-containing 22 (TRIM22) (0.54 fold) ; RNA binding protein with multiple splicing (RBPMS) (0.49 fold) + heat shock 22 kDa protein 8 (HSPB8) (0.44 fold)] Prognostic Biochemical relapse Vs No biochemical Relpase p<0.002 Tissue 23028830
1014 Chromatin Assembly Factor 1 (CAF-1 p60) Protein Humans Upregulated in Prostate Cancer Diagnostic Normal Vs prostate cancer NA Tissue 23109837
1015 NA Methylation Humans Hypermethylation in PCa (Δ Log Intensity): []; Hypomethylated in PCa: (Δ Log intensity): [] Diagnostic Pca Tumor Vs Tumor Adjacent NA Tissue 23119026
1016 Aldehyde Oxidase 1 (AOX1) Methylation Humans Hypermethylation in PCa Diagnostic Pca Tumor Vs Tumor Adjacent p = 7.46 x10^-8 Tissue 23119026
1017 Spondin 2 (SPON2) Methylation Humans Hypermethylation in PCa Diagnostic Pca Tumor Vs Tumor Adjacent p = 2.1 x10^-14 Tissue 23119026
1030 miR-30d miRNA Humans Upregulated in PCa [Normal (6.23 ± 6.06) Vs Cancer (7.95 ± 7.03)] Diagnostic Cancerous Vs Cancer Adjacent from Same patient p = 0.03 Tissue 23231923
1031 miR-30d miRNA Humans Shorter Survival Time in High miRNA-30d group Prognostic Biochemical Recurrence p = 0.026 (BCR); p =0.04 (Univariate); 0.003 (multivariate) Tissue 23231923
1036 BMI1 Protein Humans Upregulated in PCa: (Normal: 0.81 ± 0.07; PCa stage 2: 1.8 ± 0.08) Diagnostic Normal Vs PCa p< 0.05 Tissue 23308129
1037 Aminopeptidase N (APN) Protein Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Non Malignant Tissue p=0.034 Tissue 23322201
1038 Alanyl membrane aminopeptidase (ANPEP) Methylation Humans Hypermethylated in PCa Diagnostic Prostate Cancer Vs Non Malignant Tissue p=0.0023 Tissue 23322201
1039 Alanyl membrane aminopeptidase (ANPEP) Methylation Humans Hypermethylated in PCa Diagnostic Prostate Cancer Vs Non Malignant Tissue p=0.0025 Tissue 23322201
1040 Aminopeptidase N (APN) Protein Humans NA Prognostic Recurrence Free Survival Univariate: p=0.002; Mutlivariate: p=0.017 Tissue 23322201
1041 Aminopeptidase N (APN) Protein Humans NA Prognostic Cancer Specific Survival Univariate: p=0.017; Mutlivariate: p=0.049 Tissue 23322201
1042 Early Growth Response 3 (Egr3) mRNA Humans Upregulated in PCa (5.35 fold) Diagnostic Prostate Cancer Vs Normal Prostate p = 2 x 10^-15 Tissue 23342084
1043 Early Growth Response 3 (Egr3) Protein Humans Upregulated in PCa (NSR (number of strong positive pixels ratio):normal prostate: 0.039 ; NSR: prostate cancer: 0.13) Diagnostic Prostate Cancer Vs Normal Prostate p = 0.00047 Tissue 23342084
1044 Prostate Specific Membrane Antigen (PSMA) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate p = 0.001 Tissue 23342084
1045 Early Growth Response 1 (Egr1) mRNA Humans Downregulated in Relapse (0.784 fold) Prognostic Relpase Vs No Relapse p = 0.017 Tissue 23342084
1049 Prostate biopsy clinical decision rule (PBCDR): (HGB+ Age+ PSA+ RBC+Hematuria+ Creatinine+ Black (Ethnicity) + Albumin+ MCV) Others Humans NA Diagnostic PC (all stages) vs. non-cancerous conditions p < 0.05 Tissue 23356551
1050 Prostate biopsy clinical decision rule (PBCDR): (HGB+ RBC+ Creatinine+ PSA+ Age+ MCV+ Black (ethnicity)) Others Humans NA Diagnostic PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis) p < 0.05 Tissue 23356551
1065 PCA3 mRNA Humans Upregulated in Cancerous Conditions (Cancerous: 7.69 Vs Non Cancerous: 7.00) Diagnostic Cancerous Vs Non Cancerous p<0.0005 Tissue 23391636
1066 PCA3 mRNA Humans Upregulated in Stage pT3/4 (1.9 Median fold difference) Diagnostic Stage pT2 Vs Stage pT3/4 p=0.015 Tissue 23391636
1067 KLK15 mRNA Humans Upregulated in Stage pT3/4 (2.71 Median fold difference) Diagnostic Stage pT2 Vs Stage pT3/4 p=0.032 Tissue 23391636
1073 Methylation Status of RASSF1A Methylation Humans Hypermethylated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.001 Tissue 23431474
1074 Methylation Status of APC Methylation Humans Hypermethylated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.001 Tissue 23431474
1075 Methylation Status of APC Methylation Humans Hypermethylated in early stages of PCa Prognostic Stage 1 & 2 Vs Stage 3 & 4 p<0.049 Tissue 23431474
1078 ACAT1 Protein Humans Upregulated in LNCAP-SF [3-hydroxy-3-methylglutaryl coenzyme A synthase ( HMGCS2 ); ( 9.2394 fold) aldehyde dehydrogenase 1 family, member A3 ( ALDH1A3 ); ( 8.1484 fold) chromosome 6 open reading frame 115 ( C6orf115 ); ( 6.6899 fold) hydroxysteroid (11-beta) dehydrogenase 2 ( HSD11B2 ); ( 5.4227 fold) anterior gradient homolog 2 (Xenopus laevis) ( AGR2 ); ( 5.0377 fold) S100 calcium binding protein P ( S100P ); ( 4.92 fold) dehydrogenase/reductase (SDR family) member 2 ( DHRS2 ); ( 4.5974 fold) monoamine oxidase B ( MAOB ); ( 4.3792 fold) thymidine phosphorylase ( TYMP ); ( 3.8776 fold) monoamine oxidase A ( MAOA ); ( 3.8563 fold) sequestosome 1 ( SQSTM1 ); ( 3.8075 fold) tropomyosin 1 (alpha) ( TPM1 ); ( 3.5117 fold) cathepsin D ( CTSD ); ( 3.3074 fold) growth differentiation factor 15 ( GDF15 ); ( 3.2564 fold) arginase, type II ( ARG2 ); ( 3.2251 fold) glutaminase ( GLS ); ( 3.2099 fold) arylacetamide deacetylase-like 1 ( AADACL1 ); ( 3.1698 fold) aldehyde dehydrogenase 4 family, member A1 ( ALDH4A1 ); ( 3.0362 fold) solute carrier family 12 (potassium/chloride transporters), member 7 ( SLC12A7 ); ( 3.0201 fold) spermatogenesis associated, serine-rich 2-like ( SPATS2L ); ( 2.9743 fold) N-acylsphingosine amidohydrolase (acid ceramidase) 1 ( ASAH1 ); ( 2.9654 fold) calpain 2, (m/II) large subunit ( CAPN2 ); ( 2.9387 fold) acyl-CoA thioesterase 9 ( ACOT9 ); ( 2.9016 fold) keratin 18 ( KRT18 ); ( 2.8839 fold) epoxide hydrolase 1, microsomal (xenobiotic) ( EPHX1 ); ( 2.8828 fold) glutathione S-transferase kappa ( GSTK1 ); ( 2.8356 fold) aldo-keto reductase family 1, member C2 ( AKR1C2 ); ( 2.8239 fold) acyl-CoA synthetase long-chain family member 3 ( ACSL3 ); ( 2.8157 fold) mannosidase, beta A, lysosomal ( MANBA ); ( 2.813 fold) vesicle-associated membrane protein 8 (endobrevin) ( VAMP8 ); ( 2.7515 fold) retinol saturase (all-trans-retinol 13,14-reductase) ( RETSAT ); ( 2.7151 fold) occludin ( OCLN ); ( 2.7082 fold) sulfide dehydrogenase like ( SQRDL ); ( 2.7062 fold) acyl-CoA dehydrogenase, C-2 to C-3 short chain ( ACADS ); ( 2.6711 fold) microtubule associated monoxygenase, calponin and LIM domain containing 1 ( MICAL1 ); ( 2.6382 fold) 3-hydroxyisobutyryl-CoA hydrolase ( HIBCH ); ( 2.5805 fold) abhydrolase domain containing 11 ( ABHD11 ); ( 2.5752 fold) acyl-CoA synthetase long-chain family member 4 ( ACSL4 ); ( 2.5729 fold) superoxide dismutase 2, mitochondrial ( SOD2 ); ( 2.536 fold) fucosidase, alpha-L- 1, tissue ( FUCA1 ); ( 2.5286 fold) sideroflexin 3 ( SFXN3 ); ( 2.5136 fold) carnitine palmitoyltransferase 2 ( CPT2 ); ( 2.5117 fold) Diagnostic Normal Prostate Vs Bone Metastatis p = 0.0001 Tissue 23443136
1086 miR-183 miRNA Humans Upregulated in Prostate Cancer Diagnostic prostate tumour Vs adjacent normal tissues p<0.05 Tissue 23538390
1087 miR-183 miRNA Humans Upregulated in Prostate Cancer Prognostic Tumor Stage pT2 Vs pT3 p<0.05 Tissue 23538390
1088 miR-183 miRNA Humans Upregulated in Prostate Cancer Prognostic Overall Survival p<0.05 Tissue 23538390
1115 Spermine; Putrescine; Cho; PCho; GPC; PE; Lactate; Alanine; Glucose; Citrate; Succinate; Glutamate; Glutamine; Glycine; Isoleucine; Leucine; Valine; Metabolites Humans Upregulated in Prostate Cancer [Cho; PCho; GPC; PE; Lactate; Alanine; Glutamate; Glutamine; Glycine; Isoleucine; Leucine; Valine;]; Downregulated in Prostate Cancer: [Spermine; Putrescine; Citrate; Creatine;] Diagnostic Normal adjacent samples Vs Cancer samples p<0.05 Tissue 23626811
1116 Spermine Metabolites Humans Downregulated in High Grade Prostate Cancer Diagnostic High Grade (GS >=7) Vs Low Grade (GS =6) p = 0.0044 Tissue 23626811
1117 Citrate Metabolites Humans Downregulated in High Grade Prostate Cancer Diagnostic High Grade (GS >=7) Vs Low Grade (GS =6) p = 0.000773 Tissue 23626811
1118 Citrate Metabolites Humans Downregulated in Gleason Score 7 Diagnostic Gleason Score 6 Vs Gleason Score 7 p = 0.014 Tissue 23626811
1119 Citrate Metabolites Humans Downregulated in Gleason Score 7 Diagnostic Gleason Score 6 Vs Gleason Score (8 & 9) p = 0.005 Tissue 23626811
1120 Spermine Metabolites Humans Downregulated in Gleason Score 7 Diagnostic Gleason Score 6 Vs Gleason Score (8 & 9) p = 0.022 Tissue 23626811
1121 Asporin; Cartilage oligomeric matrix Protein (COMP); Versican; EMILIN 3; Protein Humans Upregulated in Agressive Prostate Cancer (Fold Change); [Asporin (2.14 fold); Cartilage oligomeric matrix Protein (COMP) (100 fold) ; Versican (100 fold) ; EMILIN 3 ( 6 fold); Prognostic Agressive Vs Non Agressive Prostate Cancer Asporin (p=0.00016) ; Cartilage oligomeric matrix Protein (COMP) (p = 0.00228) ; Versican ( 0.03367) ; EMILIN 3 (0.04983); Tissue 23716368
1122 Acid ceramidase Protein Humans Downregulated in Agressive Prostate Cancer 0.18 Fold Prognostic Agressive Vs Non Agressive Prostate Cancer p = 0.04983 Tissue 23716368
1126 PCA3; GAS5; PVT1; DANCR; PCAT1; MEG3; PRINS; HOTTIP; EGOT; LncRNA Humans Upregulated in PCa: [PCA3; GAS5; PVT1; DANCR; PCAT1;]lDownregulated in PCa: [MEG3; PRINS; HOTTIP; EGOT;] Diagnostic Tumor Vs Normal Tissues p< 0.05 Tissue 23728290
1127 Aminoadipic acid Metabolites Humans Upregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1128 Cerebronic acid Metabolites Humans Upregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1129 Gluconic acid Metabolites Humans Downregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1130 Glycerophosphoethanol-amine Metabolites Humans Upregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1131 2-Hydroxybehenic acid Metabolites Humans Upregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1132 Isopentenyl pyrophosphate Metabolites Humans Upregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1133 Maltotriose Metabolites Humans Downregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1134 7-Methylguanine Metabolites Humans Upregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1135 Tricosanoic acid Metabolites Humans Upregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1136 Aminoadipic acid Metabolites Humans Increased in Patients with Recurrence Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p =0.031 Tissue 23737455
1137 Gluconic acid Metabolites Humans Decreased in Patients with Recurrence Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p =0.036 Tissue 23737455
1138 Maltotriose Metabolites Humans Decreased in Patients with Recurrence Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p =0.006 Tissue 23737455
1139 Aminoadipic acid Metabolites Humans Increased in Patients with Recurrence Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p =0.048 Tissue 23737455
1140 hsa-miR-10b; hsa-miR-15a; hsa-miR-15b; hsa-miR-16; hsa-miR-18a; hsa-miR-18b; hsa-miR-25; hsa-miR-30c; hsa-miR-32; hsa-miR-34a; hsa-miR-34c-5p; hsa-miR-92a; hsa-miR-181a; hsa-miR-181b; hsa-miR-181c; hsa-miR-184; hsa-miR-122; hsa-miR-124; hsa-miR-125a-5p; hsa-miR-125b; hsa-miR-128a; hsa-miR-133b; hsa-miR-134; hsa-miR-135b; hsa-miR-146b-5p; hsa-miR-148b; hsa-miR-193a-5p; hsa-miR-193b hsa-miR-206; hsa-miR-20b; hsa-miR-214; hsa-miR-215; hsa-miR-301a; hsa-miR-372 miRNA Humans Upregulated with fold change > 2 Diagnostic prostate tumor Vs normal epithelium p<0.05 Tissue 23781281
1141 let-7a; let-7b; let-7c, miR-515-3p; miR515-5p; miR-181b; miR-146b; miR-361 miRNA Humans Upregulated: [let-7a - 1.7 fold; let-7b 3.7 fold; let-7c 3.0 fold, miR-515-3p 3.2 fold; miR515-5p 3.2 fold;] Downregulated: [miR-181b 1.8 fold; miR-146b 1.7 fold; miR-361 1.7 fold] Prognostic Clinical progression free survival (CPFS) Vs. clinical failure (CF) p<0.05 Tissue 23798998
1142 let-7a; let-7b; let-7c miRNA Humans Downregulated in PCa: [let-7a; let-7b; let-7c] Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.01 Tissue 23798998
1144 HPN; CLDN3; AMACR; GOLPH2; TRIB1; LOC729677; GDF15; TARP; MYC; LOC731404; ZFP36; SIM2; CTGF; GJB1; CENPN; EGR2; FBP1; KLF4; LUZP2; C8orf4; PDLIM3; CREB3L1; GCNT1; CTPS; PTP4A3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.001 Tissue 23813660
1145 SLC14A1; LOC642587; TRIM29; CYP3A5; TP73L; SNAI2; PIK3R1; KRT5; NPAL3; FGFR2; CSTA; CAPG; ITGA2; FER1L3; MEIS2; LGALS3BP; GPRC5B; NEFH; GSTM2; S100A16; MME; EVA1; KRT23; ADD3; GSTP1; mRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.001 Tissue 23813660
1146 Copy Number Alterations: [PTP4A3; LOC440335; SERPINE1; PKN1; JUNB; GDF15; CLDN4; CLDN3; LOC644844; ZNF511;FOSB; FMOD; ZFP36; RASD1;ODC1; HSD17B6; GADD45G; APOF; TUBB2A; PGC; NR4A1; LOC145837; FOS; FBP1;] mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia NA Tissue 23813660
1147 Copy Number Alterations: [PTP4A3; LOC440335; SERPINE1; PKN1; JUNB; GDF15; CLDN4; CLDN3; LOC644844; ZNF511;FOSB; FMOD; ZFP36; RASD1;ODC1; HSD17B6; GADD45G; APOF; TUBB2A; PGC; NR4A1; LOC145837; FOS; FBP1;] mRNA Humans Upregulated in PCa Diagnostic Agressive Vs Non Agressive Prostate Cancer NA Tissue 23813660
1150 1,5-anhydroglucitol; 10-heptaadecenoate (17:1n7); 10-nonadecenoate (19:1n9); ; 15-HETE; 1-arachidonoylglycerophosphoethanolamine; 1- arachidonoylglycerophosphoinositol; 1-arachidoylglycerophosphocholine; 1-eicosadienoylglycerophosphocholine; 1-heptadecanoylglycerophosphocholine; 1-heptadecanoylglycerophosphoethanolamine; 1-linoleoylglycerophosphocholine; 1-linoleoylglycerophosphoethanolamine; 1-myristoylglycerophosphocholine; 1-oleoylglycerol; 1-oleoylglycerophosphocholine; 1-oleoylglycerophosphoethanolamine; 1-oleoylglycerophosphoinositol; 1-oleoylglycerophosphoserine; 1-palmitoleoylglycerophosphocholine; 1-palmitoleoylglycerophosphoethanolamine; 1-palmitoylglycerol; 1-palmitoylglycerophosphocholine; 1-palmitoylglycerophosphoethanolamine 1-palmitoylglycerophosphoinositol; 1-palmitoylplasmenylethanolamine; 1-stearoylglycerol; 1-stearoylglycerophosphocholine; 1-stearoylglycerophosphoethanolamine; 1-stearoylglycerophosphoglycerol; 1-stearoylglycerophosphoinositol; 2-aminoadipate; 2-aminobutyrate; 2-arachidonoylglycerophosphocholine; 2-arachidonoylglycerophosphoethanolamine; 2-docosahexaenoylglycerophosphoethanolamine; 2-hydroxybutyrate; 2-hydroxyglutarate; 2-hydroxypalmitate; 2-hydroxystearate; 2-linoleoylglycerophosphocholine; 2-linoleoylglycerophosphoethanolamine; 2-methylbutyrylcarnitine; 2-oleoylglycerophosphocholine; 2-oleoylglycerophosphoethanolamine; 2-oleoylglycerophosphoserine; 2-palmitoylglycerophosphocholine; 2-palmitoylglycerophosphoethanolamine; 2-stearoylglycerophosphocholine; 3-(4-hydroxyphenyl)lactate; 3-aminoisobutyrate; 3-carboxy-4-methyl-5-propyl-2-furanpropanoate; 3-dehydrocarnitine; 3-dephosphocoenzyme-A; 3-hydroxybutyrate; 3-hydroxyhippurate; 3-indoxyl-sulfate; 3-phosphoglycerate; 4-acetamidobutanoate; 4-androsten-3beta_17beta-diol-disulfate-1; 4-hydroxybutyrate; 4-hydroxyhippurate; 4-methyl-2-oxopentanoate; 5,6-dihydrouracil; 5-alpha-androstan-3beta_17beta-diol-disulfate 5-methylthioadenosine; 5-oxoproline; 6-sialyllactose; 6-sialyl-N-acetyllactosamine; 7-alpha-hydroxy-3-oxo-4-cholestenoate; acetylcarnitine; acetylcholine; Ac-Ser-Asp-Lys-Pro; adenine; adenosine; adenosine 5'-diphosphate; adenosine 5'-monophosphate; adenosine 5'-diphosphoribose; adenosine 5-triphosphate; adenylosuccinate; adrenate (22:4n6); agmatine; alanine; alanylleucine; alanylphenylalanine; alanyltyrosine; alpha-glutamylvaline; alpha-hydroxyisovalerate; alpha-tocopherol; androsterone sulfate; arabitol; arabonate; arachidonate (20:4n6); arginine; ascorbate; asparagine; aspartate; aspartylleucine; aspartylphenylalanine; beta-alanine; beta-hydroxyisovalerate; betaine; butyrylcarnitine; caffeine; caproate (6:0); caprylate (8:0); carnitine; catechol-sulfate; C-glycosyltryptophan; chiro-inositol; cholesterol; choline; choline phosphate; cis-aconitate; cis-vaccenate (18:1n7); citrate; citrulline; coenzyme-A; creatine; creatinine; cysteine; cysteine-glutathione-disulfide; cysteinylglycine; cystine; cytidine; cytidine 5'-diphosphocholine; cytidine 5'-monophosphate; dehydroisoandrosterone sulfate; deoxycarnitine; dihomo-linoleate (20:2n6); docosadienoate (22:2n6); docosahexaenoate (22:6n3); docosapentaenoate (22:5n3); docosapentaenoate (22:5n6); docosatrienoate (22:3n3); eicosapentaenoate (20:5n3); ergothioneine; erythritol; erythronate; ethanolamine; flavin adenine dinucleotide; fructose; fucose; fumarate; galactose; gamma-aminobutyrate; gamma-glutamylalanine; gamma-glutamylglutamate; gamma-glutamylglutamine; gamma-glutamylleucine; gamma-tocopherol; gluconate; glucose; glucose 6-phosphate; glucose 1-phosphate; glutamate; glutamate, gamma-methyl ester; glutamine; glutarate; glutarylcarnitine; glutathione, oxidized; glutathione, reduced; glycerate; glycerol; glycerol 2-phosphate; glycerol 3-phosphate; glycerophosphoethanolamine; glycerophosphorylcholine; glycine; glycochenodeoxycholate; glycylisoleucine; glycylleucine; glycylproline; glycyltyrosine; glycylvaline; guanine; guanosine; guanosine-5-monophosphate; hexanoylcarnitine; hippurate; histamine; histidine; hydroxyisovaleroyl-carnitine; hypotaurine; hypoxanthine; inosine; inositol-1-phosphate; Isobar: 15-methylpalmitate, 2-methylpalmitate; Isobar: alpha-linolenate, gamma-linolenate (18:3n3 18:3n6); Isobar: dihomo-linolenate (20:3n3, 20:3n6); Isobar: dimethylarginine (ADMA, SDMA); Isobar: eicosenoate (20:1n9, 20:1n11); Isobar: fructose-1,6-diphosphate, glucose-1,6-diphosphate, myo-inositol-1,4-diphosphate, myo-inositol-1,3-diphosphate; Isobar: 13-HODE, 9-HODE; isobutyrylcarnitine; isocitrate; isoleucine; isoleucylisoleucine; isoleucylserine; isovalerylcarnitine; kynurenine; lactate; laurate (12:0); leucine; leucylglutamate; leucylleucine; leucylphenylalanine; leucylserine; linoleate (18:2n6); lysine; malate; maltose; maltotetraose; maltotriose; mannitol; mannose; margarate (17:0); mead acid (20:3n9); methionine; methyl-alpha-glucopyranoside; methylphosphate; myo-inositol; myristate (14:0); myristoleate (14:1n5); myristoylcarnitine; N1-methylguanosine; N2-methylguanosine; N-acetylalanine; N-acetylaspartate; N-acetyl-aspartylglutamate; N-acetylgalactosamine; N-acetylglucosamine; N-acetylglutamate; N-acetylmethionine; N-acetylneuraminate; N-acetylputrescine; N-acetyltryptophan; nicotinamide; nicotinamide adenine dinucleotide, reduced; nicotinamide adenine dinucleotide; nicotinamide ribonucleotide; nicotinamide riboside; nonadecanoate (19:0); octanoylcarnitine; oleate (18:1n9); oleoylcarnitine; ophthalmate; ornithine; palmitate (16:0); palmitoleate (16:1n7); palmitoylcarnitine; palmitoyl sphingomyelin; pantothenate; p-cresol sulfate; phenol sulfate; phenylacetylglutamine; phenylalanine; phenylalanylalanine; phenylalanylaspartate; phenylalanylglutamate; phenylalanylleucine; phenyllactate; phosphate; phosphoethanolamine; pipecolate; piperine; pregnen-diol-disulfate; pro-hydroxy-pro-proline; propionylcarnitine; prostaglandin I2; pseudouridine; putrescine; pyridoxate; pyroglutamine; pyroglutamylvaline; pyruvate; quinate; ribitol; riboflavin; ribose; ribulose; S-adenosylhomocysteine; sarcosine; scyllo-inositoll; serine; serotonin; serylleucine; serylphenylalanine; S-methylcysteine; sorbitol; spermidine; spermine; sphingosine ; stearate (18:0); stearoylcarnitine; stearoyl sphingomyelin; succinate; succinylcarnitine; taurine; theobromine; threonine; threonylisoleucine; threonylleucine; threonylphenylalanine; thymol sulfate; tiglyl carnitine; trans-4-hydroxyproline; tryptophan; tryptophan betaine; tyrosine; tyrsoylleucine; uracil; urate; urea; uridine; uridine 5'-monophosphate; valerylcarnitine; valine; valylmethionine; valyltyrosine; VGAHAGEYGAEALER; xanthine; xanthosine; xylitol; xylonate; xylulose; Metabolites Humans Differentially Expressed Diagnostic Prostate Cancer Vs Controls p<0.05 Tissue 23824564
1151 Histidine; Glycine; Alanine; Kynurenine; Glutamate; Glycerol 3-phosphate (G3P); Betaine; Pipecolate 2-methylbutyrylcarnitin; Isobar: 15-methylpalmitate; 2-methylpalmitate; Threonine; Cytidine 50-diphosphocholine; Valine; Myristoleate (14:1n5); S-adenosylhomocysteine (SAH); Phosphate; Choline; 2-aminobutyrate 2-hydroxypalmitate; Glycerol; Adenine; 2-hydroxystearate; Deoxycarnitine; Fumarate; Docosadienoate (22:2n6); Metabolites Humans Increased with Upgraded Gleason Score Prognostic Gleason Score Upgrading [6 to 7 (3+4) to 7(4+3) to 8] p<0.05 Tissue 23824564
1152 Adenosine 50 -diphosphate (ADP); Citrate; Palmitoyl-sphingomyelin; Metabolites Humans Decreased with Upgraded Gleason Score Prognostic Gleason Score Upgrading [6 to 7 (3+4) to 7(4+3) to 8] p<0.05 Tissue 23824564
1153 5,6-dihydrouracil +choline phosphate+ glycerol + methylpalmitate Metabolites Humans Differentially Expressed Prognostic Organ Confined Vs Non Orgnan Confined p<0.05 Tissue 23824564
1154 7-HOCA+ pregnen-diol disulfate +mannosyl tryptophan Metabolites Humans Differentially Expressed Prognostic Progression Free Survival (5 years) Vs No Progression Free Survival (5 years) p<0.05 Tissue 23824564
1155 LASP1 + IQGAP3+ NFIB+ S1PR4+ THBS2+ANO7+ PCDH7 + MYBPC1+ EPPK1+ TSBP+ PBX1+ NUSAP1+ ZWILCH+ UBE2C+ CAMK2N1+ RABGAP1+ PCAT-32 + GLYATL1P4/PCAT-80 + TNFRSF19 mRNA Humans Differentially Expressed Prognostic Metastasis Vs No Metastasis p<0.01 Tissue 23826159
1160 Crystallin, alpha B (CRYAB) mRNA Humans Downregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1161 Distal-less homeobox 1 (DLX1) mRNA Humans Upregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1162 Serum deprivation response (SDPR) mRNA Humans Downregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1163 Potassium large conductance calcium-activated channel, subfamily M, alpha member 1 (KCNMA1) mRNA Humans Downregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1164 Prostate Cancer Antigen 3 (PCA3) mRNA Humans Upregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1165 Aldo-keto reductase family 1, member C1/2 (AKR1C1/2) mRNA Humans Downregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1166 Cyclin-dependent kinase 5, regulatory subunit 1 (CDK5R1) mRNA Humans Downregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1167 Claudin 7 (CLDN7) mRNA Humans Upregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1168 Activated leukocyte cell adhesion molecule (ALCAM) mRNA Humans Upregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1169 RAS, dexamethasone-induced 1 (RASD1) mRNA Humans Upregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1179 Methylation Status of BNC1 Methylation Humans Hypermethylated in PCa (β atleast ≥ 0.2) Diagnostic Prostate Cancer Vs Normal Prostate p =0.0476 Tissue 23896626
1180 Methylation Status of FZD1 Methylation Humans Hypermethylated in PCa (β atleast ≥ 0.2) Diagnostic Prostate Cancer Vs Normal Prostate p =0.0363 Tissue 23896626
1181 Methylation Status of SYN2 Methylation Humans Hypermethylated in PCa (β atleast ≥ 0.2) Diagnostic Prostate Cancer Vs Normal Prostate p =0.049 Tissue 23896626
1182 Methylation Status of ZNF783 Methylation Humans Hypermethylated in PCa (β atleast ≥ 0.2) Diagnostic Prostate Cancer Vs Normal Prostate p =0.011 Tissue 23896626
1183 Methylation Status of CYB5R2 Methylation Humans Hypermethylated in PCa (β atleast ≥ 0.2) Diagnostic Prostate Cancer Vs Normal Prostate p =0.0003 Tissue 23896626
1184 Bone Sialoprotein Protein Humans Upregulated in Bone Metastatis (BM: 38.7 ±19.3; NBM: 9.1 ± 5.8) Prognostic Bone Metastatis Vs No Bone Metastatis p<0.05 Tissue 23904377
1185 Methylation Status of AOX1 (High vs. Low) Methylation Humans Hypermethylated in Prostate Cancer Prognostic Biochemical recurrence P < 0.001 Tissue 23918943
1186 Methylation Status of AOX1 (as continous variable) Methylation Humans Hypermethylated in Prostate Cancer Prognostic Biochemical recurrence P < 0.001 Tissue 23918943
1187 Methylation Status of C1orf114 (as continous variable) Methylation Humans Lower Methylation in Patients with Longer Survival Prognostic Biochemical recurrence P < 0.001 Tissue 23918943
1188 Methylation Status of C1orf114 (High vs. Low) Methylation Humans Lower Methylation in Patients with Longer Survival Prognostic Biochemical recurrence P < 0.001 Tissue 23918943
1189 Methylation Status of GAS6 (as continous variable) Methylation Humans Hypermethylated in Prostate Cancer Prognostic Biochemical recurrence P < 0.001 Tissue 23918943
1190 Methylation Status of GSTP1 Methylation Humans Hypermethylated in Prostate Cancer Prognostic Biochemical recurrence P < 0.001 Tissue 23918943
1191 Methylation Status of HAPLN3 (as continous variable) Methylation Humans Hypermethylated in Prostate Cancer Prognostic Biochemical recurrence P < 0.001 Tissue 23918943
1192 Methylation Status of HAPLN3 (High vs. Low) Methylation Humans Hypermethylated in Prostate Cancer Prognostic Biochemical recurrence P < 0.001 Tissue 23918943
1193 Methylation Status of KLF8 (High vs. Low) Methylation Humans Hypermethylated in Prostate Cancer Prognostic Biochemical recurrence P < 0.001 Tissue 23918943
1194 Methylation Status of KLF8 (as continuous variable) Methylation Humans Hypermethylated in Prostate Cancer Prognostic Biochemical recurrence P < 0.001 Tissue 23918943
1195 Methylation Status of MOB3B Methylation Humans Hypermethylated in Prostate Cancer Prognostic Biochemical recurrence P < 0.001 Tissue 23918943
1196 Methylation Status of AOX1/C1orf114/HAPLN3 Methylation Humans Lower Methylation in Patients with Longer Survival Prognostic Biochemical recurrence NA Tissue 23918943
1197 Methylation Status of AOX1/C1orf114/HAPLN3 Methylation Humans Lower Methylation in Patients with Longer Survival Prognostic Biochemical recurrence NA Tissue 23918943
1204 hsa-mir-31; hsa-mir-145; hsa-mir-455; hsa-mir-221; hsa-mir-222; hsa-mir-143; hsa-mir-221; hsa-mir-133b; hsa-mir-376c; hsa-mir-187; hsa-mir-139; hsa-mir-455; hsa-mir-224; hsa-mir-204; hsa-mir-505; hsa-mir-149; hsa-mir-222; hsa-mir-34a; hsa-mir-152; hsa-mir-30e; hsa-mir-377; hsa-mir-181c; miRNA Humans Upregulated in PCa (log Fold Change): [] Diagnostic Cancer Vs Benign p < 0.0401 Tissue 23984644
1205 hsa-mir-33a; hsa-mir-25; hsa-mir-18b; hsa-mir-130b; hsa-mir-769; hsa-mir-182; hsa-mir-148a; hsa-mir-96; miRNA Humans Downregulated in PCa (log Fold Change): [] Diagnostic Cancer Vs Benign p < 0.0401 Tissue 23984644
1211 PSMA/PSA Protein Humans Upregulated in PCa (PCa: 4.95 ± 0.83; BPH: 0.47 ± 0.02) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.0001 Tissue 24063616
1212 PSMA/PSA Protein Humans Upregulated in PCa (PCa: 4.95 ± 0.83; NP: 1.22 ± 0.15) Diagnostic Prostate Cancer Vs Normal Prostate p= 0.0001 Tissue 24063616
1216 Cytochrome P450 family 24 subfamily A member 1 (CYP24A1) mRNA Humans Upregulated in PCa (4 fold) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p = 0.03 Tissue 24081904
1217 Cytochrome P450 family 24 subfamily A member 1 (CYP24A1) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p = 0.03 Tissue 24081904
1218 Methylation Status of APC Methylation Humans Hypermethylated in patients with Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.02 Tissue 24086370
1220 Semaphorin 4F (SF4) mRNA Humans Upregulated (high levels) had increased risk of biochemical recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.0002 Tissue 24097862
1223 Prostate Specific Membrane Antigen (PSMA) Protein Humans Upregulted in Lethal PCa Prognostic Lethal Vs Non Lethal Prostate Cancer p< 0.01 Tissue 24130224
1224 hsa-miR-367; hsa-miR-758; hsa-miR-190 hsa-miR-221; hsa-miR-205; hsa-miR-212; hsa-miR-99b; hsa-miR-214; hsa-miR-203; hsa-miR-127-3p; hsa-miR-130a; hsa-miR-335; hsa-miR-376; hsa-miR-10a; hsa-miR-589; hsa-miR-422a; hsa-miR-10b; hsa-miR-25; hsa-miR-210; hsa-miR-99a; hsa-miR-429; hsa-miR-92a; hsa-miR-100; hsa-miR-222; hsa-miR-484; hsa-miR-125b; hsa-miR-574-3p; hsa-miR-328; hsa-miR-483-5p; hsa-miR-331-3p; hsa-let-7c; hsa-miR-135a; miRNA Humans miR-367, miR-758 and miR-190 were found to be upregulated in PCa; while, rest were Downregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p ≤ 0.046 Tissue 24167554
1225 miR-205 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p<0.0001 Tissue 24167554
1226 miR-214 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p<0.0001 Tissue 24167554
1227 miR-221 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p<0.001 Tissue 24167554
1228 miR-99b miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p<0.0001 Tissue 24167554
1233 Prostate Stem Cell Antigen (PSCA) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.05 Tissue 24183365
1234 Prostate Stem Cell Antigen (PSCA) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer VS HGPIN p<0.05 Tissue 24183365
1235 Prostate Stem Cell Antigen (PSCA) Protein Humans Upregulated in PCa Diagnostic Gleason Score 6 Vs Gleason Score 8 p<0.05 Tissue 24183365
1236 Prostate Stem Cell Antigen (PSCA) Protein Humans Upregulated in PCa Diagnostic Gleason Score 7 Vs Gleason Score 8 p<0.05 Tissue 24183365
1237 Peroxisome proliferator activated receptors (PPAR) [PPARβ/δ] Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.001 Tissue 24189640
1238 cutaneous fatty acid-binding protein (C-FABP) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.001 Tissue 24189640
1239 cutaneous fatty acid-binding protein (C-FABP) Protein Humans Upregulated in PCa Prognostic Low Vs Moderate Vs High Gleason Score p<0.05 Tissue 24189640
1243 N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 ) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Tissue p<0.0001 Tissue 24240687
1244 N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 ) Protein Humans Upregulated with High Tumor Stage Prognostic Tumor Stage pT2 Vs pT3 Vs pT4 p= 0.004 Tissue 24240687
1245 N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 ) Protein Humans Upregulated with High Gleason Score Prognostic Gleason Score 3 Vs 4 Vs 5 p=0.028 Tissue 24240687
1246 N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 ) Protein Humans Increased in Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: p = 0.0038; Multivariate: p =0.036 Tissue 24240687
1254 Forkhead Box A1 [FOXA1] mRNA Humans Increased in shorter time to Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.028 Tissue 24292680
1255 ACACA; CDCA3; CEP55; CCNB1; CKS2; DLGAP5; SLC7A1;HMMR; HIG2; LOX; MMP10; MCOLN2; NLN; PDLIM5; PSD3; C20orf74; FAM80A; SDK1; STC2; SOX4; TMEM200A; TFF3; UBE2C; UBE2E3; mRNA Humans Upregulated in PCa (log 2 PCa/Normal): [] Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 24349376
1256 Discs Large Homolog 7 [DLG7] mRNA Humans Upregulated in PCa (log 2 PCa/Normal): [] Prognostic Progression Vs No Progression NA Tissue 24349376
1274 BTF3 Protein Humans Upregulated in PCa (2.5 fold) Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1275 HINT1 Protein Humans Upregulated in PCa (2.3 fold) Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1276 NDRG1 Protein Humans Upregulated in PCa (2.6 fold) Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1277 ODC1 Protein Humans Upregulated in PCa (1.8 fold) Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1278 BTF3 + HINT1 Protein Humans Upregulated in PCa [BTF3: 2.5 fold; HINT1: 2.3 fold] Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1279 BTF3 + NDRG1 Protein Humans Upregulated in PCa [BTF3: 2.5 fold; NDRG1: 2.6 fold] Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1280 BTF3 + ODC1 Protein Humans Upregulated in PCa [BTF3: 2.5 fold; ODC1: 1.8 fold] Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1281 HINT1 + NDRG1 Protein Humans Upregulated in PCa [NDRG1: 2.6 fold; HINT1: 2.3 fold] Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1282 HINT1 + ODC1 Protein Humans Upregulated in PCa [ODC1: 1.8 fold; HINT1: 2.3 fold] Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1283 NDRG1 + ODC1 Protein Humans Upregulated in PCa [ODC1: 1.8 fold; NDRG1: 2.6 fold] Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1288 F3 mRNA Humans NA Prognostic Overall Survival Vs No Survival p=0.001 Tissue 24394557
1289 WNT5B mRNA Humans NA Prognostic Overall Survival Vs No Survival p=0.004 Tissue 24394557
1290 VGLL3 mRNA Humans NA Prognostic Overall Survival Vs No Survival p<0.0001 Tissue 24394557
1291 c-MAF-a mRNA Humans NA Prognostic Overall Survival Vs No Survival p=0.008 Tissue 24394557
1292 CTGF mRNA Humans NA Prognostic Overall Survival Vs No Survival p=0.008 Tissue 24394557
1293 AMACR mRNA Humans NA Prognostic Overall Survival Vs No Survival p=0.009 Tissue 24394557
1294 MUC1 mRNA Humans NA Prognostic Overall Survival Vs No Survival p=0.025 Tissue 24394557
1295 F3 mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p<0.0001 Tissue 24394557
1296 WNT5B mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p<0.0001 Tissue 24394557
1297 VGLL3 mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.014 Tissue 24394557
1298 c-MAF-a mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.036 Tissue 24394557
1299 CTGF mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.023 Tissue 24394557
1300 IGFBP3 mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.013 Tissue 24394557
1301 c-MAF-b mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.019 Tissue 24394557
1302 EZH2 mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.018 Tissue 24394557
1303 AMACR mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.049 Tissue 24394557
1304 VGLL3 + IGFBP3 + F3 mRNA Humans NA Prognostic Overall Survival Vs No Survival Univariate: [p<0.0001;] Multivariate:[Group2: p=0.013 Group 1: p<0.0001] Tissue 24394557
1305 Clinical Parameters + VGLL3 + IGFBP3 + F3 mRNA Humans NA Prognostic Overall Survival Vs No Survival NA Tissue 24394557
1306 VGLL3 + IGFBP3 + F3 mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival Group2: [Univariate: p= 0.002; Multivariate: 0.030]; Group 1: p<0.0001 Tissue 24394557
1307 Clinical Parameters + VGLL3 + IGFBP3 + F3 mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival NA Tissue 24394557
1325 Monoclonal Antibody MIB-1 [Ki-67] Protein Humans Increased with increased risk of death Prognostic PCa Specific Mortality Vs No Mortality p<0.001 Tissue 24486077
1326 Monoclonal Antibody MIB-1 [Ki-67] Protein Humans Increased with increased risk of death Prognostic Progression Vs No Progression p<0.001 Tissue 24486077
1333 U78_x; SNORD78; U78_s; miR-182; U17b; miR-22; miR-34a*; miR-221*; miR-187; miR-221; miR-34c-3p; miRNA Humans Upregulated in PCa: U78_x (3.8 fold); SNORD78 (3.6-fold); U78_s (3.7-fold); miR-182 (4.7-fold); U17b (2.7- fold)Downregulated in PCa: miR-224 (4.05-fold); miR-34a* (3-fold); miR-221* (3.3-fold); miR-187 (12-fold); miR-221 (2.2-fold); miR-34c-3p (1.7-fold) Diagnostic Prostate Cancer Vs Normal Prostate p<0.05 Tissue 24518785
1334 miR-182 miRNA Humans Upregulated in PCa (4.7 fold) Diagnostic Prostate Cancer Vs Normal Prostate 0.717 Tissue 24518785
1335 miR-187 miRNA Humans Downregulated in PCa (12 fold) Diagnostic Prostate Cancer Vs Normal Prostate 0.052 Tissue 24518785
1336 PSA+PCA3+miR-187 miRNA Humans Downregulated in PCa (12 fold) Diagnostic Prostate Cancer Vs Normal Prostate p<0.05 Tissue 24518785
1337 PCAT18 LncRNA Humans Upregulated in PCa (8.8-11.1 fold) Diagnostic Prostate Cancer Vs Normal Prostate p<0.001 Tissue 24519926
1338 PCAT18 LncRNA Humans Upregulated in metastatic Prostatic Cancer Prognostic Localised Vs Metastatic Prostate Cancer p<0.001 Tissue 24519926
1351 miR-221 miRNA Humans Downregulation in high-risk prostate cancer Prognostic Cancer Related Death Vs No Cancer Related Death p<0.0001 Tissue 24607843
1352 ERG Protein Humans NA Prognostic Histopathological Progression For ERG Positive Vs ERG Negative samples p<0.0001 Tissue 24630684
1353 ERG Protein Humans NA Prognostic Active Survillence (AS) Progression For ERG Positive Vs ERG Negative samples p<0.0001 Tissue 24630684
1369 Hyaluronan-Mediated Motility Receptor (HMMR) Metabolites Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure Univariate: p=0.028; Multivariate: p=0.04 Tissue 24668563
1371 CCND1 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure p=0.042 Tissue 24708576
1372 HMMR Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure Univariate: p=0.005 Multivariate; p=0.008 Tissue 24708576
1373 HOXC6 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure p=0.05 Tissue 24708576
1374 IGF1 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure Univariate: p=0.039 Multivariate; p=0.015 Tissue 24708576
1375 MAP4K4 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure p=0.024 Tissue 24708576
1376 MKI67 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure p=0.026 Tissue 24708576
1377 SIAH2 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure p=0.016 Tissue 24708576
1378 SMAD4 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure Univariate: p=0.01 Multivariate; p=0.016 Tissue 24708576
1379 HMMR+ SIAH2+ SMAD4 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure (3 years) p=0.052 Tissue 24708576
1380 HMMR+ SIAH2+ SMAD4 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure (5 years) p=0.024 Tissue 24708576
1381 BTG2; CDC37L1; COL15A1; COL3A1; EIF2D; FDPS; HIST1H1C; HIST1H2BG; IFT57; IGFBP3; ITPR1; LBH; LOC284801; MARCH5; MED4; MEMO1; MXI1; PTN; RPL23AP53; SACM1L; SIRT1; SNORA20; SRSF3; SYNM; mRNA Humans Poor score with decreased BCR Survival Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 1.45E-21; Validation: p=2.85e-3 Tissue 24713434
1395 GABRE mRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Non Malignant p=0.001 Tissue 24737792
1396 miR-224 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Non Malignant p=0.000628 Tissue 24737792
1397 miR-452 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Non Malignant p=0.000494 Tissue 24737792
1398 Methylation status of GABRE + miR-224 +miR-452 miRNA + Methylation Humans Hypermethylated in PCa Diagnostic Prostate Cancer Vs Non Malignant p=0.001 Tissue 24737792
1399 Methylation status of GABRE + miR-224 +miR-452 (as continous value ) miRNA + Methylation Humans Hypermethylated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence Cohort 1: Univariate: p<0.001; Multivariate: p= 0.019 Cohort 2: Univariate: p<0.001; Multivariate: p=0.008 Tissue 24737792
1400 Methylation status of GABRE + miR-224 +miR-452 (High vs. Low ) miRNA + Methylation Humans Hypermethylated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence Cohort 1: Univariate: p<0.001; Multivariate: p= 0.019 Cohort 2: Univariate: p<0.001; Multivariate: p=0.008 Tissue 24737792
1401 GABRE + miR-224 +miR-452 mRNA + miRNA Humans Downregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Tissue 24737792
1402 GABRE RNA Humans Downregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Tissue 24737792
1403 miR-224 miRNA Humans Downregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Tissue 24737792
1404 miR-452 miRNA Humans Downregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Tissue 24737792
1405 OAZ2 mRNA Humans Downregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Tissue 24737792
1406 GABRE + miR-224 +miR-452+OAZ2 mRNA + miRNA Humans Downregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Tissue 24737792
1414 POSTN; ASPN; LAMB2; SERPH; CSPG2; ENTP1; SE1L1; ITAV; FOLH1; STIM1; PTK7; ICOSL; SPP2A; CD276; KLK3; ZA2G; FBN1; CD38; CNTP2; AMPN; FAM3B; RNT2; NAAA; PPAP; GSLG1; TSN1; DPP4; ST14; Protein Humans Upregulated in Agressive PCa; Downregulated in Agressive PCa: [] Prognostic Agressive Vs Non Agressive PCa NA Tissue 24741114
1415 TIMP1; CLUS; MFAP4; AOC3; CADM1; HYOU1; FSTL1; KLK11; NBL1; GOLM1; VTNC; CERU; A1AG2; LYVE1; A1AG1; Protein Humans Upregulated in Metastatic PCa;Downregulated in Non Metastatic PCa: [] Prognostic Metastatic Vs Non Metastatic Prostate Cancer NA Tissue 24741114
1416 ATRN; CATD; BTD; MTA1; NCAM1; PECA1; Protein Humans Upregulated in PCa: [];Downregulated in PCa: [] Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 24741114
1417 NAAA Protein Humans Downregulated in GS >7 Prognostic Gleason Score ≤ 7 and Gleason Score >7 p <0.05 Tissue 24741114
1418 PTK7 Protein Humans Upregulated in GS >7 Prognostic Gleason Score ≤ 7 and Gleason Score >7 p <0.01 Tissue 24741114
1419 NAAA+ PTK7 Protein Humans NAAA: Downregulated in GS >7; PTK7: Upregulated in GS >7 Prognostic Gleason Score ≤ 7 and Gleason Score >7 p <0.05 Tissue 24741114
1428 DAB2IP Protein Humans Reduced in lower FFBF (Freedom From Biochemical Faliure) Prognostic Freedom From Biochemical Failure Vs Biochemical Failure p=0.04 Tissue 24867541
1429 miR-19a miRNA Humans Upregulated in Cases Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1430 miR-19b miRNA Humans NA Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1431 miR-345 miRNA Humans Downregulated in Cases Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1432 miR-519c-5p miRNA Humans Downregulated in Cases Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1433 miR-19a miRNA Humans Upregulated in Cases Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1434 miR-19b miRNA Humans Upregulated in Cases Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1435 miR-345 miRNA Humans NA Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1436 miR-519c-5p miRNA Humans NA Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1437 miR_19a+ miR_345+ miR_519c_5p miRNA Humans NA Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1438 miR_19b+miR_345+ miR_519c_5p miRNA Humans NA Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1439 miR_19a + miR_19b + miR_345 + miR_519c_5p miRNA Humans NA Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1440 MUC1 Protein Humans Increased with Increased mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.02 Tissue 24909936
1441 p53 Protein Humans Increased with Increased mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.005 Tissue 24909936
1442 AZGP1 Protein Humans Increased with Decreased mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.04 Tissue 24909936
1443 MUC1 + p53+ AZGP1 Protein Humans Increased with Increased mortality Prognostic PCa Specific Mortality Vs No Mortality NA Tissue 24909936
1444 Methylation status of genes (GSTM2; GSTP1; RARB; ALOX12; APC; PDGFRB; SCGB3A1; CFTR; MT1A; PENK; TERT; CCNA1; RARA; TAL1; ERG; MET; GFI1; MYCL2; SEPT9; COL18A1; KLK10; MFAP4; MMP14; TBX1; EYA4; NEU1; POMC; GADD45A; HTR1B; RASSF1; CDH13; PDGFRA; IRAK3; ASCL2; ESR1; HFE; IGFBP7; RARRES1; CAV1; THY1; BMP4;) Methylation Humans Hypermethylated in Pca Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 24961912
1445 miR-1 miRNA Humans Downregulated in Recurrent PCa Prognostic Recurrence Vs No Recurrence p = 0.036 Tissue 24967583
1446 miR-133b miRNA Humans Downregulated in Recurrent PCa Prognostic Recurrence Vs No Recurrence p = 0.012 Tissue 24967583
1447 miR-1 + miR-133b miRNA Humans Downregulated in Recurrent PCa Prognostic Recurrence Vs No Recurrence p = 0.012 Tissue 24967583
1457 Brachyury Protein Humans Increases with increasing Gleason Score Prognostic Gleason Score GS <7 Vs GS = 7 Vs GS >7 p = 0.027 Tissue 25009296
1460 Receptor for advanced glycation end products (RAGE) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p=0.002 Tissue 25057439
1461 High Mobility Group Box 1 (HMGB1) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p=0.001 Tissue 25057439
1462 Receptor for advanced glycation end products (RAGE) Protein Humans Upregulated in Stage T3-T4 Prognostic stage T1-T2 Vs Stage T3-T4 p=0.004 Tissue 25057439
1463 High Mobility Group Box 1 (HMGB1) Protein Humans Upregulated in Stage T3-T5 Prognostic stage T1-T2 Vs Stage T3-T4 p=0.009 Tissue 25057439
1464 High Mobility Group Box 1 (HMGB1) + Receptor for advanced glycation end products (RAGE) Protein Humans Upregulated in Stage T3-T6 Prognostic stage T1-T2 Vs Stage T3-T4 p=0.007 Tissue 25057439
1465 Receptor for advanced glycation end products (RAGE) Protein Humans Upregulated in Distant Metastases Prognostic Distant Metastases Vs No Distant Metastases p=0.013 Tissue 25057439
1466 High Mobility Group Box 1 (HMGB1) Protein Humans Upregulated in Distant Metastases Prognostic Distant Metastases Vs No Distant Metastases p=0.019 Tissue 25057439
1467 High Mobility Group Box 1 (HMGB1) + Receptor for advanced glycation end products (RAGE) Protein Humans Upregulated in Distant Metastases Prognostic Distant Metastases Vs No Distant Metastases p=0.026 Tissue 25057439
1468 High Mobility Group Box 1 (HMGB1) + Receptor for advanced glycation end products (RAGE) Protein Humans Increased Coexpression in patients with Decreased overall Survival Prognostic Overall Suvival Vs No Survival p=0.047 Tissue 25057439
1469 miR-135a miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer And Adjacent Normal p<0.0001 Tissue 25065599
1470 miR-135a miRNA Humans Downregulated in GS ≥ 8 Prognostic Glesaon Score ≥ 8 and Gleason Score <8 p<0.01 Tissue 25065599
1471 miR-135a miRNA Humans Downregulated in Stage pT3a Prognostic Stage pT3a Vs Stage pT2c p<0.05 Tissue 25065599
1472 PTEN Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p=0.0011 Tissue 25075204
1473 CCND1 Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p=0.036 Tissue 25075204
1474 SMAD4 Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p=0.0035 Tissue 25075204
1475 PTEN + CCND1 +SMAD4 + SSP1 Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p = 0.00000456 Tissue 25075204
1476 pS6 Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p=0.021 Tissue 25075204
1477 pPRAS40 Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p=0.019 Tissue 25075204
1478 CCND1 +SMAD4 + SSP1 + pS6 + pPRAS40 Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p = 0.000013 Tissue 25075204
1479 miR-30c miRNA Humans Downregulated in Malignant Samples (Benign: 0.621 ± 0.06; malignant: 0.438 ± 0.022) Diagnostic Benign Vs Malignant p=0.014 Tissue 25075250
1480 miR-219 miRNA Humans Downregulated in Malignant Samples (Benign: 0.773 ± 0.082; malignant: 0.467 ± 0.019) Diagnostic Benign Vs Malignant p=0.004 Tissue 25075250
1481 miR-21 miRNA Humans Downregulated in GS ≥ 8 (Benign: 0.636 ± 0.048; malignant: 0.521 ± 0.027) Prognostic Gleason Score ≥ 8 Vs Gleason Score < 8 p=0.004 Tissue 25075250
1482 miR-21 miRNA Humans Downregulated in Metastatis (No Metastasis: 0.667 ± 0.037; Metastatis: 0.463 ± 0.027) Prognostic Metastatic Vs Non Metastatic Prostate Cancer p<0.0001 Tissue 25075250
1483 miR-30c miRNA Humans Downregulated in Metastatis (No Metastasis: 0.514 ± 0.029; Metastatis: 0.354 ± 0.032) Prognostic Metastatic Vs Non Metastatic Prostate Cancer p= 0.0003 Tissue 25075250
1484 miR-219 miRNA Humans Downregulated in Metastatis (No Metastasis: 0.532 ± 0.028; Metastatis: 0.448 ± 0.029) Prognostic Metastatic Vs Non Metastatic Prostate Cancer p= 0.039 Tissue 25075250
1485 miR-21 miRNA Humans Downregulated in Patients who suvived (Survival : 0.636 ± 0.039; No Survival: 0.507 ± 0.03) Prognostic Survival Vs No Survival p= 0.009 Tissue 25075250
1486 miR-30c miRNA Humans Downregulated in Patients who suvived (Survival : 0.500 ± 0.031; No Survival: 0.406 ± 0.028) Prognostic Survival Vs No Survival p= 0.024 Tissue 25075250
1487 miR-30c miRNA Humans Downregulated in Patients With Recurrence (No Recurrence : 0.609 ± 0.036; recurrence: 0.415 ± 0.051) Prognostic PSA Recurrence Vs No Recurrence p= 0.003 Tissue 25075250
1488 let-7c miRNA Humans Downregulated in Patients With Recurrence (No Recurrence : 0.703 ± 0.098; recurrence: 0.963 ± 0.06) Prognostic PSA Recurrence Vs No Recurrence p=0.0266 Tissue 25075250
1489 Interleukin-1β (IL-1β) Protein Humans Increased in patients with Biochemical Recurrence Prognostic Recurrence Vs No Recurrence p=0.02 Tissue 25075566
1490 Interferon β (IFNβ) Protein Humans Decreased in patients with Biochemical Recurrence Prognostic Recurrence Vs No Recurrence p=0.008 Tissue 25075566
1491 Interleukin-1β (IL-1β) + Interferon β (IFNβ) Protein Humans Interleukin-1β (IL-1β): Increased in patients with Biochemical Recurrence; Interferon β (IFNβ): Decreased in patients with Biochemical Recurrence Prognostic Recurrence Vs No Recurrence p=0.004 Tissue 25075566
1492 mir-23b miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.0001 Tissue 25115396
1493 mir-27b miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.0001 Tissue 25115396
1494 mir-24-1 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.0001 Tissue 25115396
1495 mir-27b miRNA Humans Decreased in patients with shorter progression free interval Prognostic Progression Vs No Progression p=0.0346 Tissue 25115396
1515 YWHAZ Protein Humans NA Prognostic Gleason Score ≤ 6 Vs Gleason Score 7 (3+4) Vs Gleason Score 7 (4+3) Vs Gleason Score ≥ 8 p<0.001 Tissue 25156059
1516 YWHAZ Protein Humans Increased expression in patients with PCa specific death Prognostic High Risk vs Low Risk (Survival) Univariate: p=0.004; Multivariate: p = 0.015 Tissue 25156059
1517 YWHAZ Protein Humans Increased expression in patients with Castration Resistant Prostate Cancer (CRPC) Prognostic Castration Resistant Prostate Cancer (CRPC) Vs No CRPC Univariate: p=0.005; Multivariate: p = 0.008 Tissue 25156059
1518 YWHAZ Protein Humans Increased expression in patients with PSA Relapse Prognostic High Risk vs. Low Risk (Relapse Univariate: p=0.005; Multivariate: p = 0.019 Tissue 25156059
1522 Oligophrenin-1 (OPHN1) mRNA Humans Upregulated in Prostate Cancer (Tumor/nonneoplastic prostate (T/N ratio): > 3 fold) Diagnostic Prostate Cancer Vs Non Neoplastic Samples NA Tissue 25170626
1523 Oligophrenin-1 (OPHN1) Protein Humans Upregulated in Prostate Cancer (Tumor/nonneoplastic prostate (T/N ratio): > 3 fold) Prognostic Gleason Score 6-7 Vs Gleason Score 8-9-10 univariate: p=0.0011; Multivariate: 0.0038 Tissue 25170626
1524 Oligophrenin-1 (OPHN1) Protein Humans Upregulated in Prostate Cancer (Tumor/nonneoplastic prostate (T/N ratio): > 3 fold) Prognostic Stage pT2 Vs Stage pT3 univariate: p=0.0099; Multivariate: 0.0104 Tissue 25170626
1525 Yin Yang 1 (YY1) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs PIN p<0.001 Tissue 25174820
1526 Death Receptor 5 Protein Humans Downregulated in PCa Diagnostic Prostate Cancer Vs PIN p<0.001 Tissue 25174820
1527 Yin Yang 1 (YY1) Protein Humans Downregulated in PCa Prognostic High Grade cancer Vs Low grade Cancer P<0.0001 Tissue 25174820
1528 Death Receptor 5 Protein Humans Downregulated in PCa Prognostic High Grade cancer Vs Low grade Cancer P<0.0001 Tissue 25174820
1529 8-hydroxydeoxyguanosine (8-OHDG) Protein Humans Upregulated in Malignant Tissue Diagnostic Benign Vs Malignant p<0.0001 Tissue 25175169
1530 cytoplasmic-nuclear factor erythroid 2-related factor 2 (c-Nrf-2) Protein Humans Upregulated in Malignant Tissue Diagnostic Benign Vs Malignant p=0.015 Tissue 25175169
1531 Nuclear-nuclear factor erythroid 2-related factor 2 (n-Nrf-2) Protein Humans Upregulated in Malignant Tissue Diagnostic Benign Vs Malignant p=0.016 Tissue 25175169
1532 cytoplasmic-nuclear factor erythroid 2-related factor 2 (c-Nrf-2) Protein Humans Upregulated in Malignant Tissue Prognostic Biochemical Failure Free Survival Vs No Survival Univariate: p=0.28; Multivariate: p=0.019 Tissue 25175169
1533 cytoplasmic-nuclear factor erythroid 2-related factor 2 (c-Nrf-2) Protein Humans Upregulated in Malignant Tissue Prognostic Overall Survival Vs No Survival Univariate: p=0.28; Multivariate: p=0.019 Tissue 25175169
1536 E Cadherin Protein Humans Downregulated in patients with early relapse Prognostic Biochemical Relapse Vs No Biochemical Relapse for external beam radiotherapy treated (EBRT) p=0.02 Tissue 25227682
1537 Ki-67 Protein Humans Upregulated in patients with early relapse Prognostic Early Relapse Vs No Relapse EBRT cohort: p=0.0006; PADT Cohort: p=0.0004 Tissue 25227682
1539 Anterior gradient 2 Wild Type (AGR2wt) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.05 Tissue 25237833
1540 Anterior gradient 2 Slice Variant H (AGR2-SV-H) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.05 Tissue 25237833
1548 STEAP1 (Six transmembrane epithelial antigen of the prostate) mRNA Humans Upregulated in Low Risk PCa (4.45 fold) Diagnostic Low Risk PCa Vs Normal Tissue p = 0.007 Tissue 25248617
1549 STEAP1 (Six transmembrane epithelial antigen of the prostate) mRNA Humans Upregulated in High Risk PCa (8.15 fold) Diagnostic High Risk PCa Vs Normal Tissue p=0.011 Tissue 25248617
1550 STEAP1 (Six transmembrane epithelial antigen of the prostate) mRNA Humans Upregulated in Metastatic PCa (7.45 fold) Diagnostic Metastatic PCa Vs Normal Tissue p=0.011 Tissue 25248617
1551 STEAP2 (Six transmembrane epithelial antigen of the prostate) mRNA Humans Upregulated in Low Risk Localised PCa (5.77 fold) Diagnostic Low Risk Localised PCa Vs Normal Tissue p=0.022 Tissue 25248617
1552 STEAP2 (Six transmembrane epithelial antigen of the prostate) mRNA Humans Upregulated in Locally Advanced PCa (14.10 fold) Diagnostic Localy Advanced PCa Vs Normal Tissue p=0.003 Tissue 25248617
1553 miR-221 miRNA Humans Downregulated in Recurrent Cases (Recurrent Median: 0.25; Control Median: 0.46) Prognostic Recurrence Vs No Recurrence Regulation: p=0.0002; Univariate: p=0.02; Multivariate: p=0.05 Tissue 25252191
1554 miR-21 miRNA Humans Downregulated in Recurrent Cases (Recurrent Median: 1.01; Control Median: 1.54) Prognostic Recurrence Vs No Recurrence p=0.0149 Tissue 25252191
1555 miR-141 miRNA Humans Downregulated in Recurrent Cases (Recurrent Median: 0.39; Control Median: 0.81) Prognostic Recurrence Vs No Recurrence p<0.0001 Tissue 25252191
1556 Chondroitin Sulfate Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs No Cancer p<0.0001 Tissue 9815775
1557 Chondroitin Sulfate Protein Humans Upregulated in Prostate Cancer Prognostic Progression Vs No Progression p=0.0001 Tissue 9815775
1558 Versican Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs No Cancer p=0.0006 Tissue 9563891
1559 Decorin Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs No Cancer p=0.0078 Tissue 9563891
1560 Versican Protein Humans Upregulated in Prostate Cancer Prognostic Progression Vs No Progression p=0.0003 Tissue 9563891
1561 Linoleic Metabolites Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Cancer p=0.04 Tissue 8922296
1562 WISP1 Protein Humans Increased with decreased BCR survival Prognostic Biochemical recurrence Vs No Biochemical Recurrence Cohort 1: p = 0.028;Cohort 3: p= 0.042 Tissue 31069142
1563 WISP1 Protein Humans Upregulated with increasing Stage Prognostic pTNM 2 Vs pTNM 3 Vs pTNM 4 p<0.05 Tissue 31069142
1564 WISP1 mRNA Humans Upregulated in Metastatic PCa Prognostic Primary Vs Metastatis Prostate Cancer p=0.03 Tissue 31069142
1565 TMEFF2 mRNA Humans Upregulated in PCa (Log 2 Median Centered Intensity) Diagnostic Normal/ Benign Tissue Vs Primary/Localised Prostate Cancer p<0.05 Tissue 31060542
1566 TMEFF2 mRNA Humans Upregulated in PCa (Log 2 Median Centered Intensity) Prognostic Primary/Localised Vs Metastatic/CRPC Prostate Cancer p<0.05 Tissue 31060542
1567 TMEFF2 mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p<0.0001 Tissue 31060542
1568 BUB1B; CDC45; CDK1; CENPI; CLSPN; ERCC6L; EXO1; NCAPG; NUSAP1; RAD51; RRM2; mRNA Humans Upregulated in PCa (Log 2 Median Centered Intensity) Diagnostic Normal/ Benign Tissue Vs Primary/Localised Prostate Cancer p<0.05 Tissue 31060542
1569 BUB1B; CDC45; CDK1; CENPI; CLSPN; ERCC6L; EXO1; NCAPG; NUSAP1; RAD51; RRM2; mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p<0.05 Tissue 31060542
1570 BUB1B+CDC45+CDK1+CENPI+CLSPN+ERCC6L+EXO1+NCAPG+NUSAP1+RAD51+RRM2 mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p<0.05 Tissue 31060542
1571 Osteopontin (OPN) Protein Humans increased with decreased BRFS Prognostic Biochemical Recurrence Free Survival Vs No Biochemical Recurrence Free Survival p < 0.036 Tissue 31059955
1572 Glucose Transporter 1 (GLUT1) Protein Humans increased with decreased BRFS Prognostic Biochemical Recurrence Free Survival Vs No Biochemical Recurrence Free Survival p < 0.001 Tissue 31059955
1573 Glucose Transporter 1 (GLUT1) Protein Humans increased with decreased DMFS Prognostic Distant Metastasis Free Survival Vs Distant Metastasis Free Survival p = 0.045 Tissue 31059955
1582 Ki-67 Protein Humans NA Prognostic Distant Metastatis Vs No Distant Metastatis p<0.0001 Tissue 25294917
1583 Cox-2 Protein Humans Upregulation Prognostic Distant Metastatis Vs No Distant Metastatis p=0.04 Tissue 25294917
1584 p16 Protein Humans NA Prognostic Distant Metastatis Vs No Distant Metastatis p=0.0065 Tissue 25294917
1585 MDM2 Protein Humans NA Prognostic Distant Metastatis Vs No Distant Metastatis p=0.036 Tissue 25294917
1588 XLOC_001699; XLOC_005327y; LOC400958; XLOC_008559y; LINC00340; XLOC_000495; RPS18; XLOC_012294; XLOC_l2_008560; XLOC_009911y; LncRNA Humans Upregulated in PCa [Log2 (Tumor/Normal)]: [XLOC_001699 (4.3 fold) ; XLOC_005327y (4.1 fold); LOC400958 (3.9 fold); XLOC_008559y (3.7 fold) ; LINC00340 (3.6 fold) ; XLOC_000495 (3.6 fold) ; RPS18(3.3 fold) ; XLOC_012294 (3.3 fold); XLOC_l2_008560 (3.3 fold); XLOC_009911y (3.2 fold); Diagnostic Prostate Cancer Vs Adjacent Normal p<0.05 Tissue 25307116
1589 SPRY4-IT1 LncRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p<0.05 Tissue 25307116
1591 uPA/PAI-1 Protein Humans Upregulated in PCa (PCa: 0.0479 ± 0.0060; BPH: (0.0332 ± 0.0023) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p=0.0064 Tissue 25323935
1602 Vascular endothelial growth factor A (VEGF-A) Protein Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.016 Tissue 26268996
1603 Vascular endothelial growth factor A (VEGF-A) + Vascular endothelial growth factor Receptor (VEGFR-2) Protein Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.006 Tissue 26268996
1605 let‐7c miRNA Humans Downregulated in PCa (log 2 fold change: 0.7140) Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 31045265
1606 mir-145 miRNA Humans Downregulated in PCa (log 2 fold change: 0.4020) Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 31045265
1607 mir-221 miRNA Humans Downregulated in PCa (log 2 fold change: 0.5174) Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 31045265
1608 mir-21 miRNA Humans Upregulated in PCa (log 2 fold change: 0.6068) Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 31045265
1609 mir-182 miRNA Humans Upregulated in PCa (log 2 fold change: 0.8817) Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 31045265
1610 mir-145 miRNA Humans Downregulated in Gleason Score Upgradation (Without Upgradation: -0.4831 Vs Upgradation: -1.1202) Prognostic Gleason Score Upgradation Vs No Upgradation p=0.03 Tissue 31045265
1611 mir-221 miRNA Humans Downregulated in Recurrence (Recurrence: −1.7170 Vs No Recurrence: − 0.9129) Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.04 Tissue 31045265
1624 KIF20A mRNA Humans Upregulated in prostate cancer tissues compared with HR: 2.060 Pathways include: Kinesins, Aurora B signaling, Polo-like kinase 1 (PLK1) pathway, M phase pathway, MHC class II antigen presentation Prostate Cancer Vs No Prostate Cancer Diagnostic 498 cases from TCGA-PRAD were analysed along with 52 normal prostate controls were selected for the analysis NA NA 0.8406 (95% CI: 0.6603-0.8256) NA p < 0.0001 1623 NA No NA NA Not validated on independent patient dataset 31031850 2019 CDK1 NA Expression Based mRNA Tissue Humans normal tissues Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1625 CCNB1 mRNA Humans Upregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.0166 Tissue 31031850
1626 BUB1 mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1627 CENPA mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1628 AURKB mRNA Humans Upregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p =0.0002662 Tissue 31031850
1629 CCNB2 mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.001469 Tissue 31031850
1630 BIRC5 mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p =0.0001304 Tissue 31031850
1631 AURKA mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1632 BUB1B mRNA Humans Upregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1633 TTK mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1634 KIF20A mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1636 CDKN3 mRNA Humans Upregulated in prostate cancer tissues compared with HR: 2.451 Pathways include: T cell receptor regulation of apoptosis Biochemical recurrence Vs No Biochemical Recurrence Prognostic 498 cases from TCGA-PRAD were analysed along with 52 normal prostate controls were selected for the analysis NA NA 0.6493 NA p =0.0002558 1635 NA No NA NA Not validated on independent patient dataset 31031850 2019 KIF2C NA Expression Based mRNA Tissue Humans normal tissues Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1637 NCAPG mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1638 CDCA8 mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p =0.0001771 Tissue 31031850
1639 miR-3162-5p miRNA Humans NA Prognostic Gleason grades 4+5 and 5 Vs Gleason grade 4 p=0.04 Tissue 31018918
1641 TGM4; SOSTDC1; MPO; SPRR1A; KLF4; RNU3B1; RNU3B3; RNU3B4; MT-ATP6; MT-ATP8; TMEM170A; LYNX1; IFNL3; PPP1R3G; GPR15; UGT2A3; MED13L; DNAJC10; NPY; XIST; LST1; WNT9A; LRRN3; GPR45; IFIT1; YWHAQ; KIR3DL1; EPPIN; CRLF1; MAL2; MAP3K15; H1FX; mRNA Mice Upregulated in prostate cancer tissues compared with NA Pathway include: Genes were related to 12 pathways: (i) Aryl hydrocarbon receptor (AHR) signaling, (ii) Bone metamorphosis signaling, (iii) Wnt/GSK-3β signaling, (iv) Glucocorticoid receptor signaling, (v) Immune cell signaling, (vi) Gas signaling, (vii) iNOS signaling, (viii) Hypoxia signaling, (ix) Wnt/β-catenin signaling, (x) Cancer metastasis signaling (xi) p38MAPK signaling, and (xii) Oxidative phosphorylation TRAMP mice Vs Non-Transgenic Mice Diagnostic Twenty week old TRAMP mice and non-transgenic littermates tissues were harvested NA NA NA NA p<0.05 1640 Microarrays No NA NA Validated on human patient cohort 30972102 2019 TOX4; RPL38; LSM12; RPL5; HAX1; ALPI; TCTE3; RPL7; MRTO4; HDAC1; UBE2H; KRT26; TNFSF10; DPPA2; PNLDC1; MRPS11; PFDN6; STOML2; VDAC1; RPS8; TDGF1; UBE2E2; GKAP1; RPL10A; RPS15; UMOD; RPL9; RPL30; NPNT; NR1I2; KRTAP16-1; H3F3A; H3F3B; MRPL34; CSE1L; ST6GALNAC1; UBE2Q2; RPS17; RPL35; GMCL1; NIP7; MSL2; EIF4A1; LASP1; LUZP4; EIF1AD; TUBB3; RPL34; RPL17; RPL23; RPL28; KIR3DL2; LMO2; NA; AOC3; H2AFZ; RPL37; TMSB10; AMY2A; AMY2B; PPIA; PPIH; BEGAIN; NT5C3A; RPS28; RPL27; IL24; COPS9; NEK2; SOCS2; UBL5; UBE2D3; VHL; RPL23A; AICDA; LDHA; CNEP1R1; RPL29; SPCS1; RPL41; SP110; PMP22; ARCN1; UQCRB; SLC25A19; UBE2N; SNRPE; ACKR1; RPL21; LEFTY2; RPL31; RPL35A; RPL7A; RPL39; NACA; SP140; MRPL23; VDAC3; VDAC1P5; ATP5L; DIMT1; GMCL1P1; ARFGAP2; RPL22;' NA Expression Based mRNA Tissue Mice normal tissues Diagnostic TRAMP mice Vs Non-Transgenic Mice p<0.05 Tissue 30972102
1642 ATP5L; ARFGAP2; DIMT1; GMCL1; MRPL34; RPL22; SP140; VDAC3 mRNA Mice Upregulated in Gleason Grade 5 Diagnostic TRAMP mice Vs Non-Transgenic Mice p<0.01 Tissue 30972102
1643 KLF4; MPO; SOStdc1; SPRR1A; TGM4 mRNA Mice Downregulated in TRAMP Diagnostic TRAMP mice Vs Non-Transgenic Mice p<0.01 Tissue 30972102
1644 TNFSF; RPL22; EIF4; SLC2A; LMO2/3; KRT; RPS21; RPS19; RPL21; NEK; PPP1R3; mRNA Humans Upregulated in TRAMP Diagnostic prostate cancer vs. benign prostate p<0.05 Tissue 30972102
1645 GPR15; GPR45; TME; TGM4; KLF4; LRRN3; WNT; SPRR1A; TMEM; mRNA Humans Upregulated in TRAMP Diagnostic prostate cancer vs. benign prostate p<0.05 Tissue 30972102
1657 MMP2 (Matrix Metalloproteinase-2) mRNA Humans NA Diagnostic Prostate Cancer Vs Normal Prostate p<0.05 Tissue 30917169
1658 BASP1 (Brain Abundant Membrane Attached Signal Protein 1) mRNA Humans Downregulated in High Grade PCa Diagnostic Prostate Cancer Vs Normal Prostate p<0.05 Tissue 30917169
1659 SNHG6 (small nucleolar RNA host gene 6) LncRNA Humans Upregulated in High Grade PCa Diagnostic Prostate Cancer Vs Normal Prostate p<0.05 Tissue 30911973
1660 SNHG6 (small nucleolar RNA host gene 6) LncRNA Humans Downregulated in PCa Prognostic Normal Prostate Vs T2 PCa Vs T3+T4 PCa p<0.001 Tissue 30911973
1661 SNHG6 (small nucleolar RNA host gene 6) LncRNA Humans Upregulated in PCa Prognostic Normal Prostate Vs Gleason Score 6 Vs GS 7 VS GS 8 Vs GS 9+GS10 p<0.001 Tissue 30911973
1662 SNHG6 (small nucleolar RNA host gene 6) LncRNA Humans Upregulated in PCa Prognostic Disease Free Survival Vs No Disease Free Survival p=0.0365 Tissue 30911973
1664 SNHG6 (small nucleolar RNA host gene 6) LncRNA Humans Upregulated in GS 6,7,8,9+10 Diagnostic Prostate Cancer Vs Normal Prostate p<0.05 Tissue 30911973
1665 PLZF (Promyelocytic leukemia zinc finger protein) Protein Humans High expression associated with shorter disease-free survival time Diagnostic Normal Vs Primary and Metastatic PCa NA Tissue 25807461
1704 hsv1-miR-H18 miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue, Urine: p<0.001; Serum: p=0.004 Tissue+Urine+Serum 26126436
1705 hsv2-miR-H9-5p miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue, Urine: p<0.001; Serum: p=0.002 Tissue+Urine+Serum 26126436
1706 hsa-miR-615-3p miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue: p<0.001; Tissue+Urine+Serum 26126436
1707 hsa-miR-BARTA-4 miRNA Humans Upregulated in PCa (Tissue, Serum, Urine) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue: p<0.001; Tissue+Urine+Serum 26126436
1708 hsa-miR-4316 miRNA Humans Upregulated in PCa (Tissue, Serum, Urine) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue: p<0.001; Urine: p=0.022 Tissue+Urine+Serum 26126436
1709 hsv1-miR-H18 miRNA Humans Upregulated in PCa (Tissue) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.05 Tissue+Urine 26126436
1710 hsv2-miR-H9-5p miRNA Humans Upregulated in PCa (Tissue) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.05 Tissue+Urine 26126436
1711 ERG Protein Humans Upregulated in PCa (Tissue, Serum) Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p=0.04 Tissue 26172920
1712 SPINK1 Protein Humans Upregulated in PCa (Tissue, Urine) Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p=0.004 Tissue 26172920
1713 ERG; SPINK1 Protein Humans Upregulated in PCa (Tissue, Urine) Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p=0.003 Tissue 26172920
1720 FOXM1 (Forkhead Box M1) Protein Humans NA Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.001 Tissue 30719174
1721 FOXM1 (Forkhead Box M1) Protein Humans NA Prognostic Low & Intermediate Risk Vs High Risk p<0.001 Tissue 30719174
1722 FOXM1 (Forkhead Box M1) Protein Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: p=0.022; Multivariate: p=0.035 Tissue 30719174
1729 SERPINA5; MFSD2A; ACSL6; MCF2; EMX2; HOXB8; CLDN2; AKR1B1; SPINK2; CYP19A1; mRNA Humans Upregulated in PCa: (PCa: 39.68 ± 30.00; No PCa: 15.04 ± 7.11) Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 30286759
1730 EMX2OS; LINC02137; LINC01116; LINC00839; AL161645.1; AC012123.1; AL354793.1; LINC02385; HOXB‐AS3; AC005674.1; LncRNA Humans Upregulated in High Risk PCa Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 30286759
1731 hsa‐mir‐891a; hsa‐mir‐892a; hsa‐mir‐1224; hsa‐mir‐93; hsa‐mir‐23c; hsa‐mir‐1251; hsa‐mir‐204; hsa‐mir‐323b; hsa‐mir‐200c; hsa‐mir‐96; miRNA Humans Downregulated after surgery (Before Surgery: 31.05 ± 21.01; After Surgery: 23.14 ± 11.1) Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 30286759
1732 SERPINA5; MFSD2A; ACSL6; MCF2; EMX2; HOXB8; CLDN2; AKR1B1; SPINK2; CYP19A1; mRNA Humans Differentially Expressed [Log Fold Change: SERPINA5: (-6.78954); MFSD2A (− 5.97025); ACSL6: (− 4.99597); MCF2: (−5.26855); EMX2: (− 6.79059); HOXB8: (− 6.24965); CLDN2: (−7.91887); AKR1B1: (− 3.87736); SPINK2: (−7.41992); CYP19A1: (−5.40444;] Prognostic High Risk Vs Low Risk PCa p=0.00822 Tissue 30286759
1733 Methylation Status of cg12799885 Methylation Humans Differentially Expressed [Log Fold Change: EMX2OS: (-5.98142); LINC02137 (-5.28623); LINC01116 (-3.59594); LINC00839: (- 4.30616); AL161645.1: (-4.9543); AC012123.1: (-4.63826); AL354793.1 (-5.45876); LINC02385: (-5.3465); HOXB‐AS3 (-5.22943); AC005674.1: (-3.98991);] Diagnostic Prostate Cancer Vs No Prostate Cancer p < 0.001 Tissue 30866497
1734 Methylation Status of DOCK2 Methylation Humans Differentially Expressed [Log Fold Change: hsa‐mir‐891a (-4.8); hsa‐mir‐892a (-5.14); hsa‐mir‐1224 (-3.66); hsa‐mir‐93 (1.79); hsa‐mir‐23c (-2.96); hsa‐mir‐1251 (-2.76); hsa‐mir‐204 (-1.84); hsa‐mir‐323b (-2.31); hsa‐mir‐200c (1.58); hsa‐mir‐96 (1.98);] Diagnostic Prostate Cancer Vs No Prostate Cancer p < 0.001 Tissue 30866497
1735 Methylation Status of FBXO30 Methylation Humans Differentially Expressed [Log Fold Change: SERPINA5: (-6.78954); MFSD2A (− 5.97025); ACSL6: (− 4.99597); MCF2: (−5.26855); EMX2: (− 6.79059); HOXB8: (− 6.24965); CLDN2: (−7.91887); AKR1B1: (− 3.87736); SPINK2: (−7.41992); CYP19A1: (−5.40444;] Diagnostic Prostate Cancer Vs No Prostate Cancer p < 0.001 Tissue 30866497
1736 Methylation Status of GRASP Methylation Humans Hypermethylated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p < 0.001 Tissue 30866497
1737 Methylation Status of HIF3A Methylation Humans Hypermethylated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p < 0.001 Tissue 30866497
1738 Methylation Status of MOB3B Methylation Humans Hypermethylated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p < 0.001 Tissue 30866497
1739 Methylation Status of PFKP Methylation Humans Hypermethylated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p < 0.001 Tissue 30866497
1740 Methylation Status of TPM4 Methylation Humans Hypermethylated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p < 0.001 Tissue 30866497
1741 Methylation Status of cg12799885 Methylation Humans Hypermethylated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: p=0.025 Tissue 30866497
1742 Methylation Status of DOCK2 Methylation Humans Hypermethylated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: p < 0.001; Multivariate: p=0.004 Tissue 30866497
1743 Methylation Status of GRASP Methylation Humans Hypermethylated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: p < 0.001; Multivariate: p=0.037 Tissue 30866497
1744 Methylation Status of HIF3A Methylation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: p=0.005 Multivariate: p =0.027 Tissue 30866497
1745 Methylation Status of PFKP Methylation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: p=0.001 Multivariate: p=0.028 Tissue 30866497
1746 Methylation Status of TPM4 Methylation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: p=0.038; Tissue 30866497
1747 miR-1260 miRNA Humans NA Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p=0.00001 Tissue 30250996
1748 miR-1274a miRNA Humans NA Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p=0.00001 Tissue 30250996
1753 5-hmC (5-hydroxymethylcytosin)+ ERG negative Protein Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: p=0.01; Multivariate: p=0.003 Tissue 30818754
1754 AZGP1; C0S; H3K18Ac; H3K4Me2; Ki67; p53; PML Protein Humans NA Prognostic Biochemical Relapse Vs No Biochemical Relapse AZGP1 p= 0.03; C0S: p=0.01; H3K18Ac: p=0.04; H3K4Me2: p=0.05; Ki67: p=0.02; p53: p=0.002; PML: p=0.03 Tissue 30288742
1755 AZGP1; Ki67; PML Protein Humans NA Prognostic Metastatic Relapse Vs No Relapse AZGP1: p=0.002; Ki67: p=0.04; PML:p=0.04 Tissue 30288742
1756 AZGP1 Protein Humans NA Prognostic Prostate Cancer Specific Death Vs No Death p=0.002 Tissue 30288742
1757 AZGP1+Ki67 Protein Humans NA Prognostic Metastatic Relapse Vs No Relapse Discovery: Univariate: p=0.03; Multivariate: p=0.04 Tissue 30288742
1758 AZGP1+Ki67 Protein Humans NA Prognostic Prostate Cancer Specific Death Vs No Death Discovery: Univariate: p=0.005; Multivariate: p=0.03;Validation: Univariate: p=0.05 Tissue 30288742
1822 BUB1 mRNA Humans Methylated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1823 TPX2 mRNA Humans Methylated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1824 NCAPG mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1825 UBE2C mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1826 MELK mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1827 CCNA2 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1828 CCNB1 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1829 CDK1 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1830 E2F2 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1831 DLGAP5 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1832 TMEM206 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1833 CDKN3 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1834 SHMT2 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1835 SRD5A2 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1836 CSRP1 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1837 PGM5 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1838 NFIB mRNA Humans Downregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1839 HEATR5B (HEAT repeat containing 5B); DDC (Dopa decarboxylase, transcript variant 6); TAS1R3 (Taste 1 receptor member 3); XIAP (X-linked inhibitor of apoptosis, transcript variant 2); mRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 30890858
1840 GABPB1-AS1 (GABPB1 antisense RNA 1); DDC (Dopa decarboxylase, transcript variant 6); HEATR5B (HEAT repeat containing 5B); CARD11 (Caspase recruitment domain family member 11, transcript variant 2); mRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 30890858
1841 GABPB1-AS1 (GABPB1 antisense RNA 1); KRT5 (Keratin 5); NCS1 (Neuronal calcium sensor 1, transcript variant 2); COL17A1 ( Collagen type XVII alpha 1 chain); ANXA1 (Annexin A1); LGALS3BP (Galectin 3 binding protein); mRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 30890858
1842 MT1IP (Metallothionein 1I, pseudogene (MT1IP), transcript variant 1); TRPT1 (tRNA phosphotransferase 1 (TRPT1), transcript variant 6); CHFR (Checkpoint with forkhead and ring finger domains, E3 ubiquitin protein ligase (CHFR), transcript variant 2); ZNF830 (Zinc finger protein 830); REXO1L2P (RNA exonuclease one homolog (S. cerevisiae)-like 2); SLC25A21 (SLC25A21 antisense RNA 1); mRNA Humans Differentially Expressed Prognostic Tumor Stage T1C Vs T2 p<0.05 Tissue 30890858
1843 FXR2 (Fragile X mental retardation, autosomal homolog 2); GADD45GIP1 (Growth arrest and DNA-damage-inducible, gamma interacting protein 1); STX4 (Syntaxin 4, transcript variant 1); CALCOCO2 (Calcium binding and coiled-coil domain 2, transcript variant 1); BEST4 (Bestrophin 4); URI1 (Prefoldin-like chaperone, transcript variant 3); DCP2 (Decapping mRNA 2, transcript variant 3); mRNA Humans Differentially Expressed Prognostic Tumor Stage T2 Vs T2a p<0.05 Tissue 30890858
1844 RASSF4 (Ras association (RalGDS/AF-6) domain family member 4); SIRPA (Signal-regulatory protein alpha (SIRPA), transcript variant 3); COMP (Cartilage oligomeric matrix protein); SOD3 (Superoxide dismutase 3, extracellular); DIDO1 (Death inducer-obliterator 1, transcript variant 3); PRELP (Proline/arginine-rich end leucine-rich repeat protein, transcript variant 1); mRNA Humans Differentially Expressed Prognostic Tumor Stage T2a Vs T2b p<0.05 Tissue 30890858
1845 BGN (Homo sapiens biglycan); RASSF4 (Ras association (RalGDS/AF-6) domain family member 4); USP21 (Ubiquitin-specific peptidase 21, transcript variant 3); NR1D1 (Nuclear receptor subfamily 1 group D, member 1); ANGPTL2 (Angiopoietin-like 2); mRNA Humans Differentially Expressed Prognostic Tumor Stage T2b Vs T2c p<0.05 Tissue 30890858
1846 SMAP2 (Small ArfGAP2 (SMAP2), transcript variant 2); TMSA (Prothymosin, alpha (PTMA), transcript variant 1); YY1AP1 (YY1 associated protein 1 (YY1AP1), transcript variant 6); DOCK9 (Dedicator of cytokinesis 9 (DOCK9), transcript variant 2); KITLG (KIT ligand (KITLG), transcript variant b); mRNA Humans Differentially Expressed Prognostic Tumor Stage T2c Vs T3a p<0.05 Tissue 30890858
1847 FAM133DP (Family with sequence similarity 133 member D pseudogene); SAMM50 (Sorting and assembly machinery component 50 homolog, protein coding); OR4F13P (Olfactory receptor family 4 subfamily F member 13 pseudogene); mRNA Humans Differentially Expressed Prognostic Tumor Stage T3a Vs T3b p<0.05 Tissue 30890858
1848 IKZF3 (IKAROS family zinc finger 3 (Aiolos), transcript variant 12); USP13 (Ubiquitin-specific peptidase 13 (isopeptidase T-3)); CLASP1 (Cytoplasmic linker associated protein 1, transcript variant 3); CEP112 (Centrosomal protein 112kDa, transcript variant 3); TSEN15 (tRNA splicing endonuclease subunit, transcript variant 1); FLVCR2 (Feline leukemia virus subgroup C cellular receptor family, member 2,transcript variant 2); GOLGA8B (Golgin A8 family, member B, transcript variant 1); ZNF438 (Zinc finger protein 438, transcript variant 1); SCARNA22 (Small Cajal body-specific RNA 22); LPPR1 (Lipid phosphate phosphatase-related protein type 1, transcript variant 2); PTGFR (Prostaglandin F receptor (FP), transcript variant 1); NREP (Neuronal regeneration related protein, transcript variant 1); mRNA Humans Differentially Expressed Prognostic Tumor Stage T2c Vs T3/4 p<0.05 Tissue 30890858
1852 miR-425-5p miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p<0.001 Tissue 30720162
1854 miR-424 miRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p=0.043 Tissue 30345533
1855 miR-572 miRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p= 0.031 Tissue 30345533
1856 miR-572+ miR-424 miRNA Humans Upregulated in PC3 and DU145 Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p= 0.031 Tissue 30345533
1857 miR-572+ miR-424+ miR-1 + miR133b miRNA Humans Downregulated in Recurrent PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p= 0.031 Tissue 30345533
1860 Promoter methylation of: miR-193b+ miR-34b/c Methylation Humans Upregulated in Recurrent PCa Diagnostic Prostate Cancer Vs Controls p<0.05 Tissue 30373654
1861 Methlyation Status of APC, GSTP1 RARβ2 Methylation Humans Upregulated in PCa (Non PCa: 1504.7 Vs PCa: 1657.1) Diagnostic Prostate Cancer Vs Controls p<0.05 Tissue 30373654
1865 Methlyation Status of APC Methylation Humans Methylated in PCa Prognostic Gleason Grade 1 Vs Gleason Grade 2-5 p<0.01 Tissue 30373654
1866 Methlyation Status of GSTP1 Methylation Humans Methylated in PCa Prognostic Gleason Grade 1 Vs Gleason Grade 2-5 p<0.01 Tissue 30373654
1867 Methlyation Status of RARβ2 Methylation Humans Methylated in PCa Prognostic Gleason Grade 1 Vs Gleason Grade 2-5 p<0.01 Tissue 30373654
1868 Methlyation Status of miR-34b/c Methylation Humans Methylated in Gleason Grade 2-5 Prognostic Gleason Grade 1 Vs Gleason Grade 2-5 p<0.01 Tissue 30373654
1869 Methlyation Status of APC Methylation Humans Methylated in Gleason Grade 2-5 Prognostic Low & Intermediate Risk Vs High Risk p<0.01 Tissue 30373654
1870 Methlyation Status of APC Methylation Humans Methylated in Gleason Grade 2-5 Prognostic Low & Intermediate Risk Vs High Risk p<0.05 Tissue 30373654
1871 Promoter methylation of: miR-193b+ miR-34b/c Methylation Humans Methylated in Gleason Grade 2-5 Prognostic Prostate Cancer Specific Survival Vs No Survival p=0.017 Tissue 30373654
1872 Methlyation Status of APC Methylation Humans Methylated in High Risk Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p=0.044 Tissue 30373654
1873 Promoter methylation of: GSTP1 Methylation Humans Methylated in High Risk Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p=0.017 Tissue 30373654
1874 Methlyation Status of miR-34b/c Methylation Humans Methylated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p=0.017 Tissue 30373654
1876 PD-L2 (Programmed death ligand 2) mRNA Humans Methylated in PCa Prognostic Biochemical Recurrence Free Survival Vs No Biochemical Recurrence Free Survival p=0.01 Tissue 30321406
1877 PD-L2 (Programmed death ligand 2) mRNA Humans Methylated in PCa Prognostic Distant Metastatic Free Survival Vs No DMFS Survival p=0.01 Tissue 30321406
1878 PD-L2 (Programmed death ligand 2) mRNA Humans Upregulated in PCa: []; Downregulated in PCa: [] Prognostic Prostate Cancer Specific Survival Vs No PCSS Survival p<0.001 Tissue 30321406
1894 ASAP1 DNA (Copy Number variations) Humans NA Prognostic Gleason Grade 4 in Gleason Score 7 p<0.01 Tissue 30611450
1895 HDAC9 DNA (Copy Number variations) Humans NA Prognostic Gleason Grade 4 in Gleason Score 7 p<0.01 Tissue 30611450
1896 CHD1 DNA (Copy Number variations) Humans NA Prognostic Gleason Grade 4 in Gleason Score 7 p<0.01 Tissue 30611450
1897 RB1 DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic Gleason Grade 4 in Gleason Score 7 p<0.01 Tissue 30611450
1898 PTEN DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic Gleason Grade 4 in Gleason Score 7 p<0.01 Tissue 30611450
1899 MYC DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic Gleason Grade 4 in Gleason Score 7 p<0.01 Tissue 30611450
1900 ASAP1 DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic GP3 in GS7 Vs GP3 in GS6 p<0.01 Tissue 30611450
1901 HDAC9 DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic GP3 in GS7 Vs GP3 in GS6 p<0.01 Tissue 30611450
1902 CHD1 DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic GP3 in GS7 Vs GP3 in GS6 p<0.01 Tissue 30611450
1903 RB1 DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic GP3 in GS7 Vs GP3 in GS6 p<0.01 Tissue 30611450
1904 PTEN DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic GP3 in GS7 Vs GP3 in GS6 p<0.01 Tissue 30611450
1905 MYC DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic GP3 in GS7 Vs GP3 in GS6 p<0.01 Tissue 30611450
1906 AFP; AKR1C1; AKR1C3; AKR1C4; C1orf229; C5orf28; C5orf34; CCNE1; DNMT1; E2F3; ENSA; FBXO4; G6PD; KPNA2; LETM2; LGSN; MRPS30; OPLAH; OR4K15; OR4L1; PAIP1; SKP1; SPEF2; WDR70; ZNF124; ZNF280A; ZNF324B; ZNF669; ZNF695; mRNA Humans Upregulated in Agressive PCa Prognostic Primary Prostate Cancer Vs Metastatic Prostate Cancer p<0.05 Tissue 30401717
1907 ANO7; NSA2; BOK; PDE8B; CECR6; PER3; CNNM1; PPP1R7; CNTNAP3; SCAMP1; COX15; SEMA4G; DMGDH; SLC7A8; DUSP1; TMEM18; EPHA7; TRIM8; FAM20C; TSLP; FOXC1; WDR41; ZNF658; GABRG3; GLB1L3; GLOD4; KCNMB1; LOC100128239; LOXL4; MTERFD2; NCAM1; NDN; mRNA Humans Upregulated in Agressive PCa Prognostic Primary Prostate Cancer Vs Metastatic Prostate Cancer p<0.05 Tissue 30401717
1908 ADAM12; AURKA; AURKB; C7orf49; CDCA8; CENPF; CIT; DNMT3B; DYRK2; FANCD2; FGD1; GDAP1; GPI; GTSE1; HNRNPUL1; IPO9; KIF23; LIG1; NCAPH; NHSL1; PEG10; SKP2; TMEM65; TOP2A; TPX2; UBE2T; mRNA Humans Upregulated in Agressive PCa Prognostic Primary Prostate Cancer Vs Metastatic Prostate Cancer p<0.05 Tissue 30401717
1909 ALDH1A3; APH1B; ATAD1; CTBS; CTSO; DHRS7; ESR1; FOXC1; MEIS2; NR4A1; PDE8B; RPS27L; SEC62; SPCS3; ZMAT1; mRNA Humans Upregulated in Metastatic PCa Prognostic Primary Prostate Cancer Vs Metastatic Prostate Cancer p<0.05 Tissue 30401717
1910 HSP27; prohibitin; GSTP1; fibrinogen β chain; ALDH6A1; A1AT; HSP60; Protein Humans Downregulated in Metastatic PCa Diagnostic Metastatic Prostate Cancer Vs No Prostate Cancer NA Tissue 30396985
1911 HSP27 Protein Humans Upregulated in Metastatic PCa Prognostic Survival Vs No Survival p=0.007 Tissue 30396985
1912 Prohibitin Protein Humans Upregulated in Metastatic PCa Prognostic Survival Vs No Survival p<0.001 Tissue 30396985
1913 ALDH6A1 Protein Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Prognostic Survival Vs No Survival p<0.001 Tissue 30396985
1914 Prohibitin+ HSP27+ALDH6A1 Protein Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);]Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Prognostic Survival Vs No Survival NA Tissue 30396985
1915 Prohibitin+ HSP27 Protein Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);] Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Prognostic Survival Vs No Survival NA Tissue 30396985
1916 Prohibitin+ALDH6A1 Protein Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Prognostic Survival Vs No Survival NA Tissue 30396985
1917 CAV1; TP53; MAGEA11; CALM1; EGFR; UBE2I; CALR; SMAD3; FHL2; HDAC1; APP; MYC; JUN; ESR1; GNB2L1; HIPK3; SMAD2; APPBP2; CDC2; BRCA1; RB1; SMAD1;PXN; XRCC6; IL6ST; STAT3; DLG1; AES; TRAF6; FLNA; TRIM29; PCAF; REPS2; AKT1; PRKCA; RAF1; HLA-B; TRAF2; SMARCA4; MAPK1; CHGB; RANBP9; CCND1; GSK3B; HSPA1A; BCL2; VCL; RAI17; TGFBR1; SELENBP1; Protein Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);]Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 22654636
1918 CAV1; MAGEA11; CALM1; CALR; TP53; FHL2; EGFR; APP; JUN; SMAD3; SMAD2; ESR1; RB1; HIPK3; BRCA1; SMAD1; GNB2L1; XRCC6; UBE2I; HDAC1; CDC2; AES; STAT3; IL6ST; APPBP2; PCAF; REPS2; FLNA; RAF1; MYC; MAPK1; TRAF6; CCND1; SMARCA4; HLA-B; TRAF2; RANBP9; PIAS4; GSK3B; TRIM29; FOS; IDE; SRC; PXN; SLC25A4; SP1; NR5A1 YWHAG; AKT1; CCNE1; Protein Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);]Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Prognostic Prostate Cancer Vs Lymph Node Metastasis NA Tissue 22654636
1943 Methylation status of A0X1 Methylation Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1944 Methylation status of CYBA Methylation Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1945 Methylation status of EDG3 Methylation Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1946 Methylation status of ELF4 Methylation Humans Differentially Methylated between PCa and Normal Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1947 Methylation status of EPB41L3 Methylation Humans Differentially Methylated between PCa and Normal Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1948 Methylation status of FLJ12056 Methylation Humans Differentially Methylated between PCa and Normal Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1949 Methylation status of FLJ90650 Methylation Humans Differentially Methylated between PCa and Normal Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1950 Methylation status of FLT4 Methylation Humans Differentially Methylated between PCa and Normal Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1951 Methylation status of GAS6 Methylation Humans Differentially Methylated between PCa and Normal Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1952 Methylation status of GRASP Methylation Humans Differentially Methylated between PCa and Normal Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1953 Methylation status of GSTP1 Methylation Humans Differentially Methylated between PCa and Normal Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1954 Methylation status of HAAO Methylation Humans Differentially Methylated between PCa and Normal Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1955 Methylation status of HIF3A Methylation Humans Differentially Methylated between PCa and Normal Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1956 Methylation status of HOXC11 Methylation Humans Differentially Methylated between PCa and Normal Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1957 Methylation status of LEP Methylation Humans Differentially Methylated between PCa and Normal Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1958 Methylation status of MGC39606 Methylation Humans Differentially Methylated between PCa and Normal Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1959 Methylation status of MOBKL2B Methylation Humans Differentially Methylated between PCa and Normal Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1960 Methylation status of RAB34 Methylation Humans Differentially Methylated between PCa and Normal Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1961 Methylation status of RARb Methylation Humans Differentially Methylated between PCa and Normal Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1962 Methylation status of RHCG Methylation Humans Differentially Methylated between PCa and Normal Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1963 Methylation status of RND2 Methylation Humans Differentially Methylated between PCa and Normal Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1964 Methylation status of SLC34A2 Methylation Humans Differentially Methylated between PCa and Normal Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1965 Methylation status of SPATA6 Methylation Humans Differentially Methylated between PCa and Normal Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1966 Methylation status of TPM4 Methylation Humans Differentially Methylated between PCa and Normal Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1967 Methylation status of ZNF154 Methylation Humans Differentially Methylated between PCa and Normal Diagnostic Tumor Vs Normal Tissues <0.0001 Tissue 22589488
1968 Methylation status of ACTL6B Methylation Humans Differentially Methylated between PCa and Normal Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1969 Methylation status of AEBP1 Methylation Humans Differentially Methylated between PCa and Normal Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0021 Tissue 22589488
1970 Methylation status of AMID Methylation Humans Differentially Methylated between PCa and Normal Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1971 Methylation status of CD8A Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1972 Methylation status of CRIP1 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0037 Tissue 22589488
1973 Methylation status of FLJ30934 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1974 Methylation status of FLNC Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1975 Methylation status of FMOD Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1976 Methylation status of FOXE3 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1977 Methylation status of GAS7 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1978 Methylation status of GDPD5 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1979 Methylation status of HS3ST2 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1980 Methylation status of LOC349136 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1981 Methylation status of NEUROG1 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1982 Methylation status of PLTP Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1983 Methylation status of PTGER2 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1984 Methylation status of RASGRF2 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1985 Methylation status of RUNX3 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1986 Methylation status of SIX6 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1987 Methylation status of SLC9A3 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1988 Methylation status of SPSB4 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0008 Tissue 22589488
1989 Methylation status of SRD5A2 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1990 Methylation status of SUSD3 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0014 Tissue 22589488
1991 Methylation status of SYT10 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1992 Methylation status of TMEM74 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0005 Tissue 22589488
1993 Methylation status of CHST7 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Clinical recurrence vs. biochemical recurrence <0.0050 Tissue 22589488
1994 Methylation status of LMX1B Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Clinical recurrence vs. biochemical recurrence <0.0021 Tissue 22589488
1995 Methylation status of PHLDA 3 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Clinical recurrence vs. biochemical recurrence <0.0772 Tissue 22589488
1996 Methylation status of RAFTLIN Methylation Humans Differentially Methylated in Clinical recurrence Prognostic Clinical recurrence vs. biochemical recurrence <0.0050 Tissue 22589488
1997 Methylation status of RASGRF2 Methylation Humans Differentially Methylated in Clinical recurrence Prognostic Clinical recurrence vs. biochemical recurrence <0.0015 Tissue 22589488
1998 Methylation status of TNFRSF10D Methylation Humans Differentially Methylated in Clinical recurrence Prognostic Clinical recurrence vs. biochemical recurrence <0.0008 Tissue 22589488
1999 Methylation status of ZNF135 Methylation Humans Differentially Methylated in Clinical recurrence Prognostic Clinical recurrence vs. biochemical recurrence <0.0061 Tissue 22589488
2000 Methylation status of ALPL Methylation Humans Differentially Methylated in Clinical recurrence Prognostic Systemic recurrence vs. local recurrence <0.0182 Tissue 22589488
2001 Methylation status of AMPH Methylation Humans Differentially Methylated in Clinical recurrence Prognostic Systemic recurrence vs. local recurrence <0.0021 Tissue 22589488
2002 Methylation status of BCDIN3 Methylation Humans Differentially Methylated in Clinical recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2003 Methylation status of BCL11B Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2004 Methylation status of BRD4 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0038 Tissue 22589488
2005 Methylation status of C18orf34 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2006 Methylation status of DCAMKL1 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2007 Methylation status of FGF5 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2008 Methylation status of FLJ42486 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2009 Methylation status of JAM2 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2010 Methylation status of LHX9 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2011 Methylation status of LOC283537 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2012 Methylation status of LRAT Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0034 Tissue 22589488
2013 Methylation status of PDE4B Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2014 Methylation status of POU3F3 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2015 Methylation status of PTGS2 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0153 Tissue 22589488
2016 Methylation status of RASGRF2 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0002 Tissue 22589488
2017 Methylation status of SLC27A6 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0017 Tissue 22589488
2018 Methylation status of SLC03A1 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2019 Methylation status of SPSB4 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2020 Methylation status of STAT3 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0017 Tissue 22589488
2021 Methylation status of SYN2 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2022 Methylation status of TACR3 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0086 Tissue 22589488
2023 Methylation status of TIRAP Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0003 Tissue 22589488
2024 Methylation status of WNT11 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0011 Tissue 22589488